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ABSTRACT OF DISSERTATION 
 
 
ANALYSIS OF THE ROLE OF TWO AUTOPHAGY PATHWAY RELATED GENES, BECN1 AND 
TSC1, IN MURINE MAMMARY GLAND DEVELOPMENT AND DIFFERENTIATION  
The mammary gland is a dynamic organ that undergoes the majority of its 
development in the postnatal period in four stages; mature virgin, pregnancy, lactation, 
and involution. Every stage relies on tightly regulated cellular proliferation, programmed 
cell death, and tissue remodeling mechanisms. Misregulation of autophagy, an 
intracellular catabolic process to maintain energy stores, has long been associated with 
mammary tumorigenesis and other pathologies. We hypothesize that appropriate 
regulation and execution of autophagy are necessary for proper development of the 
mammary ductal tree and maintenance of the secretory epithelia during late pregnancy 
and lactation. To test this hypothesis we examined the role of two genes during 
development of the mammary gland.  
Beclin1 (Becn1) is an essential autophagy gene. Since the Becn1 knockout model 
is embryonic lethal, we have generated a Becn1 conditional knockout (cKO). We used 
two discrete mammary gland-specific Cre transgenic lines to interrogate the role of 
BECN1 during development. We report that MMTV-CreD; Becn1fl/fl mice have a hyper-
branching phenotype and WAP-Cre; Becn1fl/- mice are unable to sustain a lactation 
phase. Becn1 mutants exhibit abnormal glandular morphology during pregnancy and 
after parturition. Moreover, when autophagy is chemically inhibited in vitro, mammary 
epithelial cells have an increased mean number of lipid droplets per cell.  
 MTOR inhibits autophagy upstream of BECN1; we looked higher in the regulatory 
pathway for regulatory candidates. It has been well characterized that Tuberous 
sclerosis complex 1 (TSC1), in a heterodimer with its primary binding partner TSC2, 
inhibits MTOR signaling via inhibition of RHEB. Using the Tsc1 floxed model we 
generated a mammary gland specific Tsc1 cKO and found that these mice phenocopy 
the Becn1 cKO mice, including a gross lactation failure. Tsc1 cKO glands have altered 
morphology, retained lipid droplets in secretory epithelia, and an overall increase in 
MTOR signaling. We show that TSC1 and BECN1 are interacting partners, and that the 
interaction is nutrient responsive.  
 These results suggest that Becn1 and Tsc1 are necessary for proper mammary 
gland development and differentiation. Furthermore, we have demonstrated a novel 
murine protein-protein interaction and an important link between regulation of MTOR 
pathway and regulation of autophagy in a developmental context. 
KEYWORDS: Autophagy, Bax, Beclin1, mammary gland, Tuberous Sclerosis Complex 1 
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Chapter One: Autophagy: Regulation and Role in Development 
Overview 
This chapter has been published and is included here for completeness of the 
dissertation.1 
Mammalian autophagy refers to three cellular processes: chaperone-mediated 
autophagy, microautophagy, and macroautophagy.  This review will focus on the latter, 
macroautophagy, hereafter referred to simply as “autophagy.”  Autophagy proceeds in 
successive stages to form a mature autophagosome, which include: 1) de novo 
formation of a double membrane bound structure or phagophore, 2) elongation of 
these lipid-based membranes, and 3) encapsulation of intracellular cargo to form the 
mature autophagosome.  Autolysosomes, formed from the fusion of autophagosomes 
and lysosomes, then degrade and recycle the macromolecule components in order to 
maintain energetic homeostasis in the cell.  Autophagy is an ancient process that is 
highly conserved among eukaryotes.  The initial characterization of the autophagy 
pathway was worked out in yeast 2-4 with the identification of approximately 30 
autophagy-related (ATG) genes, and many mammalian genetic homologs have been 
identified.  Autophagy has been implicated in longevity/lifespan extension, disease 
prevention and promotion, as well as mammalian development (reviewed in: Autophagy 
and longevity: lessons from C. elegans,5 Autophagy in the pathogenesis of disease,6 
Autophagy and disease: always two sides to a problem,7 The Role of Autophagy in 
Mammalian Development: Cell Makeover Rather than Cell Death.8) This review will 
concentrate on the process and regulation of autophagy, as well as the role for 
autophagy in murine development. 
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Core machinery involved in autophagosome formation 
Mechanistic (mammalian) target of rapamycin (MTOR), upstream of autophagy 
induction, senses cellular nutritional levels and regulates cell growth and survival and 
directly inhibits autophagy.  MTOR is a cellular survival pathway that is the crux of many 
interconnected cellular pathways and integrates information to modulate cellular 
growth, metabolism and survival.  MTOR is active in nutrient rich conditions, inhibiting 
autophagy and protein degradation.  While in nutrient poor conditions MTOR is inactive 
and autophagy is induced by alleviating MTOR phosphorylation on unc-51 like kinase 1 
(ULK1) and ATG13. When MTOR is inactivated by starvation conditions, 
dephosphorylated ULK1 dissociates from the MTOR complex and phosphorylates ATG13 
and RB1CC1 (RB1-inducible coiled-coil 1, also known as FIP200) to induce the nucleation 
phase (Figure 1.1A).9  Autophagosome nucleation is a highly orchestrated process 
relying on the PtdIns3K/VPS34 (phosphoinositide-3-kinase, class 3) complex that serves 
to phosphorylate phosphatidylinositol to phosphatidylinositol 3-phosphate (PtdIns3P) 
(Figure 1.1B).  This modified lipid targets membranes to be recruited into the 
autophagosome.  The PIK3 complex, anchored by the interaction between core 
members PtdIns3K and Beclin1 (BECN1), exhibits different functions depending upon 
the composition of ancillary proteins in the complex.  UVRAG (UV irradiation resistance-
associated gene) and ATG14 are found in BECN1 complexes in a mutually exclusive 
manner.  For example, the complex of ATG14 (proposed mammalian homolog of yeast 
Atg14, or Barkor), PIK3R4/VPS15, PtdIns3K and BECN1 positively regulate 
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autophagosome formation at the nucleation step.  In contrast, a complex including 
UVRAG, BIF1, PtdIns3K, PIK3R4, and BECN1 reportedly controls autophagosome 
maturation and RAB7 (GTPase)-dependent lysosomal fusion.10  Autophagy regulation 
may be influenced through additional protein-protein interactions to either promote or 
inhibit autophagy.  BIF1 directly associates with UVRAG and is a positive regulator of 
autophagy; similarly, AMBRA1 (autophagy/Beclin1 regulator 1) directly binds BECN1 to 
stimulate autophagy.  In contrast, Rubicon (RUN domain and cysteine-rich domain 
containing, Beclin1-interacting protein) also directly binds BECN1 but acts as a negative 
regulator of autophagy.11 
Elongation of the autophagosome membranes is accomplished by two ubiquitin 
like conjugation systems (Figure 1.1C).  An ATG12–ATG5-ATG16L1 complex associates 
on the forming membrane.  ATG12 is first activated by an ATP dependent reaction with 
ATG7, an E1-like enzyme.  ATG12 is then conjugated to ATG5 by ATG10, an E2-like 
enzyme.  ATG16L1 then interacts with the ATG12–ATG5 conjugate, forming a multimeric 
complex.  Components of the complex dissociate from the autophagosome and return 
to the cytoplasm when elongation is complete.  The second ubiquitin like conjugation 
that contributes to membrane elongation modifies MAP1 LC3, the mammalian homolog 
of yeast protein Atg8.  ATG4B, one of the four mammalian ATG4 homologs, cleaves the 
C-terminal 22 residues of precursor LC3 (proLC3) producing LC3-I.  Cytoplasmic LC3-I is 
then conjugated with phosphatidylethanolamine (PE) by ATG7 and ATG3, an E2-like 
enzyme.  Lipidated LC3 (LC3-II) is selectively incorporated into the forming 
autophagosomal membrane.  LC3-II remains associated with the autophagosome until 
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fusion with the lysosome, when LC3-II associated with the outer membrane dissociates 
and LC3-II associated with the inner membrane is degraded by lysosomal proteases 
along with the autophagosomal cargo (Figure 1.1D).  This specific association of LC3-II 
makes it an attractive autophagy marker and will be discussed in further detail in later 
sections.  The autophagosome fuses with a lysosome, forming the autolysosome (or 
autophagolysosome).  Fusion with the lysosome results in breakdown of the inner 
autophagosomal membrane and cargo by lysosomal proteases and recycling of 
macromolecules.  Soluble NSF attachment protein receptors (SNAREs), RAB7 and the 
homotypic vacuole fusion protein sorting (HOPS) complex likely are primary regulators 
of autophagosome/lysosome fusion.12, 13 
Sources of Autophagosomal Membranes 
The main lipid sources that are recruited in the formation of autophagosomes 
are thought to emanate from the endoplasmic reticulum (ER), mitochondria, Golgi 
apparatus, or the plasma membrane (PM).  Integral membrane proteins normally found 
in the rough ER have been localized to the inner and outer autophagosome membranes 
by immunostaining.14  This was also supported by electron microscopy (EM)-3D 
tomograms that identified points of contact between the rough ER and the nascent 
phagophore, which indicated that the growing isolation membrane might be a 
subdomain of the rough ER.15, 16 Moreover, ER regions enriched in PtdIns3P have also 
shown to be the sites of emerging omegasomes.  The ER protein ZFYVE1 can be found in 
omegasomes extending out from the ER by EM-3D tomography, and the PI3K-complex 
protein ATG14 is localized at the ER surface.17  Contrary to the ER-based models, Hailey 
 5 
 
et al18 have proposed a novel model suggesting that the mitochondrial outer membrane 
may provide a membrane source for the biogenesis of autophagosomes.  Following 
amino acid starvation, investigators observed by fluorescence microscopy that 
fluorescently labeled LC3 and ATG5 transiently localized to the outer mitochondrial 
membrane (OMM) and NBD–PE (7-nitro-2-1,3-benzoxadiazol-4-yl-phosphoserine; 
loaded into cells as NBD–PS and converted to NBD–PE in the mitochondria) could be 
detected in autophagosomes.  Further, loss of the mitochondrial protein Mitofusin2 
caused a dramatic depletion in starvation-induced autophagy.  Other recent 
observations have suggested that cytoplasmic vesicles derived from the Golgi apparatus 
may act as a membrane source for forming autophagosomes in an ATG9-dependent 
manner.  In yeast overexpressing Atg9, EM confirmed that under starvation conditions, 
post-Golgi ATG9-positive vesicles were transported to the vacuole and could be seen 
forming large tubulo-vesicular structures.19, 20 Recent reports have described findings 
indicating that exocytic and endosomal SNARE proteins may mediate fusion of post-
Golgi Atg9-positive vesicles and remodeling of tubulo-vesicle clusters in phagophore 
assembly.21  Exocytic Q/t-SNAREs Sso1/2 and Sec9 were shown to be essential for 
homotypic fusion of Atg9-positive vesicles in starvation-induced autophagy in yeast.  As 
well, endosomal Q/t-SNARE Tlg2 and R/v-SNAREs Ykt6 and Sec22 were found to interact 
with Q/t-SNAREs Sso1/2 and Sec9 and are essential for trafficking of post-Golgi Atg9-
positive vesicles to the vacuole and during phagophore assembly.  Finally, a number of 
studies have also indicated that the PM is capable of directly contributing membrane to 
forming isolation membranes.  An analysis by Ravikumar et al22 described interaction of 
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the clathrin heavy chain (associated with endocytic vesicles) with ATG16L1 at the 
extending phagophore and later confirmed that disruption of the interaction resulted in 
decreased autophagosome formation.23  Recently, experimental data has also suggested 
that the action of PM SNAREs in complexes with tethering proteins may be essential for 
fusion of membranes in the phagophore.  In HeLa cells, it was shown that the 
membrane protein LC3 is sufficient to tether PM-integral PE, potentially facilitating the 
activity of PM SNAREs.24  
Cellular Stress Responses 
Although the core machinery for autophagy was initially identified in yeast, 
seminal experiments defining the induction of autophagy were performed in a 
mammalian cell- the hepatocyte.  These studies defined the importance of hormonal 
regulation, energy status, and nutrient levels as key modulators of autophagy.  Initially, 
the presence of double-membrane organelles were found to be induced in rat 
hepatocytes exposed to glucagon;25 these organelles were eventually demonstrated to 
be autophagosomes years later.26 Conversely, treatment of hepatocytes with insulin 
gave the opposite result, which invariably defined autophagy as a catabolic, energy-
generating mechanism for the cell.27 The dependence of the cell on autophagy for 
energy homeostasis was confirmed the same year by showing that amino acid 
supplementation inhibited autophagy in the rat liver.27 A final, important mechanistic 
link between autophagy and nutrient-energy sensing was established when rapamycin, 
an inhibitor of the energy sensor MTOR, was found to induce autophagy in 
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hepatocytes.28 Thus, cellular stress became a focal point upon which to understand how 
autophagy could be regulated.   
In addition to nutrient status and hormonal regulation, environmental stressors 
such as: hypoxia,29 heat stress,30 and reactive oxygen species (ROS) accumulation can 
also induce autophagy (Reviewed in: Autophagy signaling through reactive oxygen 
species ).31 Additionally, ER stress is also a potent inducer.  The ER is a highly active and 
tightly regulated organelle responsible for protein folding fidelity, biogenesis of 
membrane structures, metabolism and a veritable menagerie of cellular processes.  If 
the delicate microenvironment of the ER is disrupted, for instance by accumulation of 
unfolded (or misfolded) proteins, then the unfolded protein response (UPR) will be 
activated. There are three main pathways activated by the UPR: ATF6 (activating 
transcription factor-6), IRE1 (inositol requiring enzyme 1), and PERK (PKR-like eIF2α 
kinase, also known as EIF2AK3).  All of these proteins are typically bound to an 
inactivating chaperone molecule, BIP/Grp78, and released/activated in response to 
unfolded proteins.  It has been reported that autophagy is activated in response to ER 
stress and UPR by both PERK and ATF6 pathways, perhaps in an effort to ameliorate the 
accumulation and aggregation of misfolded proteins.  Interestingly, IRE1 activation 
inhibits autophagy in some systems and is required for autophagy induction in others; 
however, more systematic work is needed to define these pathways in mammalian 
systems.32 Although evidence is supportive of ER stress inhibiting MTOR- and Akt-
mediated cell survival pathways, which would alleviate autophagy inhibition 
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independently of the UPR, additional studies are needed to elucidate this process. 
(Reviewed in: Autophagy and the Integrated Stress Response).33 
Autophagy may also be induced as a survival mechanism in response to hypoxic 
conditions in normal and tumor cells.34  Induction of autophagy can proceed through 
different pathways depending on the severity of hypoxia and cell type.35  The best 
characterized means of hypoxia-induced autophagy is by activation of the transcription 
factor HIF1 (Hypoxia-inducible factor 1).36  HIF1 is capable of transcriptional activation of 
a variety of target genes involved in offsetting the damaging effects of hypoxia including 
erythropoiesis, angiogenesis, and autophagy.  The HIF1-target gene Bnip3 
(BCL2/adenovirus E1B 19kDa interacting protein 3) encodes a putative BH3-only (Bcl2 
homology domain-only) protein that is necessary and sufficient to induce autophagy by 
competitively binding BCL2 (B cell leukemia/lymphoma 2) and disrupting the BCL2-
BECN1 interaction.37, 38  Bnip3 has also been identified as a target gene of the 
transcription factor E2F, which can be activated by inhibition of the RB1 (retinoblastoma 
1) protein via severe hypoxia.39  This suggests that BNIP3 can trigger autophagy by HIF1-
dependent and HIF1-independent mechanisms.  Severe hypoxia/anoxia (<0.1% oxygen) 
can also induce autophagy by AMP-activated protein kinase (AMPK)-mediated MTOR 
inhibition as well as protein kinase C activation of MAPK8 (mitogen-activated protein 
kinase 8) and BECN1.40 41 42     
The ubiquitin proteasome system (UPS) and autophagy act as the major 
pathways for cellular catabolism and were initially thought to function independently of 
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one another.  However, new observations suggest that the two degradation pathways 
function in a highly coordinated manner to maintain cellular homeostasis.  The UPS 
pathway specifically targets soluble proteins in the nucleus or cytoplasm, which are 
labeled for proteasomal degradation by the addition of the small peptide ubiquitin at 
various lysine residues.  Through the action of three classes of enzymes, E1 ubiquitin-
activating, E2 ubiquitin-conjugating, and E3 ubiquitin-ligases, the UPS pathway can 
ensure high levels of specificity in labeling protein targets for degradation.  The most 
well-known limitations of the UPS pathway result from the small size and cylindrical 
structure of the 26S proteasome to which poly-ubiquitinated-proteins must enter for 
degradation by a series of peptidases.  It appears that proteins may need to be partially 
denatured and monomeric in order to be degraded within the proteasome, greatly 
limiting the UPS pathway for clearance of aggregated proteins or large multimeric 
complexes.43  In contrast, autophagy is limited in its activity to the cytoplasm and can 
efficiently degrade soluble proteins, protein aggregates, and organelles by engulfment 
by the isolation membrane followed by lysosomal fusion.  Previously, autophagy was 
viewed as a non-specific degradation pathway for cellular recycling; however, it is clear 
that several proteins and common aggregates are selectively degraded in the 
autolysosome, rather than the proteasome.44, 45 46  It has been observed that 
ubiquitinated proteins could be selectively degraded by autophagy.45  Suppression of 
the UPS pathway by siRNA is offset by an increase in autophagy.47 However, inhibition 
of autophagy results in inhibited degradation of UPS substrates.48, 49 As a result, current 
models for the autophagy and UPS pathways suggest not only overlapping roles for the 
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two systems, but a more dynamic and coordinated approach than previously 
described.(Reviewed in: Mechanisms of crosstalk between the ubiquitin-proteasome 
and autophagy-lysosome systems).50 
SQSTM1 (Sequestosome 1, also known at p62) is a scaffolding protein with 
several known functions in various tissues and is the most well-known target of selective 
autophagy.44  As SQSTM1 is constitutively expressed, it shows a consistent turnover and 
normally forms aggregates in the cytoplasm, which are selectively degraded by 
autophagy.  These characteristics are easily observed by immunohistochemistry and 
have been used to monitor successful autophagy in vitro.  Tissue-specific ablation of 
autophagy results in accumulation of SQSTM1 aggregates and proteins carrying poly-
ubiquitinated Lys-63 residues.51  The SQSTM1 protein contains both an ubiquitin-binding 
domain as well as an LC3-interacting domain, which has led to its implication as a central 
link between autophagy and the UPS pathway.  Current models describe SQSTM1 as a 
cargo receptor for autophagic degradation of various proteins.52, 53 
Autophagy can also be pharmacologically stimulated or inhibited in a number of 
ways; each method is accompanied by its own set of advantages and disadvantages 
(Table 1.1).  Autophagy can be stimulated indirectly through inhibiting the UPS pathway, 
inducing an ER stress response, reducing intracellular calcium levels, or modifying the 
acetyl proteome.  Use of proteasomal inhibitors MG132 or bortezomib in human cancer 
cell lines induces both the accumulation of the lipidated form of LC3B and the 
localization of a green fluorescent protein (GFP) tagged reporter (GFP-LC3) to 
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autophagosomes.54  Tunicamycin, an inhibitor of N-acetylglucosamine 
phosphotransferase, is used widely in the literature to induce ER stress.55  Tunicamycin 
treatment in vitro increases autophagosomes and autolysosomes as detected by EM and 
GFP-LC3 puncta formation, a fluorescent marker of autophagy.  Although thapsigargin 
acts as an ER stressor to inhibit the sarco/endoplasmic reticulum Ca2+ ATPase 
(ATP2A1/SERCA1), it can also act directly by blocking the fusion of autophagosomes with 
lysosomes by preventing recruitment of RAB7.56  Intracellular calcium can activate 
CAPN-1 (calpain 1), a protease that targets ATG5 for degradation, thus inhibiting 
autophagy.57  Fluspirilene induces autophagy through reducing calcium stores, which 
leads to a deactivation of CAPN-1 and stabilization of the ATG5–ATG12 conjugate.  
Lastly, resveratrol and spermidine are being studied for their ability to induce autophagy 
in vivo in order to promote longevity.58, 59  The apparent mechanism though which they 
act is through modification of the acetylproteome, principally through cytoplasmic 
deacetylation reactions mediated by the sirtuins.60  
Rapamycin is a highly specific inhibitor of MTOR and is commonly used both in 
vitro and in vivo.61-63  In contrast, lithium chloride is an MTOR-independent inducer of 
autophagy that inhibits inositol monophosphatase, leading to a decrease in inositol 
availability. Inositol monophosphatase inhibition results in increasing cellular levels of 
PtdIns3P, thus inducing autophagy.64  L-690,330 also inhibits inositol monophosphatase 
and is more potent, but has a reduced ability to permeate the PM and blood-brain 
barrier.65  Carbamazepine also works by a similar mechanism to lithium, and has been 
used in vivo to ameliorate proteinopathies in mice either suffering from mutant 
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SERPINA1 (α1-antitrypsin)  Z or TAR DNA binding protein (TARDBP) accumulations.66, 67 A 
broader range of pharmacological agents used to induce autophagy in the treatment of 
proteinopathies has been previously reported.68  The xestospongin family of natural 
compounds purified from marine sponges, xestospongin B (XeB) and xestospongin C 
(XeC), are inducers of autophagy.  XeC inhibits both the inositol 1,4,5-trisphosphate 
receptor 1 (ITPR1) and ER Ca2+ receptors indiscriminately, thus altering Ca2+ flux.69  XeB 
was originally identified as an inhibitor of inositol 1,4,5-trisphosphate-mediated Ca2+ 
signaling70 and has more recently been shown to act as an antagonist of ITPR1 on the ER 
membrane.  Evidence supports a mechanism wherein ITPR1 facilitates BCL2-mediated 
sequestration of BECN1 to inhibit autophagy.  XeB would rapidly induce autophagy by 
interfering with these protein-protein interactions, freeing BECN1 in an organelle-
specific manner.71  The induction of autophagy by XeB appears to be independent of 
steady state Ca2+ levels in the ER or cytoplasm.72  
For autophagy inhibition, 3-methyladenine (3-MA) inhibits autophagy in nutrient 
poor conditions by inhibiting PI3K and autophagosome formation. However, 3-MA 
inhibits both PIK3C1 and PI3CK3 indiscriminately which could lead to pleiotropic cellular 
effects.  Interestingly, in complete media 3-MA is pro-autophagic, leading to an 
accumulation of autophagic markers and increased conversion of LC3-I to LC3-II.  Wu 
and colleagues were able to show that the increase in autophagic markers is a result of 
increased autophagic flux rather than an effect of autophagosome accumulation and 
seems to be cell line independent.  Therefore, use of 3-MA as an autophagic inhibitor is 
well supported and substantiated when used in starvation conditions and at relevant 
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concentrations.73  Another PI3K inhibitor, wortmannin, functions in a similar way but 
does not show pro-autophagic effects in complete media.  This difference is attributed 
to wortmannin more stably inhibiting PtdIns3K compared to 3-MA, which has a 
transient effect on PtdIns3K but a stable effect on PIK3C1.74  The second group of 
inhibitors either target PI3K stabilization or autophagosome-lysosome interaction.  A 
recently identified inhibitor, spautin-1 (specific and potent autophagy inhibitor-1), 
blocks the deubiquitinase activities of USP10 and USP13, leading to the UPS-mediated 
degradation of the PtdIns3K component of the PI3K complex.75  Vacuolar ATPase is an 
enzyme that resides on the lysosomal membrane and regulates the lysosomal 
acidification.  Bafilomycin A1 (BafA1) is a vacuolar ATPase inhibitor. BafA1 inhibits fusion 
of autophagosomes with lysosomes and leads to an accumulation of autophagosomes in 
the cell as well as a reduction of protein degradation, another indication that autophagy 
is impaired.76  The fusion blockage seems to be an effect secondary to the reduced 
acidification of the lysosome.77  Conflicting reports in the literature imply that both cell 
type and length of drug treatment affect the degree of inhibition as well as more 
general effects.  It is important to note here that interpretation of commonly used 
autophagic activity and flux assays may be altered when using drugs affecting lysosomal 
acidification. In a short communication, Klionsky et al78 discuss the complications that 
may arise such as reduced LC3-II degradation at early time points and the difficulty in 
discriminating autophagosomes from autolysosomes in this system due to GFP 
persistence in the less acidified lysosomes. 
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Types of Autophagy 
Aggrephagy 
 Aggrephagy refers to the autophagic process of degrading proteins that are 
assembled into large protein aggregates, which are less toxic to the cell than more 
numerous small protein aggregates.  Although this is seen as a companion system to the 
UPS to promote protein degradation, there are subtle distinctions as to the intertwining 
of these pathways.  For example, proteins targeted for degradation by this means can 
be ubiquitinated but do not necessarily have to be.  Histone deacetylase 6- (HDAC6) 
mediated dynein transport of proteins along microtubules occurs preferentially with 
proteins that have K-63 linked polyubiquitin chains.  Conversely, BAG3-mediated 
aggresome formation, which also uses dynein transport along microtubules, does not 
require such protein modifications.  The forming aggresome requires K-63 linked 
polyubiquitination to recruit autophagy receptors SQSTM1, NBR1, and WDFY3.  These 
receptors provide a physical link to ATG8, found in the developing phagophore, to 
ultimately envelope the aggresomes.79 
Allophagy, crinophagy, and zymophagy 
 
Allophagy refers to the autophagic degradation of paternally derived 
mitochondria upon fertilization in the zygote.  As such, this mechanism is a 
developmental-specific form of mitophagy.  Sperm mitochondria, located in the mid-
piece region, are initially tagged with K63-linked ubiquitin prior to fertilization.  This 
labeling increases immediately after fertilization, presumably to insure their quick and 
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successful degradation prior to fusion of the male and female pronuclei.80  Historically, 
crinophagy refers to the process by which secretory granules containing hormones are 
directly routed to lysosomes without contribution from autophagy.  However, a parallel 
mechanism involving encapsulating these granules within autophagosomes does occur, 
as demonstrated within Paneth cells and pancreatic β-cells.81, 82  This provides a 
turnover mechanism to regulate appropriate granule numbers in these cells.  Autophagy 
is also responsible for the regulation of neurotransmitter vesicle levels, as dopamine 
responses are substantially increased in the dorsal striatum of Atg7-deficient mice.83  
Conversely, induction of autophagy through rapamycin administration attenuates 
dopamine responses.  Although it has not been demonstrated, these processes are most 
likely ubiquitin-dependent.  For example, the closely related process of zymophagy 
allows for the autophagic degradation of activated zymogen granules,84 which is 
dependent on VMP1 (vacuole membrane protein 1), SQSTM1 and the ubiquitin protease 
USP9X.85  This mechanism prevents acute pancreatitis from occurring by removing 
potentially harmful activated zymogen granules.  
Exophagy 
Autophagy is also associated with non-degradative processes involved in protein 
secretion known as exophagy.  Deretic et al86 review the roles of autophagy in 
conventional (regulated and constitutive) and unconventional secretion.  Conventional 
secretion pathways normally route through the Golgi complex or occasionally directly 
from the ER; however, the TOR-autophagy spatial coupling compartment87 is a newly 
identified region that is responsible for constitutive secretion of IL-6 and IL-8. Regulated 
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secretion examples include lysozyme release by Paneth cells and cathepsin K by 
osteoclasts.  Autophagy-based unconventional secretion, or autosecretion, involves 
omegasome formation at the ER to secrete proinflammatory factors IL-1β and HMGB1 
in mammalian cells.  
Heterophagy and endosomal microautophagy 
Heterophagy is distinguished from autophagy in the sense that it is a process 
devoted to degrade extracellular material that has been internalized within the cell, in 
contrast to the degradation of pre-existing intracellular material.  Upon endocytosis, 
proteins are routed into early endosomes and late endosomes/multivesicular bodies 
(MVBs) for fusion with lysosomes.  However, there is synergy with the endosomal 
system and autophagy, as early endosomes and MVBs can both fuse with 
autophagosomes to form amphisomes, which in turn fuse with lysosomes.  These 
amphisomes have been shown to carry protein markers early endosome antigen 1 
(EEA1) and mannose 6-phosphate receptor (M6PR), present in early and late 
endosomes, respectively.88  These fusion events are driven by GTPases, as MVB-
autophagosome fusion is RAB11-dependent and amphisome-lysosome fusion is RAB7-
dependent.89  In contrast to internalized materials, cytosolic proteins can be routed into 
MVBs through endosomal microautophagy either hsc70-mediated or through a non-
specific mechanism.  This process occurs during MVB formation and requires the ESCRT I 
and ESCRT III protein machinery.90 
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Immunophagy 
More broadly, autophagy plays a larger role in both innate and adaptive 
immunity in a process termed immunophagy.91  As recently reviewed, immunophagy is 
subdivided into three types: Type I, Type II, and Type III.92, 93  Type I immunophagy 
involves the processing of foreign or endogenous immunologically active molecules. This 
would include: xenophagy, the autophagic activation of macrophages, pattern 
recognition receptor activation, MHC II endogenous antigen presentation, and thymic 
selection.  Type II immunophagy regulates cell viability and immune cell function.  
Specific roles for this type include: T/B cell homeostasis, T cell maturation, and Paneth 
cell maintenance.  Type III immunophagy utilizes specific ATG proteins but doesn't 
require the entire process of autophagy to occur.  Examples in this class include: 
inhibition of RIG-I-like receptor signaling by ATG5–ATG12, and the negative regulation of 
TBK1 signaling for type I interferon secretion by ATG9.  
Lipophagy 
Lipophagy involves the metabolic regulation of lipids through degradation of 
lipid droplets (LDs) by autophagy.  Ultimately, fusion with lysosomes contributes to 
lipolysis of LDs, or the breakdown of triglycerides into free fatty acids.  In addition to 
lipophagy, cytosolic lipases promote free fatty acids from lipolysis in an autophagy-
independent fashion.  Although these cytosolic lipases are well characterized, the 
autophagy proteins involved in the detection and mobilization of LDs are not known.  
This field has recently expanded due to the pathologies associated with autophagy-
deficient mice.  Liver-specific ablation of Atg7 results in LD accumulation known as liver 
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steatosis (fatty liver).94  Similar studies have shown that lipophagy is a sensor for 
appetite regulation in hypothalamic cells,95 whereas reduced lipolysis in macrophages 
causes their premature conversion into foam cells to promote atherosclerosis.96 
Mitophagy 
Mitophagy is the selective degradation of mitochondria through autophagy, 
although the process may be cell specific within mammals.  For example, reticulocytes 
lose their mitochondria as they mature into red blood cells, an interaction-dependent 
process driven by BNIP3L (BCl2/adenovirus E1B 19kDa interacting protein 3-like) located 
on mitochondria and LC3 found on phagophores.97  Within other cells, a PINK1 (PTEN-
induced putative kinase protein 1)-Parkin system seems to regulate mitophagy.98, 99  
PINK1 localization at the OMM of damaged mitochondria recruits the E3 ubiquitin ligase 
Parkin to cause K63-ubiquitination of three known mammalian proteins: mitofusin1, 
mitofusin2 and voltage-dependent anion selective channel protein 1 (VDAC1).  
Autophagy can subsequently be directed by SQSTM1- and HDAC6-dependent 
mechanisms.  Given the enrichment of Parkin within skeletal muscle, brain, heart, and 
liver, it is possible that other tissues may use distinct E3 ubiquitin ligases for selective 
removal of mitochondria.  A recent genomic mammalian screen revealed 96 proteins 
required for Parkin-mediated mitophagy, underscoring the complexity and uncertainty 
of this mechanism.100 
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Nucleophagy 
Although yeast undergo piecemeal microautophagy of the nucleus, where 
portions of the yeast nuclear membrane and nucleoplasm are invaginated into a vacuole 
for degradation,101 mammalian cells can exhibit complete encapsulation of the nucleus 
known as nucleophagy.  This was initially demonstrated in murine models that exhibit 
nuclear envelopathies from mutations in nuclear membrane associated proteins such as 
lamin A and emerin.102  Murine embryonic fibroblasts (MEFs) isolated from these 
mutant mice demonstrated decreased cell viability and increased nuclear abnormalities 
when pharmacological inhibitors of autophagy were used.  Wild-type MEFs also 
exhibited signs of nucleophagy, although at lower levels than mutant MEFs, suggesting a 
control mechanism when nuclear damage occurs.  This notion is strengthened by 
findings that anti-cancer drugs that elicit DNA damage can trigger nucleophagy.103  
Topoisomerase inhibitors (e.g. camptothecin, etoposide), DNA intercalating agents (e.g. 
cisplatin), and oxidative stress damage (e.g. vanadyl (IV)) can induce nucleophagy in 
cancer cells.  It is possible that basal piecemeal nucleophagy occurs to maintain nuclear 
architecture, energy production, and nucleotide stores for DNA repair enzymes.  
Pexophagy 
Pexophagy, or degradation of peroxisomes through autophagy, is probably the 
most utilized of the three known mechanisms to eliminate superfluous peroxisomes.  
Analysis of liver-specific Atg7-deficient mice showed pexophagy contributed to about 
70-80% of the turnover, compared to the remainder linked to both a LON protease-
mediated mechanism and 15-LOX-mediated autolysis.104  The only known mammalian 
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peroxisome receptor involved in pexophagy is PEX14, which can associate with LC3 on 
the phagophore membrane.105  An LC3-RAB7-FYCO1-kinesin complex is responsible for 
the transport of engulfed peroxisomes along microtubules to the lysosome.  Although 
ubiquitination of a distinct membrane protein of the peroxisome allows for SQSTM1-
mediated autophagy to occur, the identity of this protein is currently not known.106 
Reticulophagy and Ribophagy 
Degradation of the ER through reticulophagy occurs in response to ER stress, and 
is seen as an additional stress coping mechanism like the UPR and ER-associated 
degradation.107, 108  The trigger for all three mechanisms lies in the accumulation of 
unfolded protein aggregates within the ER lumen.  Activation of the resident ER 
membrane protein PERK occurs when chaperones dissociate from the luminal side of 
PERK to assist in protein folding.  This causes dimerization of PERK, phosphorylation of 
EIF2A, and activation of ATG12, thus triggering the autophagic response via ATG12–
ATG5-ATG16L1 complex formation.  Ribophagy, the selective elimination of free 
ribosomes in the cytosol, is also linked to the ER stress response similar to 
reticulophagy.  ER stress leads to reduced translation levels, via phosphorylated EIF2A, 
to avoid the additional burdening of chaperone recruitment to nascent peptides.109  In 
modeling neurodegenerative disorders in Purkinje cells, polyribosomes were 
disassembled into non-translational monosomes, which became associated with 
autophagosomes.110  However, it is not known which ATG proteins mediate the 
recognition and sequestration of ribosomes and ER fragments into autophagosomes.  
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Xenophagy 
Viruses, bacteria, and parasites can be eliminated in an autophagic process 
involved in innate immunity defense termed xenophagy, which has been previously 
reviewed.93, 111  Invading bacteria can generally be classified as vacuolar (e.g. 
Salmonella) or cytosolic (e.g. Listeria, Shigella).  Cytosolic bacteria can undergo 
ubiquitin-dependent and ubiquitin-independent mechanisms for autophagosomal 
envelopment followed by translocation to lysosomes.  Vacuolar bacteria can be routed 
into autophagosomes, or in the instance of Mycobacteria, autophagy proteins can 
resume the maturation of the vacuole and promote fusion with the lysosome.112 The 
main recognition receptors that link detection and autophagy induction include the 
membrane TLRs (Toll-like receptors) and the cytoplasmic nucleotide-binding 
oligomerization domains (NOD)-like receptors (NLRs).  The receptors can recognize the 
lipopolysaccharides and peptidylglycans of Gram-negative bacteria.  Microbial 
interference with autophagy can occur due to the adaptive nature of bacteria.  For 
example, Shigella flexneri secretes the protein lcsB, which prevents ATG5-induced 
autophagy at the bacterial surface.113  Yersinia pseudotuberculosis resides within 
arrested autophagosomes in macrophages, since it can inhibit the fusion process with 
lysosomes.114  
Transcriptional Regulation 
A multitude of studies have focused on discovering the transcription factors 
responsible for controlling ATG genes.  Thus far these studies have culminated in nine 
transcription factors that orchestrate the expression of autophagy-related genes in 
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mammals.  We have learned that autophagy is under the regulatory control of circadian, 
metabolic, inflammatory and cell death factors.   
Circadian Regulation 
As might be expected, autophagy genes are transcribed with a circadian rhythm 
under control of the biological clock due to metabolic demands.  A circadian rhythm 
refers to the oscillation of a biochemical process (e.g. transcription, translation, 
phosphorylation, etc.) that goes through a cycle roughly every 24 hours.  The circadian 
clock is a transcription/translation feedback loop between the positive transcription 
factors CLOCK and ARNTL/BMAL1 and the negative transcription factors PER1 and PER2.  
These signals originate in two clusters of hypothalamic neurons of the suprachaismatic 
nucleus (SCN), which is reset by a light-dark cycle.  The oscillation in the SCN is 
considered the “master pacemaker” and is responsible for coordinating “subordinate 
pacemakers” throughout an organism, giving rise to circadian rhythms in every tissue.  
Autophagy is under circadian control likely because metabolism demands change 
throughout the day, an idea recently reviewed.115  While only ~10% of transcripts are 
globally rhythmically expressed,116-119 research using mice has shown that the mRNA 
expression of many autophagy genes such as Becn1, and Map1lc3b are rhythmic in the 
distal colon,120 liver, kidney, heart and skeletal muscle.121  In addition, the conversion of 
LC3-I to LC3-II is rhythmic in the liver of mice.121  The expression of the transcription 
factor CEBPβ, known to be controlled by the clock, was found to coordinate autophagy 
gene rhythms by directly binding to the promoters of autophagy genes, such as, Bnip3, 
Ctsl and gamma-aminobutyric acid receptor-associated protein (Gabarap).  Additionally, 
 23 
 
CEBPβ has been identified as the transcription factor responsible for rhythmic 
autophagy gene expression in the mouse liver.121  Furthermore, this rhythm was 
abolished in Arntl knockout livers, proving that autophagy rhythms from CEBPβ are 
dependent on the clock and thus, are circadian.121  It remains untested if CEBPβ or 
another component of the clock controls autophagy rhythmicity in other tissues such as 
the distal colon, but logic would dictate this to be the case.  While there have not been 
any direct links to disease caused by interrupting the link between autophagy and the 
circadian clock, there are several lines of research suggesting this link exists.  Metabolic 
disorders like diabetes have been shown to be similarly exasperated independently by 
both autophagy and CLOCK deficiencies.122, 123  It is surely to be found that the link 
between autophagy and the biological clock is stronger than we currently understand. 
FoxO Family 
The FoxO (forkhead box, class O) family is comprised of four proteins in 
mammals: FOXO1, FOXO3, FOXO4 and FOXO6.  FOXO proteins are transcription factors 
known to be involved in metabolism, longevity, oxidative-stress resistance, apoptosis 
and autophagy.  Once FOXO proteins are activated in the cytosol, FOXO proteins are 
shuttled into the nucleus where they bind to promoters to initiate transcription.  Their 
role in controlling autophagy gene transcription comes from studies on skeletal 
muscle,124-126 neurons,127 ischemic insults on the heart128 and human cancer cell lines.129  
Upon starvation or denervation of skeletal or heart muscles, both autophagy and FOXO 
activity are increased suggesting a transcriptional control link.  These studies have 
shown that FOXO1 and FOXO3 can induce the expression of Gabarapl1 (GABARAP-like 
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1), LC3b, Atg12l, Atg4B, PtdIns3K, Ulk2, Becn1, Bnip3, and Bnip3l.  Further analysis by 
ChIP has found FOXO proteins bound to the consensus sequence (T/C/G) (G/A/T) AAA 
(C/A) A found in the promoters of several autophagy genes including Becn1, Gabarapl1, 
LC3b, Atg12 and Bnip3.128  The activation of autophagy by FOXO is one major arm of 
autophagy activation as FOXO is independent of MTORC1 signaling.  FOXO1 can be 
activated in neurons through loss of Mapk8.127  Studying Mapk8-/- mouse brains and 
neurons it is clear that MAPK8 is a negative regulator of autophagy by inhibiting FOXO1.  
Mapk8-/- neurons have increased levels of dephosphorylated, nuclear-localized, 
activated FOXO1 and greater autophagic flux.  In cardiomyocytes, Sirtuin 1 (SIRT1) and 
nuclear protein transcription regulator 1 (NUPR1 also known as P8) play crucial roles in 
regulating autophagy through modification of FOXO1 and FOXO3.130, 131  SIRT1 regulates 
the activation of autophagy by directly deacetylating and activating FOXO1 during 
glucose deprivation (GD).132  Knockdown of either Sirt1 or Foxo1 leads to no increase in 
expression of ATG genes and failure of autophagy induction during GD.131  Utilizing a 
mutated FOXO1 (3A/LXXAA), which cannot be recognized by SIRT1, leads to increased 
acetylation of FOXO1 and failure to induce of autophagy after GD.131  Additionally, Foxo1 
conditional KO or Foxo1 (3A/LXXAA) overexpression in cardiomyocytes of mice 
significantly deteriorates cardiac function after GD proposed to be a direct cause of the 
significant decrease in autophagic flux.  Knockdown of Nupr1, a transcriptional 
corepressor of Foxo3, leads to activation and nuclear localization of FOXO3 where it 
associates more with target gene promoters such as Bnip3, which in turn have increased 
mRNA and protein expression.  Subsequently, Nupr1 knockout mice have increased 
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Bnip3 expression and increased autophagic flux in cardiac tissue, likely due to the 
increased FOXO3 activity.130  In primary skeletal muscle myotubules, AMPK is a potent 
activator of autophagy through both activation of FOXO3 and inhibition of MTORC1.126  
While more regulators of FOXO proteins are likely to be found, this research shows a 
clear link between FOXO activation and autophagy induction, through the increased 
expression of ATG-genes in several cell types. 
Trp53 
Transformation related protein 53 (TRP53 or TP53/p53) is a tumor-suppressor 
protein with well-known roles in regulating both cell cycle progression and the cell 
survival/death axis.  Recently, it has also been shown to provide both positive and 
negative regulation of autophagy.  In normal cells, TRP53 remains in the cytoplasm at 
low levels, which are maintained by the E3-Ubiquitin ligase MDM2 and the UPS.  Upon 
activation by post-translational modifications, TRP53 translocates to the nucleus where 
it functions to transactivate a number of target genes involved in cell survival, death, 
and cell cycle regulation.  Initial observations that TRP53 inhibition resulted in increased 
autophagy were complicated by the discovery that nuclear TRP53 was able to induce 
autophagy by transactivation of specific target genes.133  The current model for TRP53 
regulation of autophagy describes distinct, independent roles for cytoplasmic TRP53 and 
nuclear TRP53.  Analysis in vitro in a variety of cell types and in vivo in various organisms 
has shown that cytoplasmic TRP53 functions as a repressor of autophagy.   Trp53 
knockout (in enucleated cells) as well as inhibition or inactivation of cytoplasmic TRP53 
results in increased levels of autophagy, similar to that of cells following induction by 
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starvation or treatment with rapamycin.134  As well, induction of autophagy by 
starvation or rapamycin results in rapid depletion of cytoplasmic TRP53 by UPS 
degradation.  Mutant TRP53, lacking an ubiquitylation site, has been shown to strongly 
inhibit the induction of autophagy in vitro.134, 135  In contrast, nuclear TRP53 has shown 
to transactivate several genes known to stimulate autophagy following genotoxic stress.  
The TRP53 target gene, Dram1, encodes a highly conserved lysosomal protein whose 
function is unclear but has shown to strongly induce autophagy in a variety of cell 
types.133  Other nuclear TRP53 transactivation targets include Sesn2, Tsc2, and genes 
encoding AMPK α/β subunits, which function together to stimulate autophagy during 
nutrient deprivation.  AMPK can activate the TSC1/2 complex, which functions as a 
potent and sensitive inhibitor of MTOR, thereby de-repressing autophagy.  The AMPK 
activator SESN2 functions to amplify the TRP53-directed autophagic response.136, 137 
While it is widely accepted that TRP53 levels in normal cells are maintained by 
MDM2 ubiquitylation and proteasomal degradation,138 it is also well demonstrated that 
tumor cells commonly carry various TRP53 mutants capable of escaping the regulation 
by MDM2 and proteolytic degradation.139-141  Accumulation of mutant TRP53/TP53 in 
tumor cells is associated with metastases and resistance to chemotherapeutic agents.  It 
has also previously been shown that various post-translational modifications can 
stabilize and destabilize cytoplasmic TRP53.142  Recent analyses have shown that glucose 
restriction of tumor cells results in deacetylation and subsequent autophagy-dependent 
degradation of mutant TRP53, followed by apoptotic cell death.  Inhibition of autophagy 
prevented degradation of the mutant TRP53 and promoted tumor cell survival during 
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glucose restriction.143  This finding presents an interesting link in regulation of TRP53 
and the cell death/survival axis by selective autophagy because cytoplasmic TRP53 has 
classically been characterized as a negative regulator of autophagy.            
RB1-E2F1 
The Rb1 – E2F pathway is a well-characterized regulator of the G1/S cell cycle 
transition.  Under normal conditions, RB1 directly inhibits E2F so that the cell remains in 
G1.  When RB1 is phosphorylated by CCND1−CDK4, RB1 disassociates from E2F proteins, 
which allows them to bind to promoters of several genes including Ccne1 and virtually 
all initiators of the pre-replication complex necessary for entrance into S-phase.  As this 
pathway is the major pathway augmented to increase proliferation in many cancer 
models, Rb1 and E2F have become targets of many therapies.  E2F1, a member of the 
E2F family of eukaryotic transcription factors, is unique in that when DNA damage is 
sensed E2F1 can directly promote apoptosis through expression of TRP73 and indirectly 
through TRP53 accumulation by expression of CDKN2A/p19arf (Reviewed in p53 and E2f: 
partners in life and death.144)  Evidence for how RB1-E2F regulates autophagy is 
confusing, as both RB1 and E2F1 can induce autophagy separately and often in an 
inverse relationship to each other.  E2F1 indirectly increases the expression of 
autophagy related genes after E2F activation in U2-OS cells.145  A comprehensive 
analysis of ATG-gene promoters in the presence of E2F1 reveals that E2F1 promotes the 
expression of Ulk2, Atg4B, Atg4D, Atg7, Gabarap2, LC3a, LC3b, Atg9, Atg10, Atg12 and 
Dram1.146  More recently, E2F1 overexpression in SK-MEL2 and MEFs induces 
autophagic flux by LC3-II conversion and GFP-LC3, irrespective of a functional 
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transactivation domain.147  While the E2F2 transactivation domain contains the RB1 
binding site, autophagy induction cannot be linked to E2F1-RB1 interaction since the 
expression of RB1 compared to E2F1 was not investigated.  This data also does not 
address whether E2F1tr (deletion of transactivation domain) can still induce expression 
of ATG genes.  As might be expected, removal of RB1 a negative regulator of E2F1, 
increases autophagic flux and expression of ATG genes in myoblasts.148  Together these 
data suggest that regulation of autophagy by RB1-E2F is dependent on active E2F to 
promote transcription.  However, when Rb1 is overexpressed in several human cancer 
cell lines (U2-O2, Saos-2, Hep3b and U-87MG) autophagic flux is dramatically increased 
by detection through LC3-II conversion, GFP-LC3 localization and transmission EM.149  
Furthermore, when mutant RB1 that cannot bind to E2F family members is 
overexpressed in these same cell lines, autophagy is not induced which suggests that 
the repression of E2F by RB1 is necessary for autophagy induction.  To corroborate 
these findings, knockdown of E2F1 in the same cells increases autophagy, suggesting 
that the regulation of autophagy by RB1-E2F is dependent on RB1 inhibiting E2F.  To 
best determine if the control of autophagy by RB1-E2F is physiological, more studies 
conducted in non-cancer cell lines are needed since discrepancies could be due to the 
models used.  Either way, RB1-E2F is clearly a transcriptional regulator of ATG-genes and 
could be involved in post-transcriptional regulation. 
TFEB 
The transcription factor EB (TFEB) is a well-characterized master regulator of 
lysosome biogenesis.  TFEB directly promotes the transcription of several lysosomal 
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specific genes.  Recent work in several labs has shown that when TFEB is phosphorylated 
it remains inactive at the lysosome membrane and does not translocate to the nucleus.  
Along these lines, it has been elucidated that MTORC1 at the lysosomal membrane is 
responsible for the inhibiting phosphorylation at Ser142 of TFEB.150-152  Further, the 
inhibiting activity of MTORC1 is blocked during nutrient starvation, which is strikingly 
similar to MTORC1’s inhibition of ULK1.  When TFEB is overexpressed in HeLa cells, ATG 
genes UVRAG, WIPI1, LC3b, SQSTM1, VPS11, VPS18, and ATG9b are upregulated along 
with lysosomal genes.153  Analysis of these same cells showed that autophagic flux is 
increased as well, indicating a parallel pathway to induce autophagic flux due to 
starvation.  It is interesting that TFEB, a lysosomal master switch, is implicated in the 
induction of ATG genes post-starvation and that it is regulated through the starvation 
sensor MTORC1.   
Autophagy-Apoptosis Crosstalk 
Beclin 1-Bcl2/XL Interaction 
Classically, crosstalk between autophagy and apoptosis has focused primarily on 
the interaction of the pro-autophagic protein BECN1 and the anti-apoptotic protein 
BCL2.154, 155 While the mechanisms behind the regulation of autophagy remain elusive 
and highly debated, the most widely accepted theory describes BCL2 as a BECN1 
antagonist, through direct interaction with the BH3 domain found on BECN1, preventing 
activation of the PI3K complex and induction of autophagy.156-158  Further analyses have 
identified additional components of regulation in that only ER-localized BCL2 or BCL2L1 
(BCL2-like 1/BCL X) in complex with the ITPR1 complex and the NAF1 protein can 
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sufficiently inhibit the induction of autophagy under starvation conditions.159  It has 
been stated that BCL2 and BCL2L1 in complex with BECN1 retain their anti-apoptotic 
capabilities; however, this data can be misleading as the interaction with BECN1 is 
dependent upon ER-localization of BCL2 and BCL2L1 while the regulation of intrinsic 
apoptosis occurs primarily at the mitochondria.160  This may suggest multiple 
independent roles of the BCL2 and BCL2L1 proteins, dependent upon sub-cellular 
localization; however, it is unknown what drives the specific distribution of ER- and 
mitochondrial-BCL2/BCL2L1 proteins and whether or not redistribution may occur under 
starvation conditions as a functional link between apoptosis and autophagy.  Recent 
data suggests that BCL2 may indirectly regulate BECN1 by interaction with AMBRA1, a 
positive regulator of BECN1 and autophagy.  BCL2 interaction with AMBRA1 is disrupted 
upon autophagic stimuli, at which point AMBRA1 competes with ER-localized BCL2 for 
interaction with BECN1.  Interestingly, AMBRA1 is preferentially bound by the 
mitochondrial fraction of cellular BCL2, rather than ER-localized BCL2, further linking the 
regulation of apoptosis and autophagy.161  
Becn1- BCL2L11 Interaction 
In contrast to the previous model, a novel interaction has been observed that 
suggests that the pro-apoptotic protein BCL2L11 (also known as BIM) can inhibit 
autophagy by recruitment of BECN1.  BCL2L11 is a BH3-only Bcl2 family protein that has 
been previously shown to function in an active, phosphorylated state or an inactive, 
dephosphorylated state.  Phosphorylated BCL2L11 induces mitochondrial pore 
formation and apoptosis by activating pro-apoptotic BAX/BAK1 proteins, while the 
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dephosphorylated BCL2L11 is found in complex with the dynein light chain 1/LC8 
protein.  Luo et al162 recently described the complex formed by BCL2L11 bridging the 
BECN1-LC8 interaction, which appears to sequester and inhibit BECN1 at the dynein 
motor complex.  Upon knockdown or knockout of Bcl2l11, cells in culture exhibit an 
increase in autophagosome formation, which is reversible by overexpression of Bcl2l11 
(mutants unable to induce apoptosis).  While this interaction appears sufficient to 
reduce levels of autophagy in nutrient-rich conditions, starvation-induced 
phosphorylation of BCL2L11 eliminates its interaction with BECN1, suggesting that 
inactive BCL2L11 may act to repress BECN1 until autophagy is induced by nutrient 
deprivation.  This model also proposes an interesting link between autophagy and 
apoptosis in that BCL2L11 phosphorylation potentially enables BECN1-dependent 
autophagosome formation and also activates pro-apoptotic BAX/BAK1 proteins, 
inducing mitochondrial apoptosis.  
Extrinsic apoptosis and autophagosomes 
While the models mentioned above primarily involve interactions between 
BECN1 and the BCL2 family proteins, a recent study has described autophagosomes as 
potential platforms for formation of the death-inducing signaling complex (DISC) for the 
activation of caspase 8 (CASP8).  Classically, the DISC forms near the PM off of adapter 
proteins bound to the cytoplasmic domain of various death receptors, activated by 
extracellular apoptotic signaling.  CASP8 is recruited to the DISC as a monomer, which 
then self-associates and cross activates by cleavage of the pro domain.  Active CASP8 
cleaves and activates caspase 3 (CASP3) triggering the apoptotic cascade.  It has been 
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previously reported that CASP8 requires SQSTM1 for efficient self-association; however, 
Young et al has described complex formation between ATG5 and CASP8, as well as ATG5 
and the adapter protein FADD at the autophagosomal membrane.  Atg5 knockdown is 
associated with reduced CASP8 activation upon induction of apoptosis.163  While other 
amplification mechanisms have been described in the apoptotic machinery, this appears 
to be the first that is dependent upon autophagy/autophagosome formation.   
Transgenic Models for Autophagy Detection 
GFP-LC3 
The best characterized and most widely used detection model is the GFP-LC3 
transgenic mouse generated by Mizushima and colleagues. This robustly expressing 
transgenic mouse, in which LC3 is driven by a constitutive CAG promoter, displays 
punctate GFP fluorescence that corresponds to LC3 positive phagophores and 
autophagosomes.164  With this transgenic model quantitation of autophagosomes and 
phagophores is feasible using a high-resolution fluorescent microscope. This reporter 
line has been crossed into many of the knockout and floxed autophagy models 
generated in the field. For example, Atg5-/- mice are autophagy deficient and Atg5-/-; 
GFP-LC3 mice do not exhibit the punctate fluorescence indicative of autophagosome 
formation.165  (Protocols for use are widely available and published references are 
helpful, for detailed information see Deretic, V, Autophagosome and phagosome, 
Methods in Molecular Biology, 2008).166  This model is limited in that only phagophore 
and autophagosome number, not autophagic flux can be evaluated.  In basal conditions, 
lysosomal degradation clears the autophagosome and contents from the cell, to 
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maintain a “balance” of autophagosome formation and degradation.  An accumulation 
of LC3 positive structures may represent either an increase in formation or a decrease in 
fusion events.  Ferreting out these differences is relevant for proper data interpretation, 
especially when using chemical autophagy inhibitors and inducers.  Measuring 
autophagic flux in vivo has been problematic to date and the field is in need of an 
appropriate reporter model; currently, tandem fluorescent-tagged autophagy proteins 
are a valuable in vitro tool.167 Due to its chemical nature, GFP is quenched by the low pH 
of the autolysosome; however, red fluorescent proteins are more pH-stable, thus will 
retain their fluorescence in the lower pH of the autolysosome. The need for better 
detection mechanisms with regard to cardiac autophagy has led to the generation of a 
double transgenic reporter.  A cardiac muscle specific alpha myosin heavy chain 
(αMyHC) promoter was used to drive expression of a mCherry-LC3 construct.  These 
mice were crossed with the GFP-LC3 model previously described to produce a double 
label, which allows for the detection and evaluation of autophagic flux.165   GFP-LC3 will 
still function for visualization of LC3 positive phagophores and autophagosomes, while 
mCherry-LC3 puncta will mark phagophores, autophagosomes and autolysosomes.  Any 
double-labeled puncta are indicative of phagophores or autophagosomes, while red-
only puncta correspond to autolysosomes.  The comparison of double labeled structures 
to red fluorescent only labeled structures is informative to distinguish an increase in 
formation and a decrease of fusion events. Although this model is cardiac-specific, a 
similar strategy could be used to target other tissues or to generate a global transgenic 
model.    
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GFP-GABARAP 
GFP-GABARAP transgenic mice were originally generated to address the question 
of the role of GABARAP in podocytes.  Since GABARAP was reported to be highly 
expressed in podocytes, a pCAG-GFP-GABARAP transgenic mouse was produced in order 
to examine subcellular localization in this specialized cell type.168  The expression level 
of GFP-GABARAP is low, yet visible, ameliorating many of the potential effects of highly 
expressing fluorescent proteins.  In podocytes, GFP-GABARAP merged with SQSTM1 
aggregates but not LC3-II.  Though it was shown that GABARAP was not the preferred 
Atg8 ortholog for conjugation in podocytes this is a valuable reporter model for use 
across the field as differences in Atg8 orthologs are ferreted out.  
Autophagy and development 
Since the seminal genetic studies conducted in yeast, there has been an 
explosion in global and tissue-specific mouse knockout models produced to ascertain 
the role of autophagy in mammalian development and disease.  Although this section 
stresses development over disease, the pathologies that arise from induced mutations 
frequently lead to diseased states.  More commonly, mouse models are generated to 
profile and to uncover treatment regimens to address human diseases.  The models that 
we present are segregated into 1 of 4 distinct complexes that the encoded protein 
primarily functions in rather than by resultant phenotype, these being the: 1) ULK1 
complex, 2) PI3K complex, 3) ATG9 complex, and 4) ATG12 conjugation/LC3-lipidation 
system.  Lastly, we include a section on induced mutations that impact autophagy more 
indirectly beyond these complexes. 
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ULK1 complex 
ULK1 is the namesake member of the ULK kinase complex, and was initially 
identified as the mammalian homolog of yeast Atg1.  ULK1 kinase complex functions 
early in the autophagy pathway, during the induction phase, and consists of ULK1, 
ATG13, RB1CC1 and ATG101/C12orf44.  ULK1 and ATG13 are phosphorylated by 
activated MTORC1 in nutrient rich conditions; however, during stress MTORC1 is 
inactivated and the ULK1 complex is liberated to induce autophagy.  In this sense, ULK1 
is a direct link to nutrient sensing in the cell.  Contrary to expectations based on other 
autophagy component knockouts, the ULK1 conventional knockout mice are viable and 
have no overt developmental defects.  It is noted by the authors that Ulk1 knockout 
mice exhibit LC3 conversion at the same rate as wild-type controls, indicating that 
starvation-induced autophagy is not impaired in these mutants.  Under closer inspection 
Ulk1 knockout mice exhibit specific red blood cell lineage populations retaining 
mitochondria and ribosomes, as well as delayed mitochondria elimination in 
reticulocytes and increased reticulocyte numbers.169  It is evident from these initial 
studies that ULK1 is important for organelle clearance during erythrocyte maturation 
but not necessarily for starvation-induced autophagy.  Ulk2 knockout mice, like Ulk1 
knockouts, are phenotypically normal and viable, which is not surprising since there is 
most likely some degree of functional redundancy in the mammalian system.170   To 
investigate this possibility, the authors generated Ulk1/Ulk2 double knockout mice, 
which die shortly after birth.  This result suggests that elimination of ULK function yields 
a similar phenotype to the other autophagy deficient models. Ulk1-/-/Ulk2-/- MEFs are 
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specifically impaired in response to amino acid deprivation, though they have a similar 
response to glucose deprivation as wild type MEFs.170  
RB1CC1, the mammalian functional counterpart of yeast Atg17, is a direct 
interacting partner of ULK1 and a member of the ULK kinase induction phase 
complex.171, 172 Rb1cc1 knockout mice die in utero at approximately E14.5-E15.5, with 
the lethality attributed to massive liver and cardiac cell death from increased levels of 
apoptosis.  At E14.5, Rb1cc1 knockout embryos exhibit ventricular abnormalities: the 
left ventricular wall is lacking in trabeculation, contains fewer cells, and is thinner that 
control littermates.173  Autophagy may also impact the differentiation of hematopoietic 
stem cells (HSCs) as revealed in the conditional knockout of Rb1cc1.  Tie2-Cre; Rb1cc1 fl/fl 
mice die perinatally from severe erythroblastic anemia and have 6-fold fewer HSCs than 
control mice.  There is not a proliferation defect, as apoptosis rates are similar between 
groups and proliferation is actually slightly higher in the conditional knockout (35% 
compared to 25%).  However, a 4-fold increase in myeloid cells is found in the livers of 
CKO fetuses at E14.5, possibly explaining the depletion of fetal HSCs.174, 175  Eight 
proteins have been identified as binding partners of RB1CC1, including TSC1, a tumor 
suppressor gene, which is also a negative regulator of MTOR. This interaction has been 
shown to mediate cell size and growth.  As a compliment to the Rb1cc1 KO studies, Tsc1 
knockout embryos also show defects in the heart and liver; however, the heart defects 
consist of thickened, rather than thinned, ventricular walls.176   
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As part of the ULK1 kinase complex ATG13 functions during the induction phase.  
ATG13, the mammalian homolog of yeast Atg13, is directly phosphorylated by both 
MTORC1 and ULK1/2 and has been characterized as an adapter protein. At this time 
there is not an Atg13 knockout mouse, though intriguing in vitro studies indicate that 
Atg13 is essential for autophagy induction.  Interestingly, when researchers 
simultaneously knockout both Ulk1 and Ulk2, RB1CC1 and ATG13 are able to induce 
autophagy, suggesting that ATG13 and RB1CC1 are functioning independently of 
MTORC1 input to ULK1/2.177  This higher order autophagy regulation network is 
deserving of further attention.  
PI3K complex 
AMBRA1 promotes the positive association of PtdIns3K and BECN1 to form the 
core multi-protein autophagy induction complex.  Cecconi and colleagues initially 
reported that Ambra1 knockout mice, generated by using a gene trap strategy, are non-
viable.178  The majority of Ambra1 null embryos exhibit severe neural tube defects and 
spina bifida at E10 through E14.5.  Additionally, a myriad of autophagy-deficient effects 
are seen including cell cycle abnormalities, accumulation of ubiquitinated proteins and 
increased apoptotic cell death.  AMBRA1 is expressed specifically in the developing 
nervous system and appears to serve a role in controlling neuron survival.  Like the 
Becn1 knockout model, the phenotype of the Ambra1 knockout is particularly severe 
and strongly affects the developing embryo.  Interestingly, new evidence suggests that 
AMBRA1, like its binding partner BECN1, is a regulator of the autophagy-apoptosis 
crosstalk.  Pagliarini et al. report that AMBRA1 is selectively and irreversibly degraded by 
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caspases and calpains.179  This would help shift the cell from a survival program into an 
apoptotic program by destabilizing the autophagy promotion complex 
(BECN1/AMBRA1/PtdIns3K).  To support this hypothesis, a non-cleavable mutant of 
Ambra1 introduced into a 2F cell line shows a delay and partial prevention of apoptosis 
by extending the pro-survival effect of activated autophagy.178  It has been widely 
reported in the literature that Parkin, an E3 ubiquitin ligase involved in the 
pathogenicity of Parkinson’s disease, translocates from the cytosol preferentially to 
depolarized mitochondria and prompts their selective degradation via mitophagy.180  
Emerging evidence shows that AMBRA1 directly interacts with Parkin, although it is not 
a target for ubiquination. Additionally, Ambra1 overexpression leads to an increase of 
mitophagy but only in the presence of Parkin.  These findings suggest a novel 
mechanism whereby recruitment of AMBRA1, by Parkin, to the area of depolarized 
mitochondria elicits the nucleation of a phagophore. 
BECN1 is a core protein component of the PI3K complex needed for the 
nucleation phase of autophagy, and serves as a scaffolding protein whereby a dynamic 
grouping of autophagy-related proteins hub. BECN1 is unique among the autophagy 
related proteins in that it contains an N-terminal BH3, which can be bound and inhibited 
by BCL2 and family member BCL2L1. 181 This inhibition is primarily disrupted by 
phosphorylation of BCL2/BCL2L1.182  BECN1 contains a central coiled-coil interaction 
domain, which affords it the ability to oligomerize.183  Interestingly, the other domains 
of BECN1 are non-essential for self-oligomerization, and self-oligomerization is not 
affected by starvation, rapamycin or overexpression of Bcl2l1, Uvrag, or PtdIns3K.  
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Higher-level understanding of this property has yet to be elucidated.  The evolutionary 
conserved domain is responsible for autophagic function.  BECN1 interacts with 
PtdIns3K directly to induce autophagosome nucleation and promote elongation.  
Perhaps attributed to its unique juxtaposition between two programmed cell death 
pathways or autophagy-independent functions, Becn1 knockout mice have a more 
severe phenotype than other autophagy-related genes.  Becn1-/- mice die in utero 
around E7.5 days, with the embryonic lethality ascribed to a developmental failure to 
close the pro-amniotic canal.184  As a classical tumor suppressor, heterozygous 
disruption of Becn1 results in an increase in tumor incidence.184, 185  Additional induced 
mutant models for Becn1 demonstrate a developmental-specific role for autophagy in 
blood cell lineages.  Becn1-deficient Rag1-/- chimeras have a dramatic reduction in early 
marrow-derived thymocytes and B cells, while displaying normal levels of peripheral B 
and T cells. Thus, autophagy is required for undifferentiated lymphocyte progenitor 
maintenance and is not needed for the peripheral T and B cell compartments.186  Naive 
T-cell homoeostasis is crucial for protective immunity against infection and it appears 
that autophagy is necessary for this process.  A T-cell specific deletion of PtdIns3K shows 
that T-cell development does not require autophagy; however, naïve T cell survival is 
contingent upon autophagy to effectively remove damaged mitochondria via 
mitophagy.187  
PtdIns3K is a highly conserved ancient kinase, and the only PI3K identified in 
yeast.  PtdIns3K phosphorylates phosphatidylinositol to generate phosphatidylinositol 3-
phosphate, which is used in the elongating autophagosomal membrane.  A global 
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knockout of PtdIns3K was generated by crossing a conditional PtdIns3K allele with a 
Meox-Cre transgenic strain, for conversion to a null allele early in development.  As with 
several other autophagy knockout models, the hemizygous mouse is viable and exhibits 
no obvious phenotype. In stark contrast to the hemizygous state, the homozygous 
PtdIns3K knockout is lethal in the early embryonic stages (E7.5).  The embryos fail to 
form a recognizable mesoderm and both the endosomal trafficking and 
autophagosomal pathways are disrupted.188  In a liver-specific knockout of PtdIns3K 
(Alb-Cre; PtdIns3K fl/fl), mice are smaller and have enlarged, pale livers.  At the molecular 
level, hepatocytes have reduced levels of autophagy nucleation complex and an 
increase in intracellular lipid droplet formation. Mitochondria are smaller, despite fed 
conditions, indicating a potential mitochondrial fusion defect.  Additionally, when 
challenged with a 24-hour starvation, there are no observable GFP-LC3 puncta formed in 
the mutants, indicating a cessation of autophagic flux in the PtdIns3K liver-specific 
knockout mice.189  A cardiomyocyte-specific knockout (Mck-Cre; PtdIns3K fl/fl) results in 
mice with cardiomegaly, with an increased left ventricular wall thickness, decreased 
cardiac contractility and reduced cardiac output.189  Although these mutants appear to 
be healthy at birth, they die between 5 and 13 weeks of age.  Consistent with the liver-
specific knockout, small and deformed mitochondria are observed, and autophagic flux 
is disrupted.  It is evident that PtdIns3K is essential for autophagy regulation as well as 
autophagy-independent functions such as endosomal trafficking.   
UVRAG is a coiled-coil, BECN1 interacting protein.  It has been characterized as a 
positive regulator of autophagy acting in a complex with requisite autophagy proteins 
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BECN1 and PtdIns3K.  UVRAG has tumor suppressor activity and a negative effect on 
tumor cell proliferation, as UVRAG is recurrently monoallelically mutated in human 
colon cancers.190  Although Becn1 serves a host of autophagy-independent functions, 
UVRAG may have autophagy-independent roles as well.  Liang et al. elegantly showed 
that a UVRAG- PtdIns3K complex coordinates both late endosome fusion and trafficking, 
independently of its BECN1-dependent role in mediating autophagosomal formation 
and maturation.10  Although neither UVRAG knockout nor conditional knockout mice 
currently exist, the generation of a model would be of great value to the field, aiding in 
ascribing autophagy-dependent and independent functions to each member of the 
induction complex. 
Atg9 complex 
ATG9 is the only multi membrane spanning autophagy related protein identified 
to date. Proposed to function in membrane trafficking, it dynamically shuttles between 
organelles during starvation conditions.  There are 2 mammalian homologs: Atg9a, with 
a global expression profile, and Atg9b, with a restricted expression in the placenta and 
pituitary gland.191  Not surprisingly, Atg9a-/- mice, like Atg5-/- and Atg7-/- mice, die as 
neonates.  Thus, several autophagy-deficient mouse strains are unable to survive the 
transition from placenta-derived nutrition without an intact autophagic response.  
ATG9a is necessary for LC3 to conjugate PE, which is essential for autophagy function.  
This study reveals that Atg9a is an essential autophagy gene.  In addition to autophagy 
related functions, Saitoh and colleagues show that Atg9a regulates double stranded 
DNA innate immune response.192 
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Atg12-conjugation and LC3-lipidation 
ATG3 functions as the E2-like enzyme acting with LC3 in the LC3 ubiquitin-like 
conjugation system.  Similar to Atg5-/-, Atg7-/-, and Atg9a-/- mice, Atg3-/- neonates die 
within one day of parturition, as amino acid levels are reduced and the overall energy 
homeostasis is disrupted after termination of the placental nutrient supply.  The Atg12–
Atg5 conjugate system is affected as well as the ATG8 conjugation system,193 suggesting 
cooperation between the two distinct conjugation complexes during elongation.  Atg3-/- 
cells contained small autophagosome-like, ATG16L1 positive structures, disorganized 
isolation membranes, and altered levels of GABARAP and GABARAPL2/GATE-16.  
In yeast, a single Atg4 cysteine protease is responsible for cleaving Atg8 to 
expose an essential, terminal glycine residue.  In humans and mice, four Atg4 homologs 
(also referred to as autophagins) have been identified: Atg4a, Atg4b, Atg4c, and Atg4d.  
Of the Atg4 homologs, Atg4b and Atg4c knockout mouse models have been generated 
to date.  Atg4c is the most widely expressed Atg4 homolog in human tissues, although 
Atg4b is the most efficient and broadly active family member in vitro.194  Atg4b-/- mice 
are viable but have a depletion of ATG8-like proteins in normal and nutrient poor 
conditions.  These mice have balance and coordination deficits resulting from defective 
development in the vestibular system.  The otoconia within the inner ear do not develop 
normally, resulting in abnormal, giant, or missing otoconia, a phenotype recapitulated in 
the Atg5-/- model.195  In contrast, Atg4c-/- mice have normal levels of basal autophagy, 
but are less responsive to starvation-induced autophagy in the diaphragm.  This role in 
ameliorating cell stress is highlighted in this model’s increased susceptible to methyl 
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cholanthrene (MCA)-induced fibrosarcoma formation.195  Given the functional 
redundancy of Atg4 homologs, double knockout models should be highly informative.   
Atg16L1 binds to ATG5 to regulate the localization of the Atg12–Atg5 conjugate 
to the nascent autophagosomal membrane.  Atg16L1-/- neonates do not survive the 
perinatal starvation period and have a disruption of LC3-PE conjugation.196  Crohn’s 
disease, a chronic inflammatory bowel disease, is strongly linked genetically to the 
autophagy gene ATG16L1 in humans,197 and hypomorphic Atg16l1 mice show altered 
Paneth cell morphology and decreased intestinal antimicrobial protein secretion.198  
Immunological synapse dynamics between dendritic cells (DCs) and T cells seems to be 
autophagy-dependent, as RNAi knockdown of ATG16L1 in DCs stabilizes DC-T cell 
interaction and hyperstimulates the T cell response.199  This “hyperstability” is also 
found in DCs from Crohn’s disease patients with an ATG16L1 risk allele, which suggests 
that normally autophagy is activated at the synapse to negatively regulate T-cell 
activation.  In addition, Atg16l1-/- mice may help to model an autophagy-inflammasome 
connection, since they have an induced expression of inflammatory cytokines including 
IL-1β.196   
Atg5-/- mice die perinatally, suggesting that autophagy is not essential for 
embryonic development;200 however, maternal mRNAs and proteins persist in the early 
embryo and may permit autophagic activity during the preimplantation period.  Recent 
studies demonstrate that autophagy is essential for the oocyte-to-embryo transition.  
Analysis of GFP-LC3 embryos and oocytes show that autophagy is selectively 
upregulated in fertilized embryos from the one cell to the four cell stage.201  Very little 
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evidence of autophagy is detectable in mature oocytes or ovulated, unfertilized oocytes, 
indicating that fertilization stimulates the induction of autophagy.  Mating of oocyte-
specific Atg5-deficient females (Zp3-Cre; Atg5fl/fl) with Atg5+/- males, leads to embryos 
devoid of maternally inherited autophagic protein that fail to develop.202  Autophagy 
may function to eliminate maternally inherited proteins or to catabolize cellular 
components for energy homeostasis.  Since Atg5-/- neonates die from starvation-
induced amino acid deprivation,200 conditional gene deletion models have been 
developed to characterize autophagy later in development.  From these models, 
autophagy has been shown to play a pivotal role in the prevention of 
neurodegeneration and the onset of age-related neurological diseases and 
cardiomyopathies.  Nestin-Cre; Atg5fl/fl mice are viable and do not exhibit the suckling 
defect comparable found with Atg5- or Atg7-deficient neonates.203  After three weeks of 
age, progressive motor and behavioral defects become apparent including: growth 
retardation, ataxia, poor motor coordination, and failed clasping reflex.  High levels of 
neurodegeneration are found in the cerebellar Purkinje cells, and ubiquinated protein 
accumulations are observed across several anatomical regions of the brain.203  A 
Purkinje-cell specific deletion strategy (pcp-Cre; Atg5fl/fl model) shows a later onset of 
motor defect around 10 months of age compared to the more regional nestin-Cre.204  
Autophagy-dependent cardiomyopathies may have a developmental component, as 
cardiac-specific Atg5 deletions in young and adult mice have different pathologies.205  
Inducible deletion of Atg5 in adult mice leads to cardiac myopathy, contractile 
dysfunction, altered sarcomere structure, and aberrant mitochondrial organization.  
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Conversely, cardiac-specific Atg5 deletion during gestation does not result in these 
abnormalities, which points to adaptability of cardiomyocytes during early 
development.   
Similar to Atg5, Atg7 is necessary for the survival of neonates through amino 
acid pool maintenance as shown in the traditional knockout model.200  Neuronal-specific 
Atg7-/- mice share many of the Atg5 knockout phenotypes including: abnormal behavior, 
altered limb-clasping response and reduced motor coordination.  The nestin-Cre; Atg7fl/fl 
model shows high levels of neurodegeneration in the cerebellar and cerebral cortex 
with death occurring by 28 weeks of age.206  Remaining neurons, which demonstrate 
normal proteasome function, accumulate poly-ubiquinated proteins and harbor 
inclusion bodies that increase with age.  The nestin-Cre; Vps18fl/fl model exhibits a more 
severe neurodegeneration phenotype and results in lethality by postnatal day 12,207 
perhaps due to VPS18 being part of a protein tethering complex at the lysosome needed 
for its fusion with autophagosomes or endosomes.  Ablation of Atg7 within 
dopaminergic neurons of the substantia nigra has been performed to model Parkinson’s 
disease.208  Dopamine transporter (DAT)-Cre; Atg7fl/fl and engrailed-1-Cre; Atg7fl/fl adult 
mice have ubiquitinated protein aggregates and show a 40% to 60% reduction in 
dopaminergic neurons, respectively, and a corresponding decline in dopamine by 55% 
to 65%.  Although DAT-Cre; Atg7fl/fl mice do not display locomotive deficits, engrailed-1-
Cre; Atg7fl/fl mice exhibit an ataxic gait, presumably from additional Atg7 ablation within 
the hindbrain, cerebellum, and midbrain.  Using a tyrosine hydroxylase-specific Cre 
mouse (TH-IRES-Cre) with the Atg7fl/fl model, there is a 40% reduction in dopaminergic 
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neurons compared to controls and an accumulation of α-synuclein protein.209  Seizure 
activity, in human TSC patients, is believed to occur due to a hyperstimulated MTOR 
pathway.210  Inhibition of autophagy is demonstrated in CaMKIIα-Cre; Ptenfl/fl mice, 
CaMKIIα-Cre; Tsc1fl/fl mice, and brains of TSC patients.211  Moreover, CaMKIIα-Cre; 
Atg7fl/fl mice are prone to spontaneous tremors, as 75% of the mice develop symptoms 
by 6-7 weeks of age.  A liver-specific Atg7 deletion results in hepatomegaly and an 
increase in hepatocyte size due to an accumulation of peroxisomes and deformed 
mitochondria.212 Insulin-producing pancreatic β-cells use autophagy to maintain 
homeostasis, as β-cell-specific RIP-Cre; Atg7fl/fl mice show β-cell mass reduction and 
exhibit hypoinsulinemia and hyperglycemia.213  Atg7-deficient islet cells have reduced 
numbers of insulin granules, increased mitochondrial swelling, and distended rough ER 
and Golgi complex.  Interestingly, these mice do not become diabetic until bred with 
ob/ob mice to trigger an obesity-induced ER stress response.  Obesity induces the UPR 
in β-cells, which in the absence of autophagy leads to an increase in β-cell death from an 
increase in reactive oxygen species.213, 214   
Since there are several Atg8 mammalian homologs (e.g. GABARAP, LC3s, 
GABARAPL1, and GABARAPL2), it is not surprising to find that Lc3b-/- and Gabarap-/- mice 
are viable, have normal lifespans, and exhibit normal autophagy levels in fed and 
starved conditions.215, 216  While the subcellular re-localization of LC3 is useful in 
monitoring autophagy, LC3 has been recently implicated in mitophagy.  BNIP3L, an 
outer mitochondrial membrane spanning protein, has a cytoplasmic LC3 interaction 
region (LIR) domain through which it can recruit mitochondria to the autophagosome; 
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ablation of this interaction severely affects mitochondrial clearance.97  Although 
SQSTM1 interacts with all of the LC3 orthologs, recent studies have revealed that only 
lipidated LC3 selectively binds to SQSTM1 and directs it to the autophagosome.164  Thus, 
closer examination of the Lc3b-/- model may reveal defects in mitophagy or aggresome 
clearance in a cell-specific fashion.  
Autophagy-modifying models   
Activation of autophagy, through the ectopic overexpression of peroxisome 
proliferative activated receptor gamma, coactivator 1 α (PPARGC1A, also known as PGC-
1α), results in the degradation of HTT/huntingtin protein aggregates and ameliorates 
the phenotype of Huntington’s disease mice.217  This PPARGC1A-mediated proteolysis 
occurs by activation of TFEB, a known master regulator of autophagy.   Induction of 
autophagy through rapamycin administration can reverse protein plaque formation in a 
murine model for Gerstmann–Sträussler–Scheinker disease, a prion disease that results 
in ataxia from extracellular PrP amyloid plaques.218  Rapamycin treatment eliminates 
amyloid plaque formation, reduces symptoms, and extends the survival time of these 
mice.219  Within the hippocampus, the region devoted to learning and memory, an 
increase in autophagosomes in aged mice has been correlated with short-term memory 
deficits.220  This suggests an impairment of productive autophagosome-lysosome fusion 
in aged hippocampal cells.  A genetic affirmation of this mechanism is shown in a rescue 
of the TgCRND8 mouse model for Alzheimer’s disease.221  Ablation of cystatin B, a 
lysosomal cysteine protease inhibitor, reverses this defect through an increase in 
productive autophagy and reduction of amyloid protein deposition.  The Sqstm1 
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knockout mouse displays an Alzheimer’s-like phenotype, characterized by 
accumulations of cytotoxic aggregates of ubiquitinated proteins in neurons and other 
tissues.222  Autophagy mitigates ROS-mediated cellular damage through productive 
mitophagy.  The E3 ubiquitin ligase PARKIN initially was found to be necessary for 
mitophagy in neurons,223 and Parkin mutations are associated with juvenile 
Parkinsonism.224    
However, PARKIN-mediated mitophagy is also important for increased 
myocardial survival after induced infarction.  Fatalities from myocardial infarction 
increase from 20% in control mice to 60% in Parkin-/- mice during the first week after 
insult.225  Mitophagy may be a necessary process after injury to eliminate damaged 
mitochondria to avoid an inflammatory response.  Lysosomal DNase II functions to 
degrade mitochondrial DNA upon autophagy-mediated trafficking of mitochondria to 
the lysosome.  Upon pressure overload, mice with DNase II-deficient hearts exhibit 
myocarditis from an inflammatory response and dilated cardiomyopathy.226   Autophagy 
could impact cell differentiation by restructuring the cell through the elimination of 
organelles, proteins, and structures while providing necessary ‘building block’ 
metabolites.  FGF signaling inhibits the transition from cardiac precursor cells to 
differentiated cardiomyocytes.  Abrogation of FGF signaling through the conditional 
deletion of floxed FGFR1/2 or FRS2α causes premature cardiomyocyte differentiation 
through precocious autophagy activation.227  A potential regulatory mechanism for 
autophagy induction comes from a recent study that examined potent miRNAs that are 
expressed upon hypertrophic stimuli.228  miRNA-212/132-/- mice are protected from 
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transaortic constriction-induced hypertrophy and exhibit increased basal levels of 
autophagy.  Transgenic overexpression of miRNA-212/132 causes a decrease in the pro-
autophagic transcription factor FOXO3, impairment of starvation-induce autophagy, and 
leads to hypertrophy and heart failure.  Lastly, blocking the fusion of autophagosomes 
and lysosomes in cardiomyocytes through a cardiac-specific deletion of Mitofusin 2 
(Mfn2) leads to increased sensitivity to ischemia and late onset cardiac dysfunction.229   
Sonic hedgehog (SHH) is a crucial morphogen that promotes angiogenesis during 
development230 and after ischemia in adults.231  Ligation of mouse common carotid 
arteries induces neointimal lesion formation due to SHH-mediated, autophagy-
dependent smooth muscle cell proliferation.232  Inhibition of autophagy with 3-MA or 
BafA1 inhibits cell proliferation and neointima formation.  This potentially signifies an 
angiogenic role for autophagy in SHH-mediated smooth muscle cell proliferation during 
development as well.  A reduced level of autophagy is associated with arterial 
endothelial cell ageing and dysfunction in older humans, as autophagy markers are 
decreased by 50% and endothelium-dependent dilatation (EDD) is lowered by 30%.233  
In addition, aged mice have a 40% decrease in autophagy markers and a 25% reduction 
in EDD due to suppressed nitric oxide generation and an increased inflammatory 
response.  Induction of autophagy with trehalose reverses the EDD through normalizing 
both nitric oxide levels and inflammatory cytokine expression.   The dependence of cell 
differentiation on autophagy is probably cell specific, since autophagy may inhibit 
skeletal muscle differentiation from myoblasts.  TGF-β1, an inhibitor of muscle 
differentiation, induces autophagy through phosphoprotein enriched in 
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diabetes/phosphoprotein enriched in astrocytes (PED/PEA-15) activation.234  Ectopic 
overexpression of PED/PEA-15 in transgenic mice activates autophagy leading to 
atrophic fibers accumulation in skeletal muscle. 
Summary 
 Autophagy is a complex process with many constituent players and is highly 
regulated. Autophagic degradation of cellular contents and turnover of organelles is 
crucial for cell vitality and for the fidelity of organismal development. The concerted 
effort of specific types of autophagy is essential for cellular homeostasis and immune 
function. Transgenic mouse models of autophagic deficiency, both global and 
tissue/temporal specific, have revealed the importance of autophagy in the oocyte-to-
embryo transition, post-natal survival, development, differentiation, and aging.  A 
synopsis of the induced genetic models discussed in this review is provided in Table 1.2.  
From the collection of phenotypes of these models, a common thread emerges to assert 
that autophagy may not be essential for embryogenesis.  Six models (Atg3-/-; Atg5-/-; 
Atg7-/-; Atg9a-/-; Atg16L1-/-; Ulk1-/-Ulk2-/-) exhibit a perinatal lethality partly based on an 
inability for the neonates to maintain a pool of amino acids after parturition.  In 
contrast, a separate cluster of mutations, three within the PI3K complex (Ambra1-/-; 
Becn1-/-; PtdIns3K-/-) and one in the ULK complex (Rbc1cc1-/-), demonstrate early to mid-
gestation lethality in the respective knockout models.  Reconciliation of these 
phenotypic differences may be argued by functional redundancies or alternative 
mechanisms (e.g. cell-specific Atg5/7-independent autophagy) found within the former 
group, or additional autophagy-independent roles for members of the latter group.  
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With regards to the ULK complex, a recent study showed that both Atg13- and Rbc1cc1-
deficient avian DT40 cells had impaired autophagy, which was independent of 
Ulk1/Ulk2.177  Generation of an Atg13-deficient mouse model should help in discerning 
the developmental consequences of ULK1/2-independent autophagy.  In addition to this 
ULK1/2-independent activation, ULK3 can also contribute to the induction of autophagy 
as well.235 This affirms Einstein’s notion that a problem, when looked at in the right 
context, becomes increasingly more complicated.  It also illustrates that there is 
considerable work to be done in this area, especially as our methods of detection 
improve. 
Our understanding of autophagy has increased tremendously in the past decade 
and continues to do so as the research effort in this area continues to accelerate.  A 
more productive growth will be greatly benefitted with the advent of more specific 
pharmacological agents to induce or inhibit autophagy both in vitro and in vivo, as well 
as the generation of a global reporter model to monitor autophagic flux in currently 
existing induced mutant strains.  The interconnectedness of many cell regulation 
pathways (e.g. Akt, MTOR, apoptosis regulation) and autophagy implicitly underscore 
the importance of these processes to cellular function. It is conservative to predict that 
as the field continues to mature the tenuous nature of each of these interactions will 
become clearer.  
  
 52 
 
 
Figure 1.1 The core machinery of autophagy. Autophagy is a complex degradation 
process in which general cytoplasm or organelles are engulfed by a double membrane 
bound structure and degraded and recycled following fusion with a lysosome. (A) 
Dephosphorylated ULK1 dissociates from the MTOR complex and phosphorylates itself, 
ATG13 and RB1CC1 to induce the nucleation phase. (B) The PI3K complex is assembled 
at the site of the nascent autophagosomal membrane. UVRAG and ATG14 are found in 
BECN1 complexes in a mutually exclusive manner. BECN1 is inhibited when bound by 
anti-apoptotic BCL2, which results in downregulated autophagy. (C) The two ubiquitin-
like conjugation systems essential for membrane elongation are outlined schematically. 
(D) The autophagosomal membrane (orange crescent) is studded with ATG8 (stylized in 
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black).  The membrane elongation is dependent on the ATG12–ATG5-ATG16L1 
conjugation system. During fusion with the lysosome (blue oval) ATG8 associated with 
the outer membrane is cleaved and recycled by ATG4 while ATG8 associated with the 
inner-membrane is degraded by lysosomal proteases along with the cargo of the 
autophagosome.   
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Table 1.1 Pharmacological inducers and inhibitors of autophagy 
Autophagy 
Inducer 
Action Reference 
MG132 Inhibit 26S Proteasome  54 
Bortezomib Inhibit 26S Proteasome  54 
Tunicamycin Induce ER stress by inhibiting N-acetylglucosamine 
phosphotransferase 
55 
Thapsigargin Induce ER stress via SERCA inhibition 
Prevent autophagosome/lysosomal fusion by 
inhibiting Rab7 recruitment   
56 
Fluspirilene Stabilize ATG5–ATG12 by preventing Ca2+-mediated 
CALPAIN-1 activation 
57 
Resveratrol Sirtuin-mediated deacetylation of cytoplasmic 
proteins 
58, 60 
Spermidine Sirtuin-mediated deacetylation of cytoplasmic 
proteins 
59, 60 
Rapamycin Inhibit MTOR 61-63 
Lithium 
chloride 
Increase PI3P levels by inhibition of IMPase  64 
L-690,330 Increase PI3P levels by inhibition of IMPase 65 
Carbamazepine Increase PI3P levels by inhibition of IMPase 66, 67 
Xestospongin B Antagonize IP3R (and IP3R-mediated BCL2-BECN1 
interaction) 
70-72 
Xestospongin C Inhibit IP3R and ER Ca2+ receptors  
Autophagy 
Inhibitor 
Action Reference 
3-
Methyladenine 
Inhibit PI3K (PI3KC1 and PI3KC3) 73 
Wortmannin Inhibit PI3K (PI3KC1 only) 74 
Bafilomycin-A1 Inhibit vacuolar ATPase 76 
Spautin-1 Inhibit USP10 and USP13 deubiquitinase activity 75 
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Table 1.2 Atg knockout and conditional knockout mouse phenotypes 
Gene Genotype Phenotype Reference 
Ulk1 Ulk1-/- Viable; No developmental defects or 
impairment to starvation-induced 
autophagy; Delayed mitochondria 
elimination from reticulocytes 
169 
Ulk2 Ulk2-/- Viable; No overt phenotype/fertility defects 170 
 Ulk1-/-; Ulk2-/- Neonatal lethal; impaired response to amino 
acid deprivation 
170 
Rb1cc1 Rb1cc1-/- Embryonic lethal at E14.5-15.5; Excessive 
liver and cardiac apoptosis; Thin left 
ventricular wall, lacking trabeculation 
171-173 
 Tie2-Cre; 
Rb1cc1fl/fl 
Perinatal lethal; Severe erythroblastic 
anemia; 6-fold decrease in HSCs; Increased 
number of myeloid cells in liver 
174, 175 
Atg13 Currently no KO mouse  
Atg101 Currently no KO mouse  
Ambra1 Ambra1-/- Non-viable; Embryos show neural tube 
defects, spina bifida at E10-E14.5, 
accumulation of ubiquitinated proteins, and 
increased apoptosis in various tissues 
178 
Becn1 Becn1-/- Embryonic lethal at E7.5; Failure to close pro-
amniotic canal 
184 
 Becn1+/- Increased tumor incidence in various tissues 185 
 Becn1-/-; Rag1-/- Reduced levels of early marrow-derived 
thymocytes and B cells 
186 
PtdIns3k Meox-Cre; 
PtdIns3kfl/fl 
Embryonic lethal at E7.5; Embryos fail to 
form recognizable mesoderm 
188 
 Alb-Cre; 
PtdIns3kfl/fl 
Smaller adult mice; Enlarged, pale liver. In 
hepatocytes: Reduced levels of autophagy 
nucleation complex; Arrested autophagic 
flux; Increased intracellular lipid droplet 
formation; Reduced size of mitochondria 
189 
 Mck-Cre; 
PtdIns3kfl/fl 
Lethal between 5-13 weeks; Cardiomegaly 
with increased thickness of left ventricular 
wall, decreased cardiac contractility/reduced 
cardiac output; Arrested autophagic flux; 
Reduced size of mitochondria 
189 
Uvrag Currently no KO mouse  
Atg9a Atg9a-/- Neonatal lethal during perinatal starvation 192 
Atg9b Currently no KO mouse  
Atg3 Atg3-/- Neonatal lethal at P1; Many cells contain 
small ATG16L1-positive structures and 
scattered isolation membranes 
193 
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Table 1.2 Continued 
Gene Genotype Phenotype Reference 
Atg4a Currently no KO mouse  
Atg4b Atg4b-/- Viable; Inner ear developmental defects 
and associated defects in 
balance/coordination 
195 
Atg4c Atg4c-/- Viable; No overt phenotype/fertility 
defects; Decreased starvation-induced 
autophagy in diaphragm 
195 
Atg4d Currently no KO mouse  
Atg16l1 Atg16l1-/- Neonatal lethal during perinatal 
starvation; Induced expression of IL-1β 
196 
Atg5 Atg5-/- Neonatal lethal during perinatal starvation 236 
 Nestin-Cre; Atg5fl/fl Viable; Neurological defects appear after 3 
weeks of age: growth retardation, ataxia, 
poor motor coordination, failed clasping 
response; Increased accumulations of 
ubiquinated proteins; Abundant 
neurodegeneration of cerebellar Purkinje 
cells 
203 
 Pcp-Cre; Atg5fl/fl Viable; Neurological defects appear after 
10 months of age 
204 
Atg7 Atg7-/- Viable; Neurological defects appear after 
10 months of age 
237 
 Nestin-Cre; Atg7fl/fl Lethal by 28 weeks of age; Abundant 
neurodegeneration/neuron death in 
cerebrum and cerebellum, ubiquitinated 
protein accumulations in remaining 
neurons; Motor and clasping defects 
206 
 DAT-Cre; Atg7fl/fl Viable; 40% reduction of dopaminergic 
neurons and 55% reduction in dopamine; 
ubiquitinated protein accumulations in 
remaining neurons 
208 
 En1-Cre; Atg7fl/fl Viable; 60% reduction of dopaminergic 
neurons and 65% reduction in dopamine; 
ubiquitinated protein accumulations in 
remaining neurons; Ataxic gait 
208 
 TH-IRES-Cre; 
Atg7fl/fl 
Viable; 40% reduction of dopaminergic 
neurons; accumulation of α-synuclein 
protein 
209 
 CaMKIIαCre;Atg7fl/fl Viable; Spontaneous tremors in 75% of 
mice by 6-7 weeks of age 
211 
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Table 1.2 Continued 
Gene Genotype Phenotype Reference 
 Alb-Cre; Atg7fl/fl Viable; Enlarged hepatocytes; 
Hepatomegaly; Accumulation of 
peroxisomes and mitochondria 
212 
 RIP-Cre; Atg7fl/fl Viable; Hypoinsulinemia and hyperglycemia; 
Reduced number of insulin granules; 
Swelling of mitochondria, rough ER, and 
Golgi 
213 
Lc3b Lc3b-/- Viable; No overt phenotype/fertility defects 215 
Gabarap Gabarap-/- Viable; No overt phenotype/fertility defects 216 
Sqstm1 Sqstm1-/- Alzheimer’s-like phenotype; Accumulation 
of ubiquitinated proteins in neurons and 
various tissues 
222 
Parkin Parkin-/- 40% increase in fatalities from induced 
myocardial infarction due to mitophagy 
defect 
225 
Mfn2 Mfn2-/- (cardiac 
sp.) 
Increased sensitivity to ischemia and late 
onset cardiac dysfunction 
229 
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Chapter Two: Altering Autophagy: Mouse Models of Human Disease 
Introduction 
This chapter has been published and is included here for completeness of the 
dissertation.238 
Since the advent of knockout technologies using mouse embryonic stem cells in 
the late 1980s, there has been an explosion of murine models to profile human 
diseases. The understanding of the genetic contribution to these diseases has been 
further enhanced with the incorporation of tissue-specific gene deletion strategies 
through the use of the Cre-lox and FLP-FRT site-specific recombination systems. 
Autophagy, a crucial regulator of cell energy homeostasis, is also a companion process 
to the ubiquitin-proteasome system to assist in the turnover of proteins. Two distinct 
types of mouse models have been engineered to characterize autophagy. The first type 
is based on the reporter model system to both detect and quantitate the in vivo levels of 
autophagy in all tissues and organs. The second type is based on genomic modification 
to perform global or tissue-specific gene deletions for generation of pathological disease 
conditions. A wide array of human diseases and conditions have been shown to be 
intimately linked to alterations in autophagy and include: 1) cancer, 2) heart disease, 3) 
neurodegenerative diseases (e.g. Alzheimer’s and Parkinson’s disease), 4) aging, 5) 
lysosomal storage disorders, 6) infectious disease and immunity (e.g. Crohn’s disease), 
7) muscle atrophy, 8) stroke, 9) type 2 diabetes, and 10) reproductive infertility. This 
article will address the role of autophagy in human disease progression by reviewing the 
strengths and weaknesses of current murine models, as well as discussing their utility as 
therapeutic models for disease prevention and amelioration. 
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Transgenic models for autophagy detection 
GFP-LC3 
 The best characterized and most widely used detection model is the GFP-LC3 
transgenic mouse generated by Mizushima and colleagues.164 This robustly expressing 
transgenic mouse, in which LC3 is driven by a constitutive CAG promoter, displays 
punctate GFP fluorescence that corresponds to autophagosomes. With this transgenic 
model, quantitation of autophagosomes is feasible using a high resolution fluorescence 
microscopy. This reporter has been crossed into many of the knockout and floxed 
autophagy models generated in the field. For example, Atg5 -/- mice are autophagy 
deficient and Atg5 -/-; GFP-LC3 mice do not exhibit the punctate fluorescence indicative 
of autophagosomes. Protocols for use are widely available and published references are 
helpful, for detailed information see reference.239 This model is limited in that only 
autophagosome numbers, not autophagic flux, can be evaluated. 
In basal conditions, lysosomal degradation clears the autophagosome and 
contents from the cell, thus maintaining a “balance” of autophagosome formation and 
degradation. An accumulation of autophagosomes could either represent an increase in 
formation or a decrease in fusion events. Ferreting out these differences is relevant for 
proper data interpretation especially when using chemical autophagy inhibitors and 
inducers. Measuring autophagic flux in vivo has been problematic to date and the field is 
in need of an appropriate reporter model; currently, tandem fluorescent-tagged 
autophagy proteins are a valuable in vitro tool. An increase in GFP puncta (denoting 
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labeled autophagosomes) could indicate an increase in autophagosome formation or a 
decrease in vesicular fusion with the lysosome. Due to its chemical nature, GFP is 
quenched by the low pH of the autolysosome. Since red fluorescent proteins are more 
pH stable, they have been utilized in assays designed to monitor autophagic flux. The 
need for better detection mechanisms with regard to cardiac autophagy has led to the 
generation of a double transgenic reporter. A cardiac muscle specific alpha myosin 
heavy chain (αMyHC) promoter was used to drive expression of a mCherry-LC3 
construct. These mice were crossed with the GFP-LC3 model previously described to 
produce a double reporter which allowed for the monitoring of autophagic flux; 
autophagosomes were identified by GFP and mCherry co-localized puncta, while 
autolysosomes were tracked by mCherry-only puncta.165 Although this model is cardiac-
specific, a similar strategy could be used to target other tissues. Additionally, a dual 
labeled RFP-GFP-LC3 construct could be used to generate a ubiquitous transgenic model 
to quantitate autophagic flux. 
GFP-GABARAP 
 GFP-GABARAP transgenic mice were originally generated to address the 
question of the role of GABARAP in podocytes. Since GABARAP was reported to be 
highly expressed in podocytes, a pCAG-GFP-GABARAP transgenic mouse was produced 
in order to examine subcellular localization in this specialized cell type. The expression 
level of GFPGABARAP is low, yet visible, ameliorating many of the potential effects of 
highly expressing fluorescent proteins. In podocytes, GFP-GABARAP co-localized with 
SQSTM1 aggregates but not LC3II. Although it was shown that GABARAP was not the 
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preferred Atg8 ortholog for conjugation in podocytes, this may prove to be a valuable 
reporter model in other tissues.168 
Cancer 
As we will see as a common thread in many of the disease models featured in 
this chapter, there is no consensus in the literature as to whether autophagy is 
protective or maladaptive. The contribution of autophagy to cancer development is the 
most demonstrable example of the Janus-like role of autophagy in disease pathogenesis, 
and perhaps the most thoroughly investigated. Autophagy is hypothecated to 
contribute to tumor progression through two distinct mechanisms. Tumor growth is 
initially restricted when the centrally-located cells undergo nutrient deprivation, 
hypoxia, and if prolonged, subsequently undergo necrosis. This metabolic stress induces 
autophagy to maintain energy homeostasis and prevent necrosis until neo-
vascularization occurs. Angiogenesis is potentially able to restore a nutrient supply 
throughout the tumor, promoting tumor survival and facilitating growth and metastasis. 
Additionally, transformed cells that harbor defects in apoptosis and autophagy 
pathways tumor cells undergo chronic necrosis, which foments vascularization of the 
necrotic area, thus promoting tumorigenesis. Conversely, intact autophagy can be 
cytoprotective by eliminating damaged or aged organelles and degrading aggregated or 
misfolded proteins, thus preventing accumulation of tumorigenic and/or cytotoxic 
cellular inclusions. 
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These two scenarios are manifested in mouse models of autophagy disruption. 
When Beclin1 (Becn1) was heterozygously disrupted (Becn1+/-), these mice exhibited an 
increase in tumor formation when compared to control littermates.185 Disruptions in 
pro-autophagy genes Becn1 184, UVRAG 240, and Bif-1241resulted in increased frequencies 
of lymphomas and mammary neoplasia through an increase in genetic instability. 
TSC1/TSC2-deficient mice, which were unable to effectively suppress MTOR, had 
reduced autophagy and a subsequent increase in tumor occurrence.242, 243 These models 
all bolster the stance that autophagy is tumor suppressive. The embryonic or neonatal 
lethality of many autophagy knockout models is prohibitive for studying diseases, such 
as cancer, that are associated with age. Tissue-specific knockout studies will provide 
more insights in elucidating gene-specific mechanisms for tumor suppression. Evidence 
is forthcoming from cancer cell lines and primary tumor profiling that autophagy is 
permissive for tumor growth and enhanced in primary tumors. In a pancreatic cancer 
cell line (8988T cells), inhibition of autophagy by Atg5 siRNA resulted in an inhibition of 
soft agar growth, a measure of tumorigenic potential.244 In cell lines with activated Ras, 
a strong oncogene, autophagy was necessary for the quick growth and high metabolic 
needs of tumor cells. These cancer cells were described as “addicted to autophagy,” and 
the phenomenon was consistent amongst several Ras-activated cell lines (e.g. T14, 
H1299, and CHT116). These data suggest that in quickly growing tumors, autophagy 
inhibition may sensitize the cells to death thus enhancing available treatment 
options.245 This study provides primarily in vitro evidence of a role for autophagy 
induction in supporting tumor growth. 
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Heart disease  
Coronary heart disease (CHD) is the leading cause of death of men and women in 
the United States. CHD is caused by narrowing of the arteries that supply the heart. In 
mouse models a standard treatment is to induce an ischemic event by surgically 
occluding one or more coronary artery. This occlusion may be relieved at a later time 
(ischemia/reperfusion) or remain (permanent occlusion). Interestingly, autophagy is 
induced in both ischemia/reperfusion (I/R) events and permanent occlusion events but 
the outcomes are differential. During I/R events autophagy is activated, however in 
Becn1+/- mice damage was reduced indicating that induction of autophagy was 
maladaptive during reperfusion.246 Conversely, autophagy appears to be protective 
during permanent occlusion events. Long term ischemia causes relief of mechanistic 
target of rapamycin (MTOR) inhibition of autophagy, thus leading to autophagy 
induction. In concordance with this, expression of a dominant negative MTOR regulator 
resulted in a reduction of autophagy and subsequent increase in cardiac damage.247 Two 
recent mouse models of heart disease provide evidence supporting a protective role of 
autophagy for the prevention of CHD.248 Razani et al provided evidence that autophagy 
prevented cholesterol crystal-induced inflammation that normally can lead to 
atherosclerosis. Since high fat diets have been shown to inhibit autophagic flux, 
competent autophagic flux may be necessary for the prevention of CHD. 249  
In addition to CAD, congenital mutations and other pathological conditions (e.g. 
type 2 diabetes) my result in cardiomyopathies. In a recent study, Choi et al showed that 
in a cardiomyopathy model resulting from a mutation in A-type lamins (A/C) resulted in 
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active MTOR in cardiomyocytes, which inhibited autophagy activation.250 This lack of 
autophagy activation was proposed to lead to an energy deficit and was detrimental to 
the survival of the cardiomyocytes and resulted in disease progression. Further evidence 
of the protective role of autophagy was obtained when autophagy was reactivated by 
the MTOR-inhibiting drug rapamycin. In mice mutant for A-type lamins, rapamycin 
treatment attenuated the cardiomyopathy phenotype. In another approach, a mouse 
model of diabetic cardiomyopathy, generated by diet alteration to include a surplus of 
saturated fatty acids, has revealed that autophagy was activated in response to pressure 
increase resultant from cardiac hypertrophy. Autophagy induction was measured by 
increased Becn1 and LC3B mRNA, as well as increased GFP-LC3 puncta in the diabetic 
hypertrophy model. In this system, isolated cardiomyocytes that were autophagy 
impaired did not develop hypertrophy, indicating that increased autophagy was 
required for hypertrophy. Furthermore, isolated cardiomyocytes treated with myristate 
led to an increase in BECN1 and ATG7 expression through a ceramide-dependent 
mechanism.251 The role of autophagy is complex and seems to be highly context specific 
with regard to heart disease. It is apparent that the method by which autophagy is 
inhibited or induced and in which type of model differentially dictates whether 
autophagy will result in a positive or negative outcome. 
Neurodegenerative diseases (e.g. Alzheimer’s and Parkinson’s disease) 
Post-mitotic neurons rely heavily on basal autophagy to clear old, damaged 
organelles and potentially harmful protein aggregates. Several neurodegenerative 
disorders result from expansions of poly-glutamine or poly-alanine stretches, including 
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Huntington’s disease, Parkinson’s disease, spinocerebral ataxias, and fronto-temporal 
dementia. Mutant proteins involved in these diseases have an increased propensity to 
aggregate and poison the cell; accordingly, the disease progression is directly related to 
the amount of protein aggregates formed in these patients. In normal physiology, 
neurons rely on both the proteasomal degradation system and autophagy to maintain 
protein and energy homeostasis. It has been shown that autophagy is used 
preferentially to remove large aggregated proteins or multiprotein plaques. In a rat 
model of Machado-Joseph disease (spinocerebral ataxia type 3) overexpression of 
BECN1 reduced both mutant ataxin-3 accumulation and ubiquitin-positive inclusions.252 
It seems that autophagy is used as a compensatory mechanism to relieve the toxic 
effects of these mutant protein aggregates in the cell, serving a protective role. 
Neuronal-specific conditional deletion of Rb1cc1 (Rb1cc1fl/fl; nestin-Cre) resulted in 
dystrophy (axonal swelling), neurodegeneration, accumulation of polyubiquitinated 
proteins, damaged mitochondria, and neuronal death. When compared to Atg5/Atg7 
neuronal conditional deletion models, the Rb1cc1-/- phenotypes were more severe, 
present at an earlier age, and resulted in premature death. Unique to the Rb1cc1-/- 
conditional knockout mice is the development of diffuse brain spongiosis, observed as 
early as 2 weeks of age, and associated with ubiquitin positive inclusions, indicative of 
impaired clearance of cytotoxic proteins by autophagy.253 Targeted deletions of either 
Atg5 or Atg7 resulted in the accumulation of polyubiquitinated proteins and sensitized 
neurons to degeneration; supporting the hypothesis that autophagy is 
neuroprotective.203, 206 Purkinje cells (PC) reside within the gray matter at the interface 
 66 
 
between the molecular and the granular layers of the cerebellar cortex and are 
important for signal integration, balance, and motor coordination. PC-specific 
conditional deletion models of Atg7 (Atg7fl/fl; pcp2-Cre) resulted in PC dystrophy and 
subsequent axon terminal degeneration. PC degeneration was followed by PC death and 
behavioral changes in the mutant mice.237 In a similar experiment, deletion of Atg5 in 
PCs (Atg5 fl/fl; pcp2-Cre) also resulted in axonal swelling and neurodegeneration.204 
Although both the nestin-Cre and pcp2-Cre have been employed as useful tools to 
investigate the result of tissue-specific autophagy loss, one important difference is that 
nestin-Cre is also expressed in some astrocyte populations as well as other CNS 
structures, while pcp2-Cre is restricted to PCs. This difference may alter the 
experimental designs, as nestin-Cre is more appropriate for diffuse CNS ablation studies 
and pcp2-Cre is more Purkinje cell-specific. 
Aging 
Autophagy and its association with aging have been explored in two distinct 
contexts: 1) the impact of autophagy on increasing lifespan or longevity, and 2) the role 
of autophagy in age-related disease states. Longevity‑promoting regimens, including 
caloric restriction (CR) and inhibition of TOR with rapamycin, resveratrol or the natural 
polyamine spermidine, have been associated with autophagy induction.254 CR can 
improve heart function through autophagy, as long-term CR preserved cardiac 
contractile function with improved cardiomyocyte function and lessened cardiac 
remodeling.255 Rapamycin prolonged median and maximal lifespan of both male and 
female mice when fed beginning at 600 days of age; this supplementation led to a life 
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span increase of 14% for females and 9% for males. In addition, rapamycin-treated mice 
beginning at 270 days of age also increased survival in both males and females.256 
Lifelong administration of rapamycin extended the lifespan of female 129/Sv mice, as 
22.9% of rapamycin-treated mice survived the age of death of the last control mouse. 
Rapamycin also inhibited age-related weight gain, decreased aging rate, and delayed 
spontaneous cancer formation.257 Although rapamycin and caloric restriction both 
increase the life span of mice, they probably do not occur through similar mechanisms. 
Dietary restricted mice (40% food restriction) and rapamycin-treated mice both 
exhibited increased levels of autophagy.258 The fat mass was similar between control 
and rapamycin-treated mice, but lower for the caloric restricted mice. There were also 
striking differences in insulin sensitivity and expression of cell cycle and sirtuin genes in 
mice fed rapamycin compared with dietary restriction. Spermidine, a natural polyamine 
whose intracellular concentration declines during human aging, extended the lifespan of 
yeast, flies and worms, and human immune cells. In addition, spermidine administration 
potently inhibited oxidative stress in aging mice.58 
Basal autophagy helps to reduce the deleterious effects from oxidative stress, 
heat stress and cytoplasmic protein aggregates. During the aging process, basal 
autophagy levels gradually decline so that the cell is not equipped to deal with these 
stressors. Since many age-related diseases correlate with a decline in basal autophagy, a 
targeted therapeutic strategy would be to increase the levels of productive autophagy 
to reduce the severity of the disease. However, it is important to keep in mind that a 
tight regulation of basal autophagy levels is important, as too much autophagy could 
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have a negative outcome. For example, in the Zmpste24-null progeroid mice, which 
model the human laminopathy Hutchinson-Gilford Progeria Syndrome (HPGS), there 
was an increase in autophagy instead of the anticipated reduction that occurs during 
normal aging. Although autophagy levels were similar to those found associated with 
caloric restriction and prolonged lifespan, in this instance autophagy was linked to 
having a potential role in the premature aging phenotype. However, these mice also 
have several metabolic alterations including changes in circulating hormones (e.g. 
leptin, insulin, adiponectin) and glucose levels that probably impact additional 
contributing cellular processes.259 Progerin, the truncated form of lamin A protein, was 
found to co-localize with the autophagic adapter protein SQSTM1 and the autophagy 
linked FYVE protein, ALFY.260 Moreover, rapamycin decreased Progerin protein levels 
through autophagy induction, which rescued the Progeria phenotype in HGPS 
fibroblasts.261 Rapamycin-induced autophagy has therapeutic implications for other 
types of laminopathies as well. For example, Lmna-null (lamin A-deficient) mice 
exhibited skeletal muscle dystrophy and cardiac hypertrophy; these pathologies were 
improved through rapamycin administration.262 An oxidative environment potentially 
plays a crucial role in the aging process, as Sqstm1-/- mice exhibited accelerated aging 
phenotypes and tissues displayed elevated oxidative stress due to defective 
mitochondrial electron transport.263 Likewise, Cisd2-null mice exhibited nerve and 
muscle degeneration and a premature aging phenotype.264 CISD2, the gene responsible 
for Wolfram syndrome 2 (WFS2), encodes for a mitochondrial protein involved in 
mammalian life-span control. Although mitochondrial degeneration was exacerbated 
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with age with a concomitant elevation of autophagy, this elevation was most likely due 
to a cellular response of mitophagy to clear damaged mitochondria. In addition to 
induced-mutation mouse models, there have been several different naturally occurring 
strains of senescence-prone (9 lines) and senescence-resistant (3 lines) mice that have 
been developed since the 1970s at Kyoto University in Japan.265 These mice have been 
important to model aging, senile dementia, and Alzheimer’s disease. By 12 months of 
age, the senescence accelerated mouse prone 8 (SAMP8) mice demonstrated a decline 
in cognitive ability that corresponded to increased levels of ubiquitinated proteins and 
autophagic vacuoles (AV) in hippocampal neurons, and decreased expression levels of 
Becn1.266 In contract, the senescence-resistant strain did not show an accumulation of 
these autophagic vacuoles. In the future, it would be interesting to examine whether 
calorie restriction or rapamycin administration could reduce the accumulation of 
ubiquitinated proteins and improve learning and memory in the senescence-prone 
model. 
Lysosomal storage disorders 
The group of degenerative disorders included in umbrella term lysosomal 
storage disorders (LSDs) is a heterogeneous and emerging list of diseases that 
commonly present with an inability to metabolize a normal cellular substrate. The 
metabolic defect may reside with the ability of the lysosome to degrade the substrate, 
or a blockade of autophagic flux, most often inhibiting fusion of the autophagosome and 
lysosome. A reduction in autophagic flux may result in an increase in autophagosome 
like structures in the cytoplasm as well as uncharacteristically large autophagosome like 
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structures being formed. Consequently, failure to eliminate/recycle the autophagosomal 
contents induces cellular stress and may result in death. 
Pompe disease, the first LSD to be characterized, is caused by an inability to 
synthesize acid α-glucosidase (GAA), a lysosomal enzyme needed to breakdown 
glycogen. Pompe mice (GAA KO) phenocopied the human condition, and abnormal 
autophagosomal and autolysosomal structures were seen intracellularly. When Pompe 
mice were crossed with Atg5/7 muscle-specific conditional knockouts to inhibit 
autophagy, mice metabolized glycogen more efficiently than the Pompe mice and had a 
more positive prognosis. In this model system, autophagy was contributing to the 
pathology of the disease and inhibition of autophagy was been shown to be a useful 
therapeutic intervention. A side effect of muscle-specific autophagy inhibition, i.e. 
muscular atrophy, will be discussed in a later section. 
Multiple sulfatase deficiency (MSD) is a disease where affected individuals have 
a reduction in the activity of all sulfatases due to mutations in Sulfatase Modifying 
Factor 1 (SUMF1), an enzyme responsible for post-translational modification of all 
sulfatases. A sumf1 knockout mouse model shared characteristic manifestations of MSD 
including: skeletal abnormalities, kyphosis, and growth retardation. Impaired 
autophagosome-lysosome fusion was implicated, as a build-up of undigested material 
was detrimental to cellular homeostasis and led to death. Though models have 
exhibited that MSD is accompanied by defective autophagic flux, whether autophagy is 
protective or detrimental to the pathogenesis of the disease is unclear. 
 71 
 
Mucopolysaccharidosis type VI (MPS VI) is caused by a specific sulfatase 
deficiency (N-acetylgalactosamine-4-sulfate) and patients may be short in stature and 
suffer from joint stiffness and destruction, cardiac valve abnormalities and corneal 
clouding. In a rat model of MPS VI, an increased number of autophagic structures were 
identified by electron microscopy.267 
Niemann Pick type C disease is a metabolic disorder characterized by the 
accumulation of lipids in late endosomes/lysosomes. The vast majority of cases are due 
to mutations in the NPC1 gene. Npc1-/- mice had higher levels of autophagy proteins 
(LC3II) than controls, and PCs were preferentially affected exhibiting an increase in 
autophagic vesicles by electron microscopy. Npc-/- mice had the ability to form 
autophagosomes but were defective in autophagosome- lysosome fusion, which 
resulted in a functional autophagic block and inability to metabolize cargo.268 
Mucolipidosis type IV disease (MLIV) is caused by mutations in the MCOLN1 gene 
which encodes a lysosomal cation channel. Affected patients suffer from psychomotor 
delays and multiple ophthalmic pathologies. The Mcoln1-/- mouse model recapitulated 
most of the symptoms observed in patients with the exception of corneal clouding. In 
Mcoln1-/- brains, lysosomal inclusions were observed in several anatomical areas and 
cell types.269 Neurons had increased LC3-II expression and failed to clear LC3-II, once 
again indicating a functional autophagic block that led to the pathogenesis.270 
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Infectious disease and immunity (e.g. Crohn’s disease) 
The innate immune system is the first line of defense against pathogens; it is 
evolutionarily more ancient than the adaptive immune system and is deployed quickly 
and effectively despite its lack of pathogen specificity or memory. Viruses, bacteria, and 
parasites can be eliminated in an autophagic process involved in innate immunity 
defense termed ‘xenophagy.’ Invading bacteria can generally be classified as vacuolar 
(e.g. Salmonella) or cytosolic (e.g. Listeria, Shigella). Cytosolic bacteria can undergo 
ubiquitin-dependent and ubiquitin-independent mechanisms for autophagosomal 
envelopment followed by translocation to lysosomes. Vacuolar bacteria can be routed 
into autophagosomes, or in the instance of Mycobacteria, autophagy proteins can 
resume the maturation of the vacuole and promoter fusion with the lysosome. The main 
recognition receptors that link detection and autophagy induction include the 
membrane TLRs (Toll-like receptors) and the cytoplasmic nucleotide-binding 
oligomerization domains (NOD)-like receptors (NLRs). The receptors can recognize the 
lipopolysaccharides (LPS) and peptidylglycans of Gram-negative bacteria. Microbial 
interference with autophagy can occur due to the adaptive nature of bacteria. For 
example, Shigella flexneri secretes the protein lcsB, which prevented ATG5-induced 
autophagy at the bacterial surface. Yersinia pseudotuberculosis resides within arrested 
autophagosomes in macrophages, since it can inhibit the fusion process with 
lysosomes.92, 111 
The more complicated adaptive immune system also relies on autophagy in 
many capacities. Studies inducing ablation of autophagy proteins have revealed an 
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essential role for autophagy in maintaining normal numbers of B cells, T cells and 
hematopoietic stem cell survival and function. Atg5- and Atg7- deficient models have 
shown that autophagy was important for T cell survival and maintenance of 
mitochondria. An increase in mitochondrial mass has been correlated with T cell death 
in circulating T cells, indicating a potential mechanism of action.271 Thymic epithelial 
cells have a high rate of basal autophagy compared to other cell types. During T cell 
selection thymic epithelial cells display decorations of “self” and “non-self” antigens, 
aiding in this process autophagy is proposed to facilitate ligand (MHC-II molecule) 
loading. When autophagy was depleted specifically in thymic epithelial cells, the mature 
T cell repertoire was diminished due to alterations in positive and negative T cell 
selection processes. Interestingly, severe colitis, patches of flakey skin, atrophy of 
uterus, absence of fat pads and enlargement of lymph nodes were observed in many 
cases. Inflammation was observed in the colon, uterus, lung and Harderian gland of 
recipient mice. These manifestations are indicative of autoimmune diseases and this 
model provides a clear linkage between autophagy and autoimmune/inflammatory 
diseases.272 A B cell-specific ablation of Atg5 was achieved by either a Cre-LoxP 
approach (Atg5fl/fl; CD19-Cre) or by repopulating irradiated mice with progenitor cells 
derived from an Atg5-/- fetal liver. In these experiments, autophagy was found to be 
essential for the survival of pre-B cells (after the pro-B cell to pre-B cell transition). 
Additionally, in peripheral circulation Atg5 was required to maintain normal numbers of 
B-1a B cell populations but not B-2 B cells.273 
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Genome wide association studies of Crohn’s Disease identified two autophagy 
associated genes, Atg16L and IRGM. A naturally occurring insertion/deletion mutation 
was identified in the 5’UTR (untranslated region) of IRGM (immunity-related GTPase 
family, M) which disrupted a transcription factor binding site.274 In another study, a SNP 
in the coding region of IRGM was identified that affected a microRNA binding site.275 
These identified mutations suggested that IRGM expression level changes were 
associated with Crohn’s disease in humans. A mouse knockout model of Irgm1 (a.k.a. 
LRG-47) has been developed and does not display any overt phenotype, including 
development of the immune system. However, when challenged with infection, Irgm-/- 
mice were unable to control the replication of intracellular pathogens.276 Unfortunately, 
the Irgm1-knockout mice have not been investigated specifically in the context of 
autophagy function in immunity to date. However in parallel with in vitro data, IRGM1 
has recently been shown to induce autophagy in a mouse model of stroke. The 
promotion of autophagy, most likely at the level of LC3I to LC3II conversion, was 
generally protective.277 
The relationship between Crohn’s disease and the autophagic process is more 
developed in terms of investigating the Atg16L risk allele association by using two 
Atg16L gene trap models and an intestinal epithelium-specific Atg5 knockout (Atg5fl/fl; 
villin-Cre). Both Atg16L gene trap models (HM1 and HM2) result in a hypomorphic 
expression of Atg16L protein. Interestingly, in the Atg16L mutants Paneth cells exhibited 
abnormal morphology including decreased granule number and disorganization of 
granules. Researchers concluded that autophagy was required to maintain fidelity of the 
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Paneth cell granule exocytosis pathway. When challenged with infection, the Atg16L 
hypomorphs performed similarly to controls. In Atg5fl/fl; villin-Cre ileum, abnormal 
Paneth cells were identified which paralleled to those identified in the ATG16L mutants. 
Human ileum samples from at risk patients were examined and also exhibited abnormal 
Paneth cell morphology.198 It is noteworthy at this point to mention that genome wide 
association studies for ulcerative colitis did not identify either of these autophagy genes, 
nor others. This suggests that Atg16L and IRMG are specific for the physiopathology of 
Crohn’s disease, not inflammatory bowel diseases generally. 
Muscle atrophy 
Muscle atrophy is a symptom of a multitude of pathological states including but 
not limited to fasting conditions, denervation, inactivity, cancer, cardiac failure, and 
diabetes. Autophagy has been shown to be active in muscular atrophy and other 
myopathies however due to the nature of the methods used it cannot be said with 
certainty whether autophagy is promoting atrophy or is activated as a cytoprotective 
mechanism and coincides with pathology. 
In a mouse tissue-specific mouse model generated to investigate the effect of 
superoxide dismutase 1 (SOD1) ablation on skeletal muscle, it was found that mutants 
developed muscle atrophy, reduction in contractile force and abnormal mitochondria. 
Significant upregulation of the mitophagy (specific and selective form of autophagy 
wherein mitochondria are preferentially enveloped and degraded) gene Bnip3, as well 
as, autophagosome marker LC3 were detected by RT-PCR, most likely as a result of 
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activation of transcription factor FoxO3. Oxidant accumulation in SOD1-/- mice resulted 
in muscular atrophy through autophagy; this phenotype was rescued by depletion of 
LC3 by siRNA knockdown suggesting that autophagy was the driving pathway of 
atrophy. These findings imply that autophagy inhibition is a potential therapeutic target 
for acute and chronic muscular atrophy.278 
Muscle-specific Atg7 conditional knockout mice were autophagy incompetent 
and morphologically diverged from wild type control littermates beginning at 40 days of 
age. Muscles of the knockout mice exhibited degenerative changes and a decrease in 
myofiber size; these abnormal changes were concurrent with the loss of muscle 
contractile force which further decreased with increasing age. Even more telling may be 
the ultrastructural changes associated with loss of autophagy in the muscles, 
abnormally large mitochondria, centrally located nuclei and dilated sarcoplasmic 
reticulum all observed via electron microscopy.279 
As discussed previously, a muscle-specific Atg5 knockout mouse was generated 
and bred onto a glycogen-degrading enzyme acid-alpha glucosidase knockout 
background (GAA-KO) to interrogate the nature autophagic degradation of glycogen in 
the pathogenesis of Pompe disease. This study provided additional evidence that 
autophagy functioned to prevent muscular wasting. Muscle-specific GAA-/-; Atg5-/- mice 
developed progressive muscular weakness and eventual paralysis beginning earlier (2-3 
months of age) and progressing more rapidly than autophagy-competent GAA KO mice. 
Ubiquitin-positive structures accumulated in both GAA KO and GAA-/-; Atg5-/- mice with a 
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differing distribution. In GAA KO myocytes, autophagic vesicles built up in the cell and 
ubiquitin-positive structures associated with the autophagosome. In GAA-/-; Atg5 -/- 
myocytes, ubiquitin-positive structures were distributed throughout the cell and 
appeared to associate with lysosomes, though were not membrane bound. These data 
indicated that the disruption of functional autophagy and accumulation of toxic 
ubiquitin-positive structures promoted muscular myopathy.280 
Stroke 
Cerebral ischemia is achieved in mice most often by surgical intervention and 
results in global, restricted, or cerebral directed ischemia depending on the method 
selected. Furthermore in some models ischemia is reversed, allowing reperfusion of the 
cerebral tissue. Autophagy is induced by hypoxia/ischemia events; however it is unclear 
whether autophagy is protective or maladaptive in stroke models. Responsibility of 
much of the dissenting opinions may be attributed to the variety of techniques used to 
induce ischemia events, these have been reviewed at length by Hossmann, see 
reference.281 Neonatal mice subjected to hypoxic/ischemic (H/I) brain injury responded 
with a robust autophagic response in neurons and hippocampal neuron death. Atg7-/- 
neonates, which are autophagy incompetent, were protected from hippocampal neuron 
death when subjected to identical (H/I) brain injury as control mice, indicating a 
neurotoxic role for autophagy induction.282 Conversely, in when wild type mice were 
subjected to H/I brain injury and reperfusion, damage was mitigated by intraperitoneal 
injection of NAD+. NAD+ administration inhibited autophagy induction. In the NAD+ 
treated group, a reduction of autophagy was correlated with a decrease in neuronal 
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damage. To further investigate this link, researchers subjected mice to H/I injury and 
treated them with 3- methyladenine (3-MA), an autophagy inhibitor, and an 
amelioration of neuronal damage was observed. These data indicated that in adults, H/I 
brain injury followed by reperfusion autophagy was maladaptive; furthermore, 
inhibition of autophagy at the time of reperfusion was neuroprotective 283. Moreover, in 
a rat ischemia model, inhibition of autophagy by Becn1- directed shRNA or 3-MA 
treatment led to a reduction in damage and neuronal loss in the ipsilateral thalamus. 
This study supported the hypothesis that autophagy induction increased damage when 
activated following an ischemia/reperfusion event.284 The variance amongst the model 
systems could account for much of the disparity seen in outcomes. The age of the 
individual, duration of ischemic event, and presence or absence of reperfusion is all 
potential modulators autophagic response. 
Type 2 diabetes 
Type 2 diabetes (T2D) is a complex disease that manifests in tissues, especially 
adipose, muscles, and liver, becoming resistant to insulin signaling and causing 
hyperglycemia. Pancreatic β–cells initially respond by increasing their production of 
insulin, but prolonged insulin resistance results in atresia of β–cells and a marked 
reduction in insulin production. Due to the high metabolic demands placed on β–cells it 
follows that autophagy would be play an important role in the pathophysiology of this 
chronic disease. In wild type C57BL/6 mice β–cells, unlike most organs, autophagosomes 
are sparingly observed after a period of starvation. However, when mice were fed high 
fat diets for 12 weeks, autophagosomes were readily observed. These results were 
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confirmed in vitro by treating INS-1 β–cells with free fatty acid (FFA), glucose, or 
tolbutamide. Cells treated with FFA had increased LC3II levels and observable 
autophagosomes while cells treated with glucose or tolbutamide (a drug regularly 
prescribed for T2D) did not show any significant change in LC3 conversion or 
autophagosome formation. To further investigate the link between autophagy and β–
cells, a β–cell specific Atg7-/- mutant mice was generated (Atg7fl/fl; Rip-Cre). As early as 4 
weeks, and degenerating in an age-dependent manner, enlarged cells with pale staining 
cytoplasm were identified near the periphery of Atg7fl/fl; Rip-Cre islets. Inclusion bodies 
were observed at a high frequency in the enlarged cells the presence of inclusion bodies 
increased with age, and deformed mitochondria were also observed in these enlarged 
cells. Resting blood glucose levels were higher and insulin secretion was reduced in 
Atg7fl/fl; Rip-Cre mice when compared to control Atg7fl/fl mice: these differences were 
amplified when control and Atg7fl/fl; Rip-Cre mice were fed high fat diets.285 In a related 
model, Marsh et al generated β–cells with a defective secretory pathway in Rab3A-/- 
mice. Although increased intracellular insulin levels were expected, this was not 
observed. Increased autophagy of the peptide hormone maintained the levels of insulin 
and prevented accumulation of potentially toxic cellular substrates.82 These 
experiments together suggested that β–cells depended on autophagy to clear damaged 
organelles and toxic intracellular protein aggregates. 
Reproductive infertility 
The role of autophagy during folliculogenesis is a comparatively new topic of 
study. In rats, LC3II expression was characterized in follicles of varying developmental 
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stages. Primordial follicles exhibited only weak expression, but antral follicles exhibited 
robust expression restricted to granulosa cells. Staining was not observed in the oocyte 
proper or theca cells in any stage follicle.286 In mice, expression studies also indicate a 
role for autophagy during folliculogenesis. An expression profile of Becn1 mRNA 
revealed significantly higher expression in primordial follicles than in other stages. 
Immunohistochemistry for BECN1 confirmed this result and consistent staining of 
granulose cells, theca cells and oocyte cytoplasm was seen in all follicular stages 
examined.287 Interestingly, when Becn1 or Atg7 is ablated specifically in the female 
germline (MMTV-CreA; Becn1fl/fl) or globally (Atg7-/-), fewer primordial follicles were 
present in the perinatal ovary. These results indicated that autophagy may be vital for 
survival of the primordial follicle pool, and be active during folliculogenesis and follicular 
atresia. In males it is well accepted that autophagy is responsible for post fertilization 
paternal mitochondrial clearance to prevent paternal mitochondrial DNA transmission; 
however, the role of autophagy during spermatogenesis is a field in its nascence. It has 
been shown in Arabidopsis that Becn1 was essential for pollen development.288 Also, 
autophagy induction in stallion sperm, as measured by LC3I to LC3II conversation, was 
important for the survival of sperm post ejaculation.289  
Conclusion 
A variety of mouse models have been established and interrogated to 
understand the implications of autophagy in human disease. These genetic-based 
models are primarily either reliant upon: 1) the generation of an autophagy-defective 
mouse to characterize a given disease state, or 2) the characterization of autophagy 
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within a pre-established murine model. As this review has shown, conditional knockout 
models have been extremely useful in disease profiling. The next wave of studies will 
invariably utilize inducible-based systems for conditional knockouts, genetic-based 
rescue experiments of disease models, or pharmaceutical-based modification of 
autophagy. A prevailing theme in the field is that autophagy can either be beneficial or 
deleterious depending on the disease and its progression state, a theme which must be 
addressed in designing and implementing appropriate treatment regimes. 
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Chapter Three: Post-pubertal mammary gland development: morphology and 
mechanisms 
Introduction 
This chapter has been published and is included here for completeness of the 
dissertation.290 
Interest in the mammary gland, the defining characteristic of the class Mammalia, 
has stretched across centuries. The primary function of the mammary gland across 
mammals is the nourishment of young; however additional functions, such as the 
transmission of immune factors to infants, are important in many species. It has been 
postulated that mammary glands arose evolutionarily from modified apocrine glands 
recently in evolutionary history, approximately 125-190 million years ago.291 Obtaining 
evidence for these theories has been technically challenging, since the soft tissue of 
mammary glands is not well preserved in the fossil record. However, we can gain insight 
from Monotremata, an order of ancient egg laying mammals that represents an 
interesting link to the reptilian past. The platypus and echidna are extant egg laying 
species that have functional mammary glands that undergo a true lactation phase. This 
lends support to the postulation that early apocrine secretions served some beneficial 
role to protect and/or nourish eggs via semi-permeable shells, thus selecting for the 
retention of these glands.291 While the evolutionary origin of the mammary gland is still 
being investigated and debated, developmental and molecular biologists have made 
astounding progress in elucidating the mechanisms controlling the development of the 
mammary gland in its current incarnation.  
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The mature mammary gland is an arboreal structure with ductal branches extending 
from a nipple area, colonizing a mammary fat pad, and finally branching and terminating 
into alveolar units. Mammary gland development is divided into four stages that align 
with the overall growth, sexual maturation and reproductive-associated changes of 
mammals, which are: embryonic, pre-pubertal, pubertal, and post-pubertal. The 
initiation of mammary development in embryos occurs during gestation with the 
establishment of the anlagen; however, the majority of development occurs in the adult 
animal. Branching and elongation of the ductal epithelium ensues at the time of 
puberty, with the expansion of the alveolar epithelium proceeding in response to 
pregnancy. However, terminal differentiation is not achieved until lactation. This 
periodic developmental profile is unique amongst tissues and lends the mammary gland 
as an excellent model to study branching morphogenesis and other developmental 
paradigms in an adult animal. Furthermore, the accessory nature of the mammary gland 
is ideal since it allows researchers to make otherwise deleterious mutations in this 
relatively large, and easily accessible tissue. Classically, post-pubertal development has 
been separated into four main stages: virgin, pregnant, lactation, and involution 
(schematically represented in Figure 3.1 and whole mounts in Figure 3.2). These stages 
will be discussed individually following a description of embryonic and pre-pubertal 
development.  
Fetal Development and Pre-Pubertal Development 
Although the focus of this chapter is post-pubertal development, it would be 
incomplete without a brief overview of embryonic and pre-pubertal mammary 
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development. In the interest of continuity, the mouse will be the primary focus of this 
chapter and only major developmental discrepancies will be addressed. In most studied 
mammalian species mammary lines, ridges of multi-layer ectoderm become visible on 
the ventral surface of the embryo running parallel to the anterior-posterior axis of the 
embryo between the limbs. The mammary lines, as anatomically evident structures, are 
controversial in the mouse; however, specific gene expression patterning corresponding 
to proposed mammary line location has been observed. Wnt10b can be detected in a 
restricted pattern and Wnt6 in a broader area just antecedent to the anatomical 
detection of anlagen presence.292 Histological analysis revealed a change in epithelia co-
localizing with the Wnt10b expression, specifically a change to multi-layered cuboidal 
epithelia from the surrounding squamous epithelia. In addition, the mammary line also 
has a characteristic dense dermis below it.292 In the mouse, the first visible surface 
feature of mammary development is five symmetrical pairs of mammary placodes at 
E11.5. Interestingly, unlike other models, the mouse placodes do not follow an anterior-
posterior developmental pattern. Instead, they proceed pairwise in the order, 
numbered anterior-posterior: 3, 4, 1 and 5, then 2. Mammary placodes retain their 
expression of Wnt10b, Wnt6, fibroblast growth factor (Fgf10), and Lymphoid enhancer 
binding factor 1 (Lef1), a WNT pathway effector. Lef1-/- embryos fail to develop placodes 
by E13.5, a phenotype shared by overexpression of Dkk1, a WNT pathway inhibitor.293, 
294 Studies on placode development by Mailleux et al revealed distinct signaling 
dependence. The thoracic placodes (1, 2, and 3) and the number 5 inguinal placode are 
dependent on FGF10/FGFR2b while placode 4 is independent of these signals.295 Of late, 
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bone morphogenic protein 4 (Bmp4) and T-box protein 3 (Tbx3) have also been shown 
to work synergistically to determine positioning of the mammary buds. For a more 
detailed review of signaling pathways involved in morphogenesis and associated 
mutants see references.296, 297 
After the buds become visible at E13.5, there is a brief resting phase during which 
very few cells are mitotically active. Beginning again at approximately E15.5 and 
persisting through gestation, each bud extends a small sprout and invades the 
mammary fat pad precursor. The sprouts are completed by the formation of a lumen 
and by E18.5 each duct has undergone branching and resembles a small ductal tree. The 
interaction of parathyroid hormone related peptide (PTHrP) and its receptor PTHR1 
drives the rudimentary ductal tree to branch. At the time of parturition, the immature 
mammary gland is comprised of approximately 10-15 small branches near the nipple.  
Puberty 
Mammary gland growth is isometric with the individual from approximately E18.5 
until puberty, wherein the development will resume under the control of hormones. 
The ductal tree is primarily established during puberty under the control of circulating 
hormones. These circulating hormones bind to receptors located in the pituitary gland 
and throughout the female reproductive system to initiate changes in gene expression. 
Estrogen receptor (EsR) and progesterone receptor (PR) are instrumental during this 
period and will be discussed in depth in sections that follow.  
At approximately 3-4 weeks of age the ducts become capped with mitotically active, 
club-shaped structures termed terminal end buds (TEBs). TEBs are composed of inner 
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“body” cells and outer, undifferentiated “cap” cells. The body cells differentiate into 
mammary epithelial cells. The cap cells ultimately differentiate into myoepithelial cells. 
The innermost layer of body cells undergoes apoptosis to form the hollow lumen. The 
programmed cell death rate in the presumed lumen is very high, with a rate far greater 
than that detected during involution when the entire gland undergoes remodeling.298 
TEB formation is dependent on the paracrine production of IGF-1 by stromal cells which 
respond to growth hormone, reviewed in reference.299 The TEBs vary both among 
glands within an animal and between animals at the same time point. The number 2 and 
3 glands have larger number and size of TEBs when compared to the number 4 inguinal 
mammary gland. The size difference of the TEBs is attributed to a larger number of cap 
cells rather than cell hypertrophy.300 Circulating estrogen (E2) stimulates allometric 
ductal elongation via TEB proliferation which terminates when the TEBs reaches the 
limit of the fat pad. Concomitantly, secondary ductal branches are formed off of the 
primary ducts by TEB division. After expansion of the ductal tree during puberty, TEBs 
are permanently replaced by terminal end ducts (TEDs) which are not mitotically active. 
TEDs are then surrounded by stroma with the center cells undergoing apoptosis. The 
resultant structure is a single layer of epithelia cells resting on a basement membrane. 
The gland remains in this mature virgin state until stimulation by pregnancy.  
Pregnancy and Lactation 
Pregnancy hormones stimulate further branching of the ductal tree, the 
development of the lobuloalveolar compartment, and the terminal differentiation of the 
secretory epithelia. The ducts are composed of three major layers; the most apical is a 
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single layer of cuboidal epithelial surrounding a hollow lumen, this layer is referred to as 
“luminal epithelia.” Basal to the luminal epithelia, specialized myoepithelial cell layer 
encircles the luminal epithelia; these cells contain smooth muscle actin and assist with 
ductal contraction and movement of milk during lactation. Beyond the myoepithelial 
cells, a tough laminin-enriched basement membrane separates the epithelia and the 
surrounding connective tissue with a layer of extracellular matrix (ECM) proteins 
including proteoglycans and glycoproteins.  
The epithelium of the alveoli is a single layer of squamous epithelium which is 
discontinuously surrounded by myoepithelial cells then finally a basement membrane. 
As pregnancy progresses, the myoepithelia becomes more discontinuous and the 
alveolar epithelium may contact the basement membrane directly. During late 
pregnancy, approximately pregnancy day 18.5, the alveolar epithelial cells produce milk 
proteins and lipids which are retained in the cells, causing them to appear more 
cuboidal or pyramidal due to the increased cytoplasmic volume. After the initiation of 
lactation, milk proteins and lipids are released into the alveolar lumen and the cells once 
again appear morphologically flattened. This is achieved in part by the contraction of 
the myoepithelial cells lining the alveoli in response to oxytocin. At this point, large milk 
fat droplets can be seen in the lumens. The alveoli continue to expand throughout 
lactation until the gland is completely filled. During the height of lactation, very few 
adipocytes can be visualized and the ratio of parenchyma to stroma is heavily weighted 
toward the parenchyma. The lactation phase will continue until the pups are weaned or 
gradually taper off as the pups begin to gain nourishment from other sources.301 The 
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pregnancy associated changes: ductal branching, lobuloalveolar development, 
proliferation, and differentiation are highly regulated processed. The signaling cascades 
responsible will be discussed at length in later sections.  
Involution 
Cessation of suckling, due to natural or acute weaning and milk stasis, results in the 
mammary gland remodeling to again resemble a resting, “virgin-like” state. Involution 
proceeds in two stages: the reversible stage and irreversible stage. The early, reversible 
stage is characterized by waves of apoptosis-mediated cell death. Transcriptional 
profiling studies have detected changes within hours of involution.302-304 Histologically, 
secretory epithelia cells are sloughed and seen in alveoli in greater numbers during early 
involution than in any other stage. Many of these cells are terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) positive, a marker for apoptosis that detects 
DNA fragmentation.305 It is estimated that during involution 80% of epithelial cells will 
die via apoptosis, a catastrophic event unparalleled in normal adult tissues. Many 
induced mutant mouse models generated exhibit involution phenotypes, see Radisky 
and Hartmann for review and references.306  
The second phase of involution is initiated approximately 72 hours post-lactation 
and is more drastic in nature. Once the gland has entered this phase, lactation cannot 
be re-initiated even if the pups are returned to the dam. The superfluous secretory 
alveoli collapse, the ECM is remodeled, and adipocytes increase in number. The 
irreversible phase is characterized by and dependent upon on a temporal increase in 
matrix metalloproteinase activity (MMPs) to stimulate ECM remodeling. Invasion of 
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immune cells, primarily phagocytic cells such as macrophages, helps to clear cellular 
debris.  
Autophagy most likely plays a role during mammary involution though at present 
this is poorly described in murine models. Autophagy, Greek for “self-eating,” is a highly-
conserved catabolic process initiated in response to cellular stress. In bovine, autophagy 
is observed morphologically and detected with molecular methods during involution. 
Additionally, pro-autophagic protein BECLIN1 has been shown to play an important role 
in mediating involution. It is clear that more work needs to be done to elucidate the role 
of autophagy during this stage in murine models.307-309 
Signaling Pathways 
Msx Family 
The class II homeobox, msh-like (Msx) genes, Msx1, Msx2 and Msx3, are common to 
vertebrates and often define mesenchymal-epithelia interaction sites. Msx3 expression 
is restricted to the dorsal neural tube310, while Msx1 and Msx2 are more broadly 
expressed during embryogenesis. Msx1 and Msx2, but not Msx3, are expressed at 
varying levels during every stage of mammary development except for pregnancy. 
During embryonic development Msx2 expression is detectable both in the epithelia and 
the mesenchymal cells, while after parturition expression is restricted to the 
mesenchymal cells in close proximity to mammary ducts. Msx2 expression is dependent 
on reciprocal interactions with epithelial cells. In cleared fat pads Msx2 is undetectable, 
indicating an essential epithelia interaction compartment for normal expression. Msx2 
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expression, but not Msx1, is regulated by E2 and progesterone (P4), indirectly via the PR 
and directly as a transcriptional target respectively.311 
Msx2 is implicated in the regulation of branching, as the in vitro overexpression of 
Msx2 is sufficient to drive branching. In addition, in vivo approximately one third of 
Msx2 null mice have arrested embryonic mammary gland development with failed 
ductal branching.312 Msx1 null neonates do not exhibit a mammary defect, which is not 
surprising since homeobox genes typically exhibit high levels of functional 
redundancy.313 However, double knockout Msx1/2 mice fail to form mammary anlagen 
with a complete penetrance of the phenotype.312 Mice that misexpress Msx1 in the 
mammary gland exhibit a reduction in pregnancy-induced differentiation and an 
increase of Cyclin D1 (Ccnd1) expression, and an increase in cell proliferation. This model 
supports in vitro experiments with Msx-1 overexpressing HC11 mammary epithelial cells 
which upregulate Ccnd1 expression and are unable to undergo functional differentiation 
in response to lactogenic hormones. The authors propose that Msx1 prevents exit from 
the cell cycle, which drives an upregulation of Ccnd1 expression; ultimately, this 
proliferative cell fate prevents the terminal differentiation of the epithelial cells.314 
Although Ccnd1 is the only verified target of Msx1 in the mammary gland identified to 
date, it can also be induced by Msx2 most likely in response to hormonal signaling by E2 
and P4. Interestingly, expression profiles of Bmp2 and Bmp4 closely resemble the 
profiles of Msx1 and Msx2, respectively. It has been suggested that this indicates a 
regulatory relationship, though the nature of this relationship is yet to be determined 
owing to the early embryonic lethality of Bmp2 and Bmp4 null mice.315  
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Lef1 
Lef1 is a nuclear target of the Wnt signaling pathway. In the presence of Wnt 
signaling, dephosphorylated β-catenin enters the nucleus and engages Lef1 to act as a 
transcriptional activator. Therefore, in the absence of Wnt signaling, Lef1 is a 
transcriptional repressor. Lef1 null neonates lack teeth, whiskers, and hair in addition to 
lacking mammary glands. Closer inspection of E13.5 embryos revealed a reduced 
number of mammary buds, indicating that the mammary rudiment develops 
improperly, arrests, and then regresses by the time of parturition. Since other visceral 
organs were unaffected, the defect seems to be specific to organs requiring epithelia of 
ectodermal origin to interact with surrounding mesenchyme.293 
Hormones 
Through both endocrine ablation studies and targeted mouse transgenic models it 
has been elucidated that E2, P4, and prolactin (PRL) drive the pregnancy-induced growth 
and differentiation of the mature mammary gland. P4 is an ovarian hormone secreted 
by a temporary endocrine structure within the ovary, the corpus luteum. PRL is a 
peptide hormone that signals through PRL receptors (two isoforms, PRLRA and PRLRB). 
Together, these hormones are responsible for initiating complex, and sometimes 
intersecting, gene pathways responsible for branching and alveologenesis during 
pregnancy. Transgenic mouse models have illuminated many of the signaling pathways 
that will be discussed in this chapter. For reference, a table has been included with a 
synopsis of the models discussed, see Table 3.1. 
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E2/EsR 
E2 is a steroid hormone with two characterized receptors, EsRα and EsRβ, which are 
members of the nuclear receptor superfamily. The canonical method of activation is: 1) 
ligand binding, 2) conformational change of receptor, 3) co-activator recruitment, and 4) 
dimerization and binding of receptor to estrogen responsive elements (EREs) in gene 
regulatory regions. Several ligand-independent, non-canonical pathways of EsR 
activation have been described but are beyond the scope of this chapter. The expression 
patterns of the two EsRs are distinct but overlapping, and EsRα is the dominant receptor 
type expressed in the mammary gland. Three knockout mouse models have been 
generated to study the importance of EsR in the overall growth and development of the 
organism. EsRαKO, EsRβKO, and EsRα/EsRβ double knockout (EsRαEsRβKO) mouse 
models are all viable and progress to adulthood without defects.316-318 EsRαKO, EsRβKO, 
and double knockout (EsRαEsRβKO) do not show defects in embryonic or pre-pubertal 
mammary gland development, but after puberty females exhibit ovulation failure 
resulting in infertility or subfertility (EsRβ). EsRαKO mice do not undergo the expected 
ductal elongation and expansion during puberty. The ductal tree remains sparse with no 
lobuloalveolar development occurring.319 Transplantation experiments of EsRαKO 
epithelia into wild-type cleared fat pads developed without defect to puberty as 
expected, but failed to undergo any development in response to pregnancy. This effect 
is epithelia intrinsic since the converse experiment; EsRαKO fat pad grafted into a wild-
type host with wild-type mammary epithelial cells grows normally and responds to 
pregnancy hormones.320  
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EsRβKO females are sub-fertile, yet develop normal mammary glands and are able to 
undergo a normal lactation phase.317 EsRαEsRβKO mammary glands phenocopy EsRαKO 
mammary glands, further underscoring the importance of EsRα in this tissue. EsR 
ablation causes defects in many reproductive tissues beyond the mammary gland and 
ovary, see reference for review.321 
The detection of residual expression from the EsRαKO necessitated the generation 
of a true null allele. To address this, the Cre-LoxP system was used to generate an EsRα 
floxed model for tissue-specific deletion strategies. Initially, a global Cre-mediated 
deletion was analyzed and the results phenocopied the EsRαKO model.322 An EsRβ 
conditional knockout based on the Cre-LoxP system has also been generated using a 
similar targeting strategy as was used to generate the conditional EsRαKO allele. LoxP 
sites were inserted flanking exon three of the EsRβ gene.323 Exon three was chosen to 
ensure a true null allele and effectually reconcile conflicting reports of phenotypes of 
the EsRβKO mice due to varying generation and housing conditions. In the context of 
the mammary gland, these models will be important to define the temporal 
requirement, if any, of EsR in pregnancy-induced mammary gland development. Using 
any one of the current mammary directed Cre transgenic models, EsR could be 
effectively attenuated at any point in the pregnancy cycle. 
As a supplement to many of the previously mentioned loss-of-function models, an 
inducible, EsRα model has also been generated using the tetracycline system. In this 
MMTV-tTA/tet-op-mEsRα model overexpressed EsRα, and administration of doxycycline 
turns off expression of EsRα.324 These recent models, will be invaluable in further 
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characterizing the role of EsR in reproductive development and in oncogenesis when 
used combination with current cancer models.  
P4/PR 
P4 is a steroid hormone produced primarily in the ovary and adrenal gland of 
females. Its activity oscillates with the estrous cycle and is required for the 
establishment and maintenance of pregnancy. P4 is a ligand for the PR, a nuclear 
receptor superfamily member. Once the ligand is bound the ligand/receptor complex 
translocates to the nucleus and affects transcriptional activity of target genes either 
directly or indirectly. The PR has two receptor isoforms, PR alpha and beta (PRA/PRB), 
which are splice variants of the gene Pgr.325, 326 The two receptors are structurally 
similar with the exception of an amino terminal extension of PRB.326, 327 
Since PR is under control of E2, a targeted approach to sort out the function of P4 
independent of E2 was needed. The PR knockout mouse (PRKO) is viable and shows no 
overt defects through embryogenesis or adulthood. As expected, female mice are 
infertile, due to the well characterized role of P4 in establishment and maintenance of 
pregnancy. However, a surprising role for P4 in the mammary gland was revealed. PRKO 
females produced a rudimentary ductal structure, indicating the P4 was not essential for 
ductal elongation, but failed to proliferate and undergo normal lobuloalveolar 
development and ductal side-branching in response to hormonal stimulation.328 This 
original characterization established a role for PR in normal mammary development and 
during pregnancy, but was insufficient to distinguish between systemic and local effects. 
To this end, several approaches have been taken to dissect the effect of PR in the 
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mammary gland. Transplantation experiments wherein mammary epithelia from PRKO 
mice were transplanted into wild-type recipients and vice versa revealed that intrinsic 
PR expression was essential in the epithelia for ductal outgrowth in response to 
circulating hormones and for lobuloalveolar development during pregnancy.329-332 A PR-
LacZ reporter helped to clarify the PR expression in both spatial and developmental 
contexts. During development, the activity is restricted to the epithelia; however, at 
puberty the activity is high in the body cells of the TEBs and ductal luminal cells. The 
localization pattern changed in the adult where the activity is clustered around the 
terminal ductal side branches, and all activity is reduced toward the end of pregnancy at 
the time of terminal differentiation.333 Interestingly, in the juvenile PR expression is 
uniform, but in the mature gland only sub-populations of mammary epithelial cells are 
PR positive, confirming earlier studies.334  
Isoform specific function was addressed elegantly with the generation of PRA and 
PRB-specific knockout alleles (PRAKO, PRKOB). The PRAKO did not show abnormal 
effects in the mammary gland, indicating that PRB was of greater importance in this 
tissue.335 This was confirmed with the PRBKO model that exhibited reduced ductal side 
branching and lobuloalveolar development during pregnancy.336 Importantly, this study 
also revealed an isoform specific activation of receptor activator of nuclear factor κβ 
ligand (RANKL) by PRB, the importance of RANKL in mammary morphogenesis will be 
addressed in another section focusing on receptor activator of nuclear factor κβ (RANK) 
signaling.  
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Two Cre-LoxP-based conditional PR knockout models have been produced allowing 
for greater spatial and temporal control of PR ablation. The models differ by targeting 
strategy, either exon 1 or exon 2 is flanked by LoxP sites, yet both produce homozygous 
null animals that phenocopy the original PRKO.337, 338 Additionally, a knock-in of the 
reverse tetracycline-dependent transactivator (rtTA) at the PR locus (driven by the 
endogenous PR promoter) has been helpful in identifying target genes of PR signaling.339 
These mice (PRrtTA/rtTA) phenocopy the PRKO model, and when treated with doxycycline 
PR promoter driven rtTA can induce expression of PR target genes in P4 responsive cells. 
This model combined with a reporter transgene allowed for the precise identification of 
PR responsive cells. In concordance with earlier studies, this model has confirmed the 
non-uniform pattern of PR expression in mature mammary epithelial cells, and has 
importantly clarified the role of RANKL as an effector of PR dependent side branching 
and alveologenesis.334, 339, 340 These models will be useful in separating tissue intrinsic 
functions from systemic effects of PR deficiency and are applicable to many studies of 
reproductive biology beyond the mammary gland. 
RANKL/RANK 
RANK is present on mammary epithelial cells and when activated by its ligand, 
RANKL, is a mammary PR effector which is essential for mammary proliferation and 
morphogenesis during pregnancy.341 In wild-type animals, RANKL is upregulated in 
response to P4 only in PR-positive cells, and PR-positive/RANKL cells cause proliferation 
in a paracrine fashion. This regulation was tested in vivo in a PRKO background with a 
conditional induction of RANKL targeted only to cells that would normally express EsR, 
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PR, and RANKL. With induction of RANKL by drug administration, the mammary defect 
observed in PRKO mice can be partially rescued.340 This study highlighted the 
importance of the spatial organization of PR positive cells and showed that when RANKL 
was induced in PR-negative and PR-positive cells, the ductal outgrowth and alveolar 
development was disorganized. RANKL/RANK leads to nuclear factor κB (NFκB) 
dependent transcriptional activation of Ccnd1, and disruption of RANKL or the 
components of this pathway result in a defect in alveolar proliferation.342 These studies 
are supported by the Ccnd1 knockout mouse which has reduced lobuloalveolar 
development during pregnancy and fails to lactate.343 
Recent evidence has revealed that RANKL serves as an intersection point between 
P4 and PRL signaling. Srivastava et al. suggest that RANKL is induced by both P4 and PRL 
signaling and is dependent on Janus kinase 2 (JAK2)/ signal transducers and activators of 
transcription 5a (STAT5a) signaling.344 Other points of intersection of P4 and PRL 
signaling and their potential consequences are reviewed in reference.345 RANKL 
regulates CCAAT-enhancer binding protein (C/EBP), to which we will now turn our 
attention. 
C/EBP 
Of the six C/EBP transcription factor family members, C/EBPβ’s three protein 
isoforms seem to be the most important for mammary gland development, though 
other family members are expressed.346 C/EBPβ is expressed throughout mammary 
gland development but is lowest in the virgin, increases during pregnancy, is reduced 
modestly during lactation, and then is increased again during the reversible phase of 
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involution.347 Ablation of C/EBPβ causes defects in ductal outgrowth manifested by 
enlarged ducts and decreased branching.348, 349 During pregnancy (transplantation or 
hormone supplementation experiments were required due to infertility of C/EBPβ-/- 
mice), ductal outgrowth occurred but lobuloalveolar development is negatively affected.  
Another family member, C/EBPδ, has an important function in involution. The 
C/EBPδ knockout mice exhibit a delayed involution phase characterized by a delay in the 
appearance of apoptotic cells, indicating a role in early involution, a time when C/EBPδ 
expression is highest in wild-type glands. Expression analysis revealed a reduction in the 
levels of pro-apoptotic BAX and BAK, and an increase in anti-apoptotic Bcl2l1. STAT3 is 
responsible for activating C/EBPδ at the initiation of involution. These results position 
C/EBPδ as a regulator of involution-induced cell death.350  
Cytokine Signaling, Stat6, and Alveolar Commitment 
STAT6 is unique amongst STATs in the mammary gland as it is important early in 
gestation and is not directly downstream of PRL signaling (discussed below). Classically, 
Stat6 has been characterized as a vital signaling molecule in the T helper (Th) cell 
lineage, specifically in the differentiation of Th2 cells. In this context, interleukin (IL) IL-
4/IL-13 binds its cognate receptor leading to activation of JAK1 and TYK2 which in turn 
facilitate recruitment and activation of STAT6. STAT6 forms homodimers which 
translocate to the nucleus activating or repressing IL-4/IL-13 target genes including 
GATA binding protein, 3 (GATA3), a transcription factor, reviewed in references.296, 351 
More recently, however, a new role for Stat6 regulating mammary alveolar cell fate has 
emerged. In two transgenic models interrogating this pathway, concomitant IL-4/IL-13 
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knockout or Stat6 knockout, resulted in curtailed alveolar development when compared 
to controls. Furthermore, in glands lacking SOCS5, a STAT6 inhibitor, accelerated 
development of the alveoli is observed.352  
Further support for this pathway’s importance in mammary gland proliferation and 
differentiation is provided by two studies centering on GATA3, a transcription factor and 
target of IL-4/IL-13/STAT6 signaling. In mice with a conditional deletion of GATA3 before 
the onset of puberty and continuously thereafter (MMTV-Cre; Gata3fl/fl), TEBs fail to 
develop punctually and the ductal epithelia does not invade the fat pad. At 8 weeks of 
age, a few TEBs are observed but these are unable to invade the fat pad. Additionally, 
the ducts that are present show a myriad of defects including structural defects and 
irregular ductal epithelia. Due to clonal expansion of GATA3-positive cells, the authors 
generated an acute, drug inducible Gata3 model wherein the rtTA-Cre is driven by the 
whey acidic protein (WAP) promoter (WAP-rtTA-Cre; Gata3fl/fl). These mice were 
administered doxycycline at 12 weeks of age and the drug was given for 14 days. By the 
fifth day of drug administration, defects in luminal epithelia were observed, reminiscent 
of those observed in the MMTV-Cre; Gata3fl/fl model. Importantly, in the GATA3-
deficient glands, luminal epithelia cells lost markers of differentiation and proliferated at 
a higher rate. Longer term deficiency led to cell death and defective lactation.353 A 
second study also reports similar phenotypes for GATA3 loss in the pre-pubertal gland. 
Two additional models are included in this study, a model of GATA3 deficiency in the 
mammary primordia (keratin14-Cre; Gata3 fl/fl), and one that causes loss GATA3 during 
gestation (WAP-Cre; Gata3 fl/fl). Embryonic loss of GATA3 in the mammary primordia 
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results in absent mammary placodes (one or more) and ablation of Lef1 expression in 
the expected areas of placode formation, though any placodes formed in the mutant 
animals also expressed Lef1. Loss of GATA3 during gestation results in defective 
lobuloalveolar development and lactation.354 These studies have indicated a clear role 
for GATA3 in formation of the mammary placodes in the embryo, ductal morphogenesis, 
maintenance of luminal cell differentiation in mature glands, pregnancy-stimulated 
lobuloalveolar development, and lactation. Based on these studies, the importance of 
the Th2 producing signaling pathway is important for mammary development, and adds 
more complexity to the tightly regulated PRL and P4 cell signaling that has been 
previously characterized.  
PRL and JAK/STAT Signaling 
PRL is a small peptide hormone produced primarily in the anterior pituitary, but may 
also be produced in other peripheral tissues. PRL historically has been characterized as a 
factor necessary for pregnancy-induced mammary alveolar development and lactation, 
for historical references see reference.355 PRL binds to the PRLR to initiate JAK/STAT 
signaling. PRLR dimerization causes activation of JAK2. JAK2 phosphorylates three target 
STATs depending on the stage of mammary gland development: STAT1, STAT3 and 
STAT5. Canonically, phosphorylated STAT forms dimers and then translocates to the 
nucleus. Dimers bind conserved, palindromic sequences (TTCNNNGAA) termed γ-
interferon activation sites (GAS), in gene promoter/regulatory regions to regulate the 
initiation of target gene activity. 
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PRL knockout mice (Prl-/-) are viable, but females are infertile and mammary gland 
development is defective, manifesting with a fully developed ductal tree devoid of 
lobuloalveolar units. Since the females are infertile, stages beyond the mature virgin 
gland were not analyzed.356 PRLR knockout mice fail to lactate and the glands appear 
poorly developed with few branches at maturity. Interestingly, multiparous females that 
are hemizygous for the PRLR knockout allele (Prlr+/-) regain mammary function, 
indicating a response to repeated hormone stimulation.357, 358 The next component in 
the cascade, JAK2, also has pleiotropic roles in both embryonic and post-natal 
development. 
Since the traditional Jak2 knockout mice (Jak2 -/-) die during embryogenesis due to 
defective hematopoiesis leading to severe anemia, a conditional knockout approach to 
study Jak2 in the post-pubertal mammary gland was warranted.359, 360 Wagner and 
colleagues developed a conditional deletion Jak2 model (Jak2fl/fl), and using two Cre 
transgenic strains (MMTV-Cre and WAP-Cre) showed that JAK2 signaling is necessary for 
both development of alveolar progenitor cells in mature virgin glands, as well as 
maintenance and survival of the secretory epithelium in pregnant mice.361 These 
functions are non-redundant and data indicates that STAT5 is activated only in a JAK2-
dependent fashion. 
The transcription factor STAT5 is produced by both Stat5a and Stat5b, two highly 
related genes derived from a recent gene duplication event.362 In mammary tissue, 
Stat5a is the more abundant and is responsible for 70% of STAT5 present.363 During late 
pregnancy and lactation, phosphorylated STAT5 increases precipitously, most likely due 
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to its activation of β-casein and WAP, genes that increase dramatically in preparation for 
lactation. Knockout studies have revealed independent and overlapping roles of Stat5a 
and Stat5b. Mammary glands from Stat5a knockout females (Stat5a -/-) fail to develop 
characteristic lobuloalveolar structure and exhibit a complete lactation failure during 
the first pregnancy.364 It is important to note that even though Stat5a and Stat5b share 
96% similarity, Stat5b does not compensate, indicating either an independent function 
or independent regulation.363 After multiple rounds of pregnancy, lactation phase is 
sustained, which may be attributed to a late compensatory increase in Stat5b.365 Stat5b 
knockout mice are viable and fertile, the mammary glands appear normal, and the 
primary reported defects are ablation of sexually dimorphic growth differences and 
liver-specific gene expression.366 Stat5a/b double knockout mice are infertile due 
ovarian dysfunction, specifically defective corpus luteum formation. Owing to the 
aforementioned infertility phenotype, Teglund et al. were unable to study the effects on 
mammary gland development but were able to conclude that either individually or 
cooperatively Stat5a and Stat5b mediate essentially all PRL and growth hormone 
dependent development.367 In effort to investigate Stat5a/b null mammary 
development, Stat5a/b null glands were transplanted into wild-type recipients. These 
glands developed a ductal tree but did not undergo alveolar morphogenesis, indicating 
that STAT5 is necessary for the proliferation and differentiation of mammary alveoli.368  
The role of STAT3 in the mammary gland is best characterized as a harbinger of 
death, as phosphorylated STAT3 increases dramatically at the onset of involution (within 
12 hours) and precedes the wave of post lactation apoptosis and alveolar collapse.369, 370 
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The involution-associated cell death is dependent only on local factors such as 
mechanical stress due to milk stasis.370 STAT3 activation is dependent on several 
secreted factors, namely leukemia inhibitory factor (LIF)371, 372, serotonin 373 and TGF-
β3.374 Stat3 null animals die during early embryogenesis (E7.5), with the lethality 
attributed to a defect in visceral endoderm function.375 Conditional deletion of Stat3 in 
the mammary gland, driven by either WAP-Cre or β-lactoglobulin- Cre (BLG-Cre), both 
result in delayed involution and an extension of the reversible phase.376, 377  
Of late, the mechanism of cell death during early involution is being revisited due to 
the observed delay in TUNEL positivity of shed cells, and cell morphology that does not 
align with classical apoptotic condensation, fragmentation, and membrane blebbing. 
Recent work from the lab of Christine Watson suggests that the cell death is a STAT3-
driven, cathepsin-dependent and executioner caspase-independent, lysosomal-
mediated programmed cells death.378, 379 This study necessitates re-evaluation of 
foundational literature and warrants further and more directed attention.  
The level of STAT1 remains constant throughout the pregnancy cycle; however, 
active STAT1 is detected in the virgin gland and in the late involution gland. This pattern 
of pSTAT1 is a unique amongst STATs and the inverse of the pSTAT5 profile.370, 377 No 
clear role has been defined for Stat1 in mammary development, and Stat1-/- mice are 
viable showing no overt developmental or mammary gland defects.380  
Cell Death Signaling 
It is currently thought that of the cells that die during involution, the vast majority 
die by the classical apoptotic pathway. Apoptosis is a highly regulated, well described 
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process wherein a cascade of intracellular signaling is initiated in response to an 
extrinsic or intrinsic signal. It is thought that a balance of pro-apoptotic and anti-
apoptotic factors determines cell fate. The Bcl2 protein family namesake, anti-apoptotic 
Bcl2, is not expressed during lactation or early involution, but its expression increases in 
late (>10 days) involution. Based on this expression profile it is not surprising that Bcl2 
knockout mice do not exhibit a gross mammary defect. Global ablation of Bcl2 (Bcl2-/-) is 
not lethal, resulting in small, hypopigmented mice with polycystic kidney disease.381 
Overexpression of Bcl2 driven by the WAP promoter results in a delayed involution.382 
Studies have revealed that Bcl2l1 is expressed at higher levels than Bcl2 in many tissues 
during development and in the adult, including the mammary gland.383, 384 The 
traditional knockout (Bcl2l1-/-) is not viable and dies embryonically due to excessive 
apoptosis of immature erythroid cells in the fetal liver.385 This model provided valuable 
information regarding the role of Bcl2l1 during development, but the embryonic 
lethality was prohibitive to study the role of Bcl2l1 in mature tissues. As a result two 
conditional, mammary specific Bcl2l1 knockout mouse models (WAP-Cre; Bcl2l1fl/fl, 
MMTV-Cre; Bcl2l1fl/fl) were generated. Bcl2l1 deficient mammary epithelia tissue 
exhibited an accelerated involution, a phenotype characterized by an increase in 
apoptosis, indicating that Bcl2l1 is necessary for cell survival during early involution.386  
Pro-apoptotic factors include Bcl2 family members Bax, Bad, and Bak among others. 
Bax mRNA is highest at the lactation to involution transition and three splicing products 
are produced, however the protein level is unchanged.387 Bax deficient mice intuitively 
exhibit hyperplasia in some cell lineages (e.g. B cells, thymocytes); however, 
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counterintuitively males are infertile due to the absence of mature sperm and abnormal 
mammary development has also been reported.388, 389 Loss of Bax delays involution, 
while overexpression of BAX in the mammary secretory epithelia in a WAP-Bax model 
results in a lactation defect as well as forced involution based on an increase in 
apoptotic cells and precocious Stat3 activation.387, 390 Bak and Bad are present 
throughout pregnancy and remain expressed highly through involution. It is 
hypothesized that the mammary gland is persistently poised to trigger involution and it 
is the balance of pro-apoptotic and anti-apoptotic factors determines lactation to 
involution transition.387, 391  
The nature of cell death signaling that occurs throughout the developmental cycle of 
the mature mammary gland is complex. In many cases canonical functions of proteins 
are observed, but many surprising roles have been elucidated using transgenic 
technologies. 
Conclusion 
The mammary gland is a dynamic organ that is reliant upon hormones, growth 
factors, and epithelial-stromal interactions to regulate well-established cell signaling 
pathways that orchestrate highly regulated developmental programs. These events span 
from mid-gestation into adolescence and through adulthood, when terminal 
differentiation occurs within a cyclical pattern of growth and regression that is linked to 
reproduction. Due to the accessory nature of the gland, ease of accessibility, and 
transplantation potential, the mammary gland is a powerful model to characterize the 
genetics behind organ development and cell differentiation. In addition to its relevance 
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in modeling normal development, the mammary gland is also essential in profiling 
breast cancer, neonate immunity, ageing and stem-cell based regeneration. The 
blossoming of mouse transgenic technologies over the past twenty years has led to 
breakthroughs in the understanding of the underlying mechanisms controlling 
mammary gland development. The early endocrine ablation studies that revealed the 
pituitary and ovarian control of mammary gland development eventually led to 
genetics-based approaches to further characterize these processes. Genetic engineering 
has advanced from gain-of-function studies to knockout strategies, giving way to the 
current state of conditional (Cre-LoxP, Flp-FRT) and inducible (tet-on, tet-off) models. 
This increased specificity for inducing mutations has allowed researchers to investigate 
gene and signaling pathway contributions at restricted developmental stages. Although 
the genetic tools will continue to expand and increase the array if potential applications, 
technology is but a tool to address the basic biological questions that remain in the field. 
What is the nature of the crosstalk between the hormonal receptors? Which, if any, of 
the other immune cell lineage pathways are relevant for mammary cell lineage 
commitment? What are the specific regulatory mechanisms at work regulating the 
upregulation of target genes controlled by multiple transcription factors? How do 
microRNAs regulate the developmental program of the mammary gland? How do 
apoptosis and autophagy interact to promote regression during involution? How does 
the methylation state of DNA and histones impact development? These questions and 
many others will continue to propel this field in the coming years. 
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Figure 3.1 Schematic overview of mouse mammary gland development and major 
influencing factors. Mammary gland development is typically divided into embryonic, 
perinatal, puberty and adult stages. After sexual maturity pregnancy induced changes 
drive the terminal differentiation of the gland. These stages are pictured; pregnancy, 
lactation and involution. Many of the influential molecules discussed in this chapter are 
included in the figure above the developmental stage/process to which they are 
integral. Major developmental stages are depicted schematically; stage labels are below 
mammary glands and process labels are below arrows. 
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Figure 3.2 Anatomic overview of mouse mammary gland development at four stages. 
Whole-mounts were taken of mouse mammary glands at four distinct developmental 
stages: A) virgin 5-week-old glands; B) pregnancy day 14; C) lactation day 1; and D) 
involution. Epithelial cells stain with the dye carmine alum, whereas the surrounding fat 
pad is cleared. Notice in the virgin gland the formation of the ductal tree, as the 
epithelia migrate into the surrounding fat pad. Representative terminal end buds (TEBs) 
are shown with arrows. Lymph nodes (LN) are shown for orientation in all figures. 
Images were taken on an Olympus SZ-PT using 6.7X magnification and the imaging 
software QCapture Pro 6.0. 
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Table 3.1 Transgenic mouse models and mammary phenotypes observed   
 Genotype Mammary phenotype Reference 
Embryo    
Lef1 lef1 
-/-
 No placode formation 293 
Dkk1 K5-rtTA/tetO-
Dkk1 
(overexpression) 
No placode formation 294 
Msx1 msx1
-/-
 No phenotype 313 
Msx2 msx2
-/-
 1/3 of embryos arrest 
mammary development 
before ductal 
branching/perinatal 
lethality 
312 
Msx1/Msx2 msx1/msx2
-/-
 Anlagen fail to form 312 
Puberty    
Esr1 EsRα-/- 
 
No ductal side-branching 
or lobuloalveolar 
development 
316, 319 
 deleter-Cre; EsRαf/f No data 322 
 MMTV-tTA/tet-
op-mEsRα 
Toolbox/kinetics study 324 
Esr2 EsRβ-/- No phenotype 319,317 
 CMV-Cre; EsRβf/f No phenotype 323 
Esr1/ Esr2 EsRα-/-; EsRβ-/- same as EsRα-/- 318 
Cebpb (C/EBPβ) cebpb-/- Enlarged ducts/decreased 
side-branching 
348,349 
Pregnancy/Lactation    
Msx1 (overexpression) Reduction in 
differentiation/increase in 
proliferation 
314 
Pgr PR
-/-
 No ductal side-branching 
or lobuloalveolar 
development in response to 
hormonal stimulation 
328 
 PRA
-/-
 No phenotype 335 
 PRB
-/-
 Reduced ductal side-
branching and 
lobuloalveolar 
development 
336 
 ZP3-Cre;PR
f/f
 Same as PR
-/-
 337 
 EIIa-Cre; PR
f/f
 Same as PR
-/-
 338 
Cebpb (C/EBPβ) cebpb-/- Reduced lobuloalveolar 
development in response to 
hormonal stimulation 
348, 349 
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Table 3.1 Continued 
 Genotype Mammary phenotype Reference 
Ccnd1 (Cyclin D1) ccnd1
-/-
 Reduced lobuloalveolar 
development/ lactation 
failure 
343 
Stat6 stat6
-/-
 Reduced lobuloalveolar 
development 
352 
Il4/Il13 (IL-4/IL-14) IL-4
-/-
;IL-14
-/-
 Reduced lobuloalveolar 
development 
352 
Gata3 MMTV-Cre; 
gata
f/f
 
Perinatal lethality/ in 
survivors TEBs do not 
form on-time/ductal 
epithelia does not invade 
the fat pad/irregular ductal 
epithelia 
354 
 WAP-rtTA-Cre; 
gata 
f/f
 
Similar to MMTV-Cre; 
gata
f/f
/ increased 
proliferation/cell death/ 
failure of lactation 
353 
 Keratin14-
Cre;gata
f/f
 
Embryonic death, absent 
placodes in survivors 
354 
 WAP-Cre; gata
f/f
 Reduced lobuloalveolar 
development/ defective 
lactation 
354 
Prl PRL
-/-
 Reduced lobuloalveolar 
development 
356 
Prlr PRLR
-/-
 Reduced ductal side-
branching /lactation failure 
357,358 
Jak2 jak2
-/-
 No data -Embryonic lethal 359,360 
 MMTV-Cre;jak2 
f/f
 Defect in establishment of 
alveolar progenitor cells  
361 
 WAP-Cre;jak2 
f/f
 Reduced survival of 
secretory epithelia 
361 
Stat5a stat5a
-/-
 Defective lobuloalveolar 
development/lactation 
failure 
364 
Stat5b stat5b
-/-
 No phenotype 366 
Stat5a/Stat5b stat5a
-/-
;stat5a
-/-
 Transplant studies reveal 
failure of alveolar 
morphogenesis 
367, 368 
Stat1 stat1
-/-
 No phenotype 380 
Involution    
Stat3 stat3
-/-
 No data -Embryonic lethal 375 
 WAP-Cre;stat3 
f/f
 Delayed involution 376 
 BLG-Cre;stat3 
f/f
 Delayed involution 377 
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Table 3.1 Continued 
 Genotype Mammary phenotype Reference 
Bcl2 bcl2
-/-
 No phenotype 381 
 WAP- bcl2 
(overexpression) 
Delayed involution 382 
Bcl2l1 Bcl2l1
-/-
 No data -Embryonic lethal 385 
 WAP-Cre; bcl2l1
f/f
 Accelerated involution 386 
 MMTV-Cre; 
bcl2l1
f/f
 
Accelerated involution 386 
Bax bax
-/-
 Delayed involution 388 
 WAP- bax 
(overexpression) 
Lactation defect/forced 
involution 
390 
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Chapter Four: Forced Involution of the Functionally Differentiated Mammary Gland by 
Overexpression of the Pro-Apoptotic Protein BAX 
Introduction 
This chapter has been published and is included here for completeness of the 
dissertation.390  
 Mammary gland development is classically compartmentalized into four distinct 
phases: virgin, pregnancy, lactation, and involution. The contributions of hormones, 
signaling pathways, and genes that give rise to the mammary gland, from the 
progression of the rudimentary anlagen during embryonic development through the 
post-natal stages described above, has been intensely studied.392 Although estrogen and 
progesterone are the predominant hormones responsible for development of the gland 
in the virgin and early pregnancy phases, prolactin directs the proliferation and 
differentiation of the epithelia during mid-pregnancy through the prolactin receptor 
PRL-R/JAK2/STAT5 signaling pathway. JAK2-STAT5 signaling is persistent through the 
lactation phase for transcriptional activation of milk protein genes, and drops at the 
lactation-involution transition phase. Involution proceeds through: (1) an initial 
reversible phase marked by programmed cell death of secretory epithelium without 
remodeling of the lobuloalveolar structure, followed by (2) an irreversible phase 
characterized by remodeling of the gland by proteases (e.g., matrix metalloproteinases, 
MMPs) and macrophages.393 
Forced involution, initiated at lactation day 10, triggers apoptosis in response to 
milk stasis within the alveolar lumen and the precipitous drop in lactogenic hormones 
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(e.g., prolactin).394 The lactation–involution transition is regulated, in part, by the 
contrasting activation of STAT5 and STAT3. STAT5 phosphorylation is maintained 
through lactation but drops precipitously at the onset of involution, while STAT3 
phosphorylation is initiated as the gland enters involution.369, 395, 396 Conditional deletion 
of Stat5 results in the loss of mammary epithelium during mid-pregnancy and lactation, 
suggesting that this transcription factor is required for cell survival. In contrast, 
transgenic overexpression of Stat5 or gene ablation of Stat3 delays the involution 
process.377, 397 Similarly, loss of Socs3, a negative regulator of the JAK-STAT pathway, 
leads to an increased rate of involution via increased STAT3 activity.398 In addition to the 
JAK-STAT pathway, genetic modifications within the IGF and AKT1 signaling pathways 
reveal their importance. Transgenic IGF-1 or IGF-2 mice have delayed involution, while 
IGFBP5 overexpressors have increased apoptosis.399-401 Downstream in the IGF signaling 
pathway, overexpression of PTEN or Akt1 in transgenic models displayed accelerated or 
delayed involution phases, respectively.402-404 Recently, STAT5 has been demonstrated 
to transcriptionally regulate Akt1, and conditional expression of Stat5 leads to persistent 
Akt1 activation and delayed involution.405 In addition, PTEN ablation increased the 
survival of alveolar cells similar to the Akt1 overexpression. 406 
Programmed cell death (PCD), an important physiological process that is 
necessary for development, is classified either as either: Type I (apoptosis), Type II 
(autophagy), or Type III (non-lysosomal vesiculate degradation). Apoptosis can be 
generally stratified into a three-tiered molecular cascade system consisting of ‘‘elicitor’’ 
death receptors (e.g., TNFR1, TNFR2, FAS)407, 408, Bcl2 family member ‘‘mediators’’ (e.g., 
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BCL2, BCL2L1L, BCL2L1S, BAX, BCL2L2)
409-411, and the caspase ‘‘executioners.’’412-414 The 
mammary gland is an advantageous organ to profile the stages of involution, as a forced 
involution allows for the synchronization of the biochemical processes. In the context of 
cell death programs, the involution phase exhibits one of the most dramatic 
physiological responses, with around 80% of the mammary epithelial cells undergoing 
programmed cell death.415 The cohort of signaling pathways and cell death genes 
necessary for this transitional period has been reviewed extensively.416-418 Although 
microarray and proteome analyses have revealed a predicted cast of proteins and 
highlighted biochemical pathways involved in involution, the most revealing studies 
have stemmed from mouse models. 303, 304 
Bcl2 family members are considered the gatekeepers of the mitochondrial-
mediated apoptosis, with the fate of the cell dependent upon the relative levels of the 
individual proteins. Bcl2-like proteins can be subdivided into two distinct groups, those 
that are pro-apoptotic (e.g., BAX, BCL2L1S, BID, and BAD) and anti-apoptotic (e.g., BCL2, 
BCL2L1L, and BCL2L2). BCL2L1L and BAX are the two most prominent Bcl2 family 
members expressed in mammary tissue. Bcl2l1L mRNA levels are low in virgin mammary 
tissue, but increase during pregnancy in parallel with STAT5 activation and cell 
differentiation. Bcl2l1L mRNA levels decrease during lactation, but increase again sharply 
within 48 h of involution. Similarly, Bax mRNA levels increase with the onset of 
involution.389 Within the Bcl2 family, several models highlight their influence on the 
maintenance of the secretory epithelium. We have shown previously that the mammary 
gland-specific deletion of Bcl2l1L resulted in an increase in apoptosis and hastened 
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involution.386 In the Bax-deficient mammary gland, involution is initially delayed but 
resembles the wild-type gland at involution day 10 after remodeling is completed.391 
Although Bax-deficient mammary glands have a delayed early involution, the loss of Bax 
does not rescue the accelerated cell death in Bcl2l1L -null mammary epithelium in our 
conditional knockout of Bcl2l1L.
386 These studies show a cell- and developmental- 
specific dependence on BAX-mediated apoptosis. Ablation of Bax or enforced 
expression of Bcl2 (WAP-Bcl2 transgenic) delays but does not prevent involution, and 
promotes mammary tumor development.382, 419 387, 420 
To date, it has not been addressed whether upregulation of a single pro-
apoptotic factor is sufficient to initiate involution and remodeling of the functionally 
differentiated mammary epithelium. To address this issue, we generated transgenic 
mice that express Bax under a mammary gland-specific promoter that is upregulated 
during secretory differentiation. WAP-Bax transgenic females display a lactation defect 
due to an increase in cell death and premature involution from ectopic STAT3 activation. 
This suggests that upregulation of BAX can override the pro-survival signaling functions 
of STAT5 and AKT1 in the lactating mammary gland. 
Results 
WAP-Bax Transgenic Mice Exhibit Impaired Alveologenesis 
 Co-injection of the WAP-Bax transgene (Figure 4.1A) and a F1 K14-agouti 
construct gave five independent founder lines out of 72 progeny as determined by PCR 
analysis (Figure 4.1B). Previous characterization of co-injected transgenes with the K-14 
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agouti demonstrated 95% co-integration, which allowed for visual determination of 
transgene inheritance.421 All WAP-Bax lines also carried the K-14 agouti transgene, 
making it possible to distinguish bi-transgenic mice by a phaeomelanin (yellow) coat 
color (Figure 4.1C, D). Q-PCR was performed to establish copy number of the WAP-Bax 
transgenic lines, with a range of 1–3 copies of the transgene per line. Upon establishing 
germline transmission of the WAP-Bax transgene, F1 females were mated with control 
C57 males to determine effects on mammary gland development. Out of the five lines, 
two lines that demonstrated protein expression (IR5, IR15) could not support litters at 
lactation day 1 (L1). Neonates from WAP-Bax dams did not have milk ‘‘spots,’’ but could 
be fostered onto control lactating females (Figure 4.1E, F). Therefore, the defect was 
not a suckling defect with the neonates but the transgenic dams. Whole mount analysis 
showed that control mammary glands at lactation day 1 predominantly consisted of 
secretory epithelia (Figure 4.2A). In addition, there was a distinct ‘‘rounded’’ 
morphology to the alveoli. In contrast, WAP-Bax mammary glands demonstrated a 
reduced epithelial compartment and altered ‘‘star-shaped’’ alveoli (Figure 4.2B, C). 
Hematoxylin-eosin staining of paraffin-embedded mammary glands showed normal, 
uniform secretory epithelia in the control glands, but reduced epithelia with altered 
morphology in the postpartum WAP-Bax transgenic glands (Figure4.3). Epithelia in the 
mutant glands displayed increased signs of apoptosis; condensed cells had pyknotic 
nuclei with many being released into the lumen (Figure 4.3D). 
 117 
 
Activation of an Apoptotic Program in Response to Expression of BAX  
To determine the activation of the apoptotic program, a series of 
immunohistochemistry (IHC) experiments were performed. For these experiments, the 
IR15 line, which showed the highest expression and greatest loss of epithelia, was used. 
At lactation day 1, expression of BAX was confined to the epithelial compartment of 
WAP-Bax mammary glands, but not detected in the controls (Figure 4.4). Upon BAX-
mediated permeabilization of the mitochondria outer membrane, it was expected that 
cytochrome C is released, culminating in the activation of Caspase 3 downstream of the 
apoptosome. Using IHC, we detected cytochrome C, ApaF1 localization, and active 
Caspase 3 within the cytosol of mammary epithelial cells of WAP-Bax transgenic females 
(Figure 4.5). This clearly suggests that overexpression of BAX is sufficient to elicits a 
classical mitochondria-mediated apoptotic program of functionally differentiated 
mammary epithelial cells. 
Secretory Mammary Epithelial Cells in WAP-Bax Females are Lost due to 
Apoptosis 
Upregulation of BAX normally coincides with the first phase of involution, which 
precedes the actual remodeling process 2–3 days later.389, 391 To confirm that 
continuous expression of exogenous BAX is sufficient to induce the second and terminal 
stage of apoptosis, we performed TUNEL staining (Figure 4.6). As expected, mammary 
glands of postpartum control females did not reveal apoptotic cells. In contrast, 
mammary glands of WAP-Bax transgenic mice had high levels of TUNEL-positive cells in 
the epithelial compartment. Transgenic lines IR62 (Figure 4.6B) and IR32 (Figure 4.6F) 
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which expressed less BAX had also fewer TUNEL-positive cells compared to lines IR5 and 
IR15 (Figure 4.6C–E). 
Clusterin is a glycoprotein that is found to be expressed at high levels during 
pregnancy and involution, but is suppressed during lactation.422 Because of its 
expression profile, it is a marker for the lactation-involution transition. Clusterin was 
found by IHC in the WAP-Bax mammary glands and not in the control glands (Figure 
4.7). More importantly, nuclear pSTAT3 was not present in control glands but was found 
in transgenic glands (Figure 4.8). pSTAT5 was expressed in control and transgenic glands 
as well. In line IR15, where most of the epithelia was already lost, pSTAT3 and pSTAT5 
was not detected. Overall, these data suggest that the lactation defect in WAP-Bax 
females is due to a ‘‘forced involution’’ process and loss of the secretory epithelia due to 
classical pSTAT3-mediated apoptosis. 
Discussion 
Programmed cell death (PCD) is a requisite cellular mechanism for development and 
homeostasis. Apoptosis, Type I PCD, can proceed via extrinsic or intrinsic pathways. 
Extrinsic pathways rely on apoptosis initiation by receptors at the cell surface, while 
intrinsic pathways from internal signals such as cellular damage.423 Both pathways can 
converge on the mitochondria to mediate the cell death program. BAX, a pro-apoptotic 
protein from the Bcl2 protein family, can induce pore formation in the mitochondria 
that ultimately leads to mitochondria outer membrane permeabilization (MOMP). Once 
MOMP occurs, cytochrome C is released from the damaged mitochondria, thus 
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triggering apoptosome formation, caspase activation, and DNA degradation. 
Alternatively, release of additional mitochondrial proteins (e.g., AIF, OMI, and EndoG) 
can lead to necrosis through caspase-independent events.423, 424 
Other genetic studies from mouse models have revealed roles for BAX in 
regulating apoptosis in reproductive tissues. Bax-null mice have phenotypes within the 
testis and ovary. Males are sterile from the developmental failure of primary 
spermatocytes to mature into secondary spermatocytes, thus prompting a wave of 
apoptosis in the adolescent testis.388 Females are endowed with three times the 
population of primordial follicles compared to wild-type females. In addition, the 
reproductive lifespan of Bax-/- females is longer due to reduced atresia.425 BAX is also 
involved with primordial germ cell (PGC) development in the fetus. BAX ensures the 
apoptotic death of ectopic PGCs that fail to arrive at the indifferent gonad.426 Moreover, 
once PGCs colonize the fetal gonads, we have shown that BAX and BCL2L1L regulate the 
survival of the germ cells.427 Reduction of BCL2L1L in PGCs leads to a sterile ‘‘Sertoli cell 
only’’ phenotype in the male, and a 30-fold reduction in primordial follicle in the male. 
The loss of germ cell populations is restored by the concomitant loss of BAX in PGCs. 
Previously we have shown that the secretory epithelia of the mammary gland are also 
impacted by the loss of BAX or BCL2L1L. These studies show a cell- and developmental-
specific dependence on BAX-mediated apoptosis. 
Our WAP-Bax transgenic model demonstrated a ‘‘forced involution’’ and 
premature cessation of lactation at parturition. The cell death we find is due to a 
Caspase-dependent induction of apoptosis, as determined by active Caspase-3 IHC and 
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TUNEL assay. Although STAT5 and AKT1 promote cell survival in the mammary gland 
during pregnancy and lactation, the ectopic overexpression of BAX overcomes these 
signals. BAX is regulated by AKT1 phosphorylation at Ser184, which serves to maintain 
the cytosolic localization of BAX and prevent its mitochondrial targeting.428 Since AKT1, 
BCL2, and BCL2L1L are all cleaved by Caspases, initial Caspase-3 activation would provide 
a positive feedback loop to inhibit these pro-survival proteins.429-432 It is unclear as to 
the mechanism of pSTAT3 activation, although either induction of C-Src or Caspase-
mediated degradation of SOCS3 could lead to premature STAT3 phosphorylation. An 
additional cell survival mechanism that the mammary gland would utilize is autophagy. 
Autophagy is active in the L1 murine mammary glands, which normally would serve to 
sequester damaged mitochondria into autophagosomes for turnover (unpublished 
observations EBR, ANH).433 Apparently, the 2 transgenic WAP-Bax lines with lactation 
defects have overcome the normal capacity of autophagy as a survival pathway within 
the epithelia. Interestingly, PUMA-dependent activation of BAX has been shown to 
concurrently induce autophagy of mitochondria (mitophagy) and a pro-apoptotic 
response.434 Thus, our WAP-Bax model may not only have an increase in BAX mediated 
apoptosis but also BAX-dependent autophagy. Quantitation of autophagosomes in the 
WAP-Bax model with the transgenic GFP-LC3 autophagy reporter line would establish 
whether both of these processes are coordinately activated.164 Some cells could be lost 
from autophagic cell death, although the abundance of pyknotic nuclei and TUNEL-
positive cells argue for apoptosis as the central programmed cell death mechanism. 
There are two classical stages of mammary gland involution: the programmed cell 
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death-driven reversible phase and the remodeling irreversible phase. However, gene 
expression studies of the early phase has demarcated seven signature profiles: (1) a 12-
h peak, (2) a 24- h peak, (3) a 24-h increase with persistent expression, (4) a 24-h peak 
with a slow decrease, (5) a 72- to 96-h peak, (6) a delayed expression for 48 h, and (7) a 
delayed expression with peak after 96 h.416 Bax mRNA is found in the fourth group with 
a 24-h peak and slow decrease. As previously stated, this is the developmental window 
when BAX has an effect on involution. From our study, BAX also has a dramatic effect on 
the survival of the secretory epithelia around parturition. This highlights the dynamic 
plasticity of the mammary gland; epithelia poised with the requisite proteome to carry 
out programmed cell death given the proper internal signal or environmental cue. In 
summary, overexpression of the pro-apoptotic protein BAX initiates programmed cell 
death of functionally differentiated mammary epithelial cells in vivo. 
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Figure 4.1 Generation of WAP-Bax transgenic lines. WAP-Bax transgenic mice were 
produced by pronuclear injection of the WAP-Bax and K14-agouti constructs. (a) 
Schematic of WAP-Bax transgene, showing the Bax cDNA cloned into a WAP promoter-
based plasmid. The WAP promoter, portions of Exons 1 and 3, Intron 3, 4, and 
downstream sequence are present. (b) Gel electrophoresis of Bax PCR products from 
negative control or transgenic WAP-Bax lines IR5, IR15, IR20, IR32, and IR62. Lanes: 1, 
100 bp ladder; 2, wild-type control; 3, line IR5; 4, line IR15; 5, line IR20; 6, line IR32; 7, 
line IR62. (c) Coat color of bi-transgenic WAP-Bax; K14-agouti mice. (d) Coat color of 
non-transgenic littermate. (e) Neonates (Day 1 of lactation) from WAP-Bax IR15 dam, 
which have failed to recover milk after suckling. (f) Neonates from WAP-Bax IR15 dam 
fostered onto control lactating dam. 
 123 
 
Figure 4.2 Expression of Bax under regulation of the WAP promoter results in reduced 
epithelial content in the postpartum mammary gland. Whole mounts from lactation 
day 1 control (a) and WAP-Bax transgenic mice (b, c) show reduced epithelial 
compartments in the transgenic mice. In addition, the wild-type alveoli have a rounded 
morphology compared to patches of collapsed, ‘‘star-shaped’’ alveoli in the transgenic 
mice (denoted by arrows). Fp = fat pad. Bar = 0.5 mm. 
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Figure 4.3 Presence of apoptotic cells in mammary glands of WAP-Bax transgenic 
females at lactation day 1. Hematoxylin-eosin staining of lactation day 1 mammary 
glands was performed on control (a) and WAP-Bax mice (b–d). (a) Control glands show 
uniform epithelial morphology and large lipid droplets in the lumens. (b) WAP-Bax 
glands show reduced epithelia and increased fat pad, and lumens have smaller lipid 
droplets. (c) Altered morphology is apparent in the epithelium and at higher 
magnification (d). Apoptotic cells are present as characterized by pyknotic nuclei 
(arrows). Fp = fat pad. Bar (a–c) = 50 μM. Bar (d) = 25 µM. 
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Figure 4.4 Expression of Bax under regulation of the Wap promoter is confined to the 
epithelial compartment of the developing mammary gland in postpartum females. 
BAX IHC shows localized expression in WAP-Bax but not control lactation day 1 
mammary glands. (a) BAX protein is not found to be expressed in the control gland using 
IHC; (b) negative control for wild-type gland. (c) and (e) reveal BAX confined to the 
epithelial compartment in WAP-Bax glands; (d) and (f) represent negative IHC controls. 
Counterstain was performed with nuclear fast red (a–d) or hematoxylin (e, f). Arrows 
point to positive cells/alveoli. Fp = fat pad. Bar = 100 μM. 
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Figure 4.5 Misexpression of Bax in the secretory mammary epithelium causes 
mitochondria-triggered Caspase activation. WAP-Bax glands showed IHC staining for 
cytochrome C (b), apaF1 (d), and active Caspase 3 (e, f), whereas control glands did not 
show cytochrome C (a) or apaF1 staining (c). (e) WAP-Bax gland revealed active 
Caspase-3 IHC staining in the alveoli (denoted with arrow) but not in the duct (du). 
Counterstain was performed with nuclear fast red (a, b, f) or hematoxylin (c, d, e). 
Arrows point to positive cells/alveoli. Fp = fat pad; du = duct; lu = lumen. Bar (a, b, e, f) = 
25 μM. Bar (c, d) = 50 µM. 
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Figure 4.6 Premature involution of secretory mammary epithelial cells in postpartum 
WAP-Bax transgenic females. WAP-Bax glands showed increased levels of apoptosis 
compared to control gland. (a) Wild-type lactation day 1 mammary gland with no 
TUNEL-positive cells. (b) WAP-Bax line IR62. (c, d) WAP-Bax line IR15. (e) WAP-Bax line 
IR5. (f) WAP-Bax line IR32. Lines IR5 and IR15 (c–e), which have lactation defects, have 
increased levels of TUNEL-positive cells compared to lines IR62 and IR32 (b and f). 
Counterstain was performed with methyl green. Arrows point to positive cells. Fp = fat 
pad; lu = lumen. Bar = 100 μM.  
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Figure 4.7 Clusterin expression in the lactating mammary gland. Clusterin expression, a 
marker for involution, was not found in the control lactation day 1 gland (a) but was 
present in the WAP-Bax gland (b). Counterstain was performed with hematoxylin. 
Arrows point to positive cells/alveoli. Fp=fat pad; Lu=lumen. Bar=50 µM. 
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Figure 4.8 pSTAT3 and pSTAT5 expression in the WAP-Bax mammary gland. pSTAT3 
(a–d) and pSTAT5 (e–h) immunolocalization in wild-type (a, e), IR15 (c, g), and IR20 (d, 
h) glands at L1. Negative control (no primary Ab) is shown for pSTAT3 (b) and pSTAT5 (f). 
Arrows show nuclear localization of pSTAT5 and pSTAT3. Counterstain was performed 
with hematoxylin. Bar=50 μM. 
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Chapter Five: An essential, autophagy-dependent role for Beclin1 in murine mammary 
gland development 
Introduction 
Macroautophagy, the process by which cytoplasmic cargo and/or organelles are 
enveloped by a double membrane structure and trafficked to the lysosome for fusion, 
degradation, and recycling, was once thought to be primarily a type of programmed cell 
death; however, it has since been shown to be indispensable for normal development 
and cell survival (reviewed in reference 1). Macroautophagy, hereafter referred to 
simply as autophagy, proceeds through four main steps: initiation, elongation, fusion, 
and degradation. The process is dependent on de novo formation of a double 
membrane structure, termed the autophagosome, which fuses with the lysosome to 
degrade and recycle cargo to maintain energy homeostasis and prevent cellular 
damage. BECN1 is an essential autophagy protein that functions during both the 
initiation and fusion steps.435 The traditional Becn1 knockout mice die during fetal 
development at embryonic day (E) 7.5 due to a failure to close the pro-amniotic canal, 
thus investigating the subsequent contribution of BECN1 to both normal growth and 
development as well as under pathologic conditions has been challenging.184, 185 Our lab 
has generated a Becn1 conditional knockout model to remedy this rift in our 
foundational knowledge.287 We wanted to explore the contribution and necessity of 
autophagy in the growth and development of the mammary gland, an organ that is 
accessory in nature and undergoes the majority of its development in the postnatal 
period. Additionally, since it has been reported that Becn1 is a tumor suppressor, owing 
to the observation that Becn1 hemizygous mice are prone to sporadic tumorigenesis 
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and that Becn1 is mutated or silenced in a majority of examined human breast cancers, 
the mammary gland is an important, clinically-relevant tissue to investigate in this 
context.184, 185, 436,437,438 
The majority of mammary gland development occurs at puberty and in 
association with reproduction. Briefly, at the time of birth the mouse mammary gland 
exists as a rudimentary structure and lengthens proportionally to the postnatal 
individual (i.e. isometric growth) until the onset of puberty, at approximately three to 
four weeks of age. Under the control of circulating hormones, most notably estrogen, 
the ducts then begin to lengthen disproportionately to the individual’s growth (i.e. 
allometric growth) and the ductal tree invades the fat pad and branches. After 
reproductive maturity is attained the gland will remain quiescent unless stimulated by 
pregnancy hormones.  
During the pregnancy cycle, mammary gland development is divided into four 
stages: mature virgin (resting), pregnancy, lactation, and involution. During the 
pregnancy to lactation transition, the secretory epithelia must terminally differentiate. 
The lobulo-alveolar structures mature and prepare for upregulation of do novo synthesis 
of nutrients, both protein and lipid, and the massive secretory burden of lactation. 
Terminal differentiation of the secretory epithelia is dependent on pregnancy hormones 
(e.g. progesterone and prolactin). Prior to the day of parturition the alveolar lumena 
enlarge and the secretory epithelia flatten against the basement membrane. After pups 
are weaned, the massive programmed cell death and remodeling that characterize the 
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involution stage return the gland to a resting like state. The majority of the programmed 
cell death is ascribed to apoptosis; however, some evidence in the literature supports a 
role for autophagy in turnover and phagocytosis. Data from bovine studies show that 
Becn1 expression and autophagy are upregulated during the dry period (i.e. involution) 
and similar results from were found using mammary epithelial cells (MECs).439, 440  In 
mice, only Becn1+/- and Atg7-deficient glands have been examined by other groups. 
Atg7, important for elongation of the autophagosome, is important for gland 
remodeling during involution. Atg7-deficient glands exhibit delayed involution and fail at 
mitigating inflammation resulting in persistent inflammation partially due to impaired 
efferocytosis.433  
In this study, we pursued a Cre-loxP based strategy centering on a Becn1 floxed 
model and two discrete mammary gland-specific Cre transgenic models to interrogate 
the role of Becn1 in mammary gland development. We report two distinct and novel 
roles for Becn1 in mammary gland biology: the regulation of branching morphogenesis 
at puberty, and the control of terminal differentiation of the secretory alveoli during 
pregnancy and lactation. We show that autophagy is reduced concurrent with 
phenotypic differences in Becn1 cKO glands, and that the phenotype can be 
recapitulated in vitro using the HC11 cell line. We suggest that Becn1 is important for 
properly regulated pubertal development and critical for terminal differentiation of the 
mammary gland due to its role in proper secretion of milk fat globules.  
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Results 
Mammary gland directed Becn1 cKO is specific and efficient 
It has been postulated that programmed cell death may be essential for 
mammary gland development and lumen formation. We hypothesized that autophagy 
was required for proper ductal tree formation. To test this hypothesis, we used our 
floxed Becn1 model and a transgenic Cre strain active in the developing mammary 
gland, MMTV-CreD.441, 442 Since the description of the MMTV-CreD transgenic did not 
include all time points we were interested in collecting, it was imperative to verify 
temporal specificity of the recombination. We generated bi-transgenic reporter mice 
which express a red fluorescent protein variant, DsRed, in cells that Cre mediated 
recombination has occurred to examine the efficiency and localization of Cre expression 
in the MMTV-CreD transgenic line.443  Nulliparous bi-transgenic females (MMTV-CreD; 
DsRed+) and littermate controls were sacrificed and mammary glands as well as other 
selected organs (data not shown) were collected at five and six weeks of age. Glands 
were either prepared for fluorescent whole mount analysis or sectioned. The reporter 
females indicate high expression was evident in the ducts (Figure 5.1B-D) as well as in 
the terminal end buds (TEBs) (Figure 5.1C) but not in the stroma. We identified little 
aberrant expression in the mammary gland with exception of the lymph node, which 
was previously reported (Figure 5.1E). We concluded that MMTV-CreD transgenic mice 
have efficient recombination and specificity in the mammary ducts and TEBs.  
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Becn1 cKO mammary glands exhibit hyper-branching phenotype 
The MMTV-CreD; Becn1fl/fl mice are viable and fertile, with no evident gross 
functional mammary defect. Mutant individuals are able to maintain a typical gestation 
length and sustain litters for three or more pregnancy cycles (data not shown). Mutant 
females (MMTV-CreD; Becn1fl/fl) were collected and examined at 3, 5, 8, and 10 week 
time points. Since whole mounts collected from five week old individuals consistently 
appeared to have increased branching (Figure 5.2A, B), we decided to analyze the 
branching network of mature nulliparous mice. We reasoned that since some variability 
exists in maturing glands between four and six weeks, all glands should be in a mature 
state by ten weeks of age. We found that secondary, tertiary, quaternary, and total 
branching was significantly increased in mutant glands when compared to sibling 
controls (Becn1fl/fl) (Figure 5.2C). Mutants exhibit a 1.71-fold increase in secondary 
branching, a 1.98-fold increase in tertiary branching, a 2.06-fold increase in quaternary 
branching and 1.94-fold increase in total number of branching (n=5 controls, n=9 
mutants). Mutant females were otherwise normal. Females are able to sustain 
pregnancy and normal lactation. Aged nulliparous or primiparous females did not show 
any sign mammary tumors, females were observed up to 10 months of age.  
Becn1 cKO mammary glands have lactation defect 
 In this series of experiments, we examined the effect of ablating BECN1 
expression in the mammary gland persistently from mid-pregnancy forward, specifically 
in secretory epithelia cells. This strategy functionally separates the effects of pubertal 
development from those of pregnancy related development, a necessity since Becn1 
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compromised ductal trees exhibit a hyper-branching phenotype. To examine pregnancy 
related development and terminal differentiation, we crossed our Becn1fl/fl model with a 
second Cre transgenic line using the Whey-Acidic-Protein promoter to drive Cre 
expression, hereafter referred to as WAP-Cre.441 Mammary development was analyzed 
from pregnancy day (P) 14.5 until 48 hours post parturition. In order to maximize the 
ablation of BECN1 in the mammary gland, we chose to use one germline null allele and 
one floxed allele in combination with the Cre transgene (WAP-Cre; Becn1fl/-). This 
strategy results in the production of an animal that is globally hemizygous for Becn1 and 
the expression from the remaining allele will be recombined by expression of Cre 
specifically in the secretory epithelial cells in the mammary gland.  The presence of a 
null allele does not have a developmental consequence in the mammary gland, as 
Becn1+/- females exhibit normal pregnancy and lactation stages. The WAP-Cre transgene 
becomes active beginning at P12.5 and continues to increase throughout pregnancy and 
remains high for the duration of lactation.441 Effective recombination of the remaining 
Becn1 floxed allele is observable by BECN1 immunohistochemistry as early as P14.5, 
with further reduction at P16.5 (Figure 5.3A). Reduction in total protein is evidenced by 
western blot conducted on whole glands, sans associated lymph nodes, harvested on 
the day of parturition (Figure 5.3E). In mutant glands, BECN1 expression is reduced 25-
fold when compared to control glands. WAP-Cre; Becn1fl/- dams are unable to sustain 
litters and all the pups succumb to starvation within 24 hours of parturition. Pups 
nursing on mutant dams did not have observable milk spots indicative of failure of 
nutrient transfer from the dam. This phenotype is a result of a lactation failure in the 
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dam, as the pups exhibit normal suckling response and are competent when fostered by 
a wild type dam.  
WAP-Cre; Becn1fl/- mammary glands are autophagy impaired and structurally 
compromised  
Since BECN1 is an essential autophagy protein, we examined autophagy function 
relative to control animals using several methods. A chief responsibility of autophagy is 
the clearance of poly-ubiquinated protein aggregates that are too large to be degraded 
by the proteasome. An ubiquitin binding protein, SQSTM1 (commonly known as p62), 
serves as an adaptor molecule for the autophagic engulfment of aggregates.44 SQSTM1 
is a useful marker of autophagic function because when autophagy is impaired SQSTM1 
tagged aggregates accumulate in the cell. In the Becn1 cKO mutant glands autophagy is 
compromised as determined by changes in SQSTM1. SQSTM1 total protein is increased 
1.61 fold relative to control on the day of parturition (Figure 5.4C), and SQSTM1 
intracellular aggregates can be detected by IHC (Figure 5.4A, B). In addition, TEM 
revealed the accumulation of enlarged autophagosomes with altered morphologies, 
many with identifiable undigested cargo (Fig 5.4E, F) in the mutants while few are 
observed in the control (Figure 5.4D). The loss of normal tissue architecture and 
morphology changes is increasingly evident as pregnancy reaches term. On the day of 
parturition, morphologic analysis reveals a loss of the functional, secretory unit 
organization and a reduction in overall epithelial content and volume. Control animals at 
48 hours post parturition have readily identifiable secretory units and lumena full of 
milk fat globules (Figure 5.5A), while mutant glands have milk fat globules retained in 
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the cytoplasm, epithelial cells are morphologically cuboidal, and have collapsed alveolar 
structure (Figure 5.5B). At the ultrastructure level, control glands have an organized 
typical secretory structure (Figure 5.5C, D) and mutant females lack organized secretory 
units. In the rarely identifiable secretory units, evidence of improper lipid secretion and 
enveloping can be seen (Figure 5.5E), as well as atypical lysosome associations with milk 
fat globules (Figure 5.5F).  
Canonical mammary signaling pathways are intact in Becn1 mutant glands 
 Classically, JAK/STAT signaling has been viewed as the intrinsic regulator of 
mammary function and involution. Stat5a KO, Stat5a/b double KO, and expectedly the 
prolactin receptor KO (Prlr -/-) do not undergo a functional lactation stage.357, 358, 364, 367, 
368 Despite the lack of direct evidence linking BECN1 or autophagy with JAK/STAT 
regulation, we wanted to investigate the possibility that JAK/STAT signaling was altered 
in Becn1 mutant glands. Antibodies recognizing phosphorylated STAT5 (pSTAT5) and 
Cyclin D1 (CCND1), a transcriptional target of STAT5 and cell cycle regulator, were used 
to perform IHC on control and mutant glands. Ccnd1 -/- animals do not lactate and have 
reduced lobulo-alveolar development.343 We found that the expression of pSTAT5 and 
CCND1 in Becn1 cKO glands was indistinguishable from control glands (Figure 5.6), 
indicating that extrinsic (i.e. progesterone-mediated) signaling is unaffected.  
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Autophagy inhibition in vitro results in retained lipid droplets and exocytosis of 
autophagosomes 
To determine if the lipid accumulation in secretory epithelial cells is autophagy 
dependent or strictly Becn1 dependent, we used an in vitro system in parallel with our 
mouse model. We chose to model our in vivo system with a mammary epithelial cell 
line, HC11, derived from a mid-pregnant BALB/c mouse.444-446 These cells can be coaxed 
into a lactogenic state by treatment with dexamethasone, insulin, and prolactin (DIP) via 
media supplementation, and are used in the field extensively to model lactation stage 
glands. To examine the effect of autophagy inhibition during lactogenic differentiation 
and during lactogenic fate, we used the chemical autophagy inhibitor BafilomycinA1 
(BafA1). BafA1 inhibits fusion of the autophagosome with the lysosome for cargo 
degradation at early time points but also prevents acidification of the lysosome at later 
time points (>2 hours of treatment). Since we are examining 24 and 48 hour time points 
and using a relatively low treatment dose (200nM), it is important to note that we will 
expect an increase in autophagosomes, amphisomes, and autolysosomes containing 
undigested cargo to verify autophagy inhibition (Figure 5.7C). We analyzed the 
differentiated HC11 cells at the 24 and 48 hour time points, time 0 indicating the 
addition of both DIP media and 200nm BafA1. After 48 hours of treatment, TEM analysis 
confirmed an inhibition of autophagy, as well as large autolysosomes containing 
undigested cargo in the BafA1 treated lactogenic cells. We identified several cases of 
direct exocytosis of autophagosome and autolysosomes in BafA1 treated cells (Figure 
5.7C). Since our Becn1 cKO model exhibited an increase in retained intracellular lipid 
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droplets we investigated if this was also the case in our autophagy-inhibited, 
differentiated HC11 cells. We used BODIPY 493/503 to stain lipid droplets and 
counterstained with DAPI. BafA1 treated cells accumulated significantly (p< 3.25E-08) 
more lipid droplets than the untreated lactogenic cells, with a mean number of lipid 
droplets per cell of 23 (SEM ± 1.3) and 14 (SEM ± 0.81) respectively (Figure 5.7A, B).  
Discussion 
We investigated the contribution of Becn1 to the formation of the mammary 
ductal tree and the terminal differentiation of secretory epithelial cells. The MMTV-
CreD; Becn1fl/fl mouse is the first in the field to genetically ablate an essential autophagy 
protein in the ductal epithelia of the postnatal mouse mammary gland prior to puberty 
and was a necessary experiment to answer a long-standing questions of whether 
autophagy is necessary for ductal lumen formation. We found that Becn1 is not 
essential for lumen formation during ductal outgrowth. We report Becn1 cKO glands 
exhibit a significant increase in higher order branching in the mature nulliparous gland. 
This effect is likely a result of removal of cell cycle repression by Becn1, as has been 
suggested in the literature by others.185 We have also shown that Becn1 is critically 
important for mammary gland development and terminal differentiation. Interestingly, 
developmental activation of autophagy increases during late pregnancy and lactation in 
wild type individuals and is highest during involution, as shown by our lab and others.433 
This confirms several studies that indicate canonical autophagy proteins have high and 
dynamic expression during pregnancy, lactation, and involution.440, 447 Our work 
indicates that canonical BECN1 function and the autophagic machinery is essential for 
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mammary gland development, despite the energy surplus conditions. This finding is 
novel and counterintuitive to prevailing opinions. The lactation failure exhibited by 
WAP-Cre; Becn1fl/- dams is completely penetrant in primiparous females and intact 
JAK/STAT signaling indicates that the glands are receiving extrinsic signaling necessary 
for lactation and prevention of involution. Thus the phenotype is distinct from the 
previously published work interrogating this pathway.363, 376, 377  
SQSTM1 IHC and western blot, as well as ultrastructure analysis by TEM, 
independently confirm an impairment of autophagy in the mutant glands; however, we 
can only conclude that autophagy reduction is correlated with, but not necessarily 
causative, with regard to the phenotype of Becn1 compromised mammary glands. The 
increased severity and advanced timing of the Becn1 cKO phenotype when compared to 
the Atg7 cKO phenotype also suggests that Becn1 is important for cellular activities 
beyond canonical autophagy, or autophagy in the mammary gland during pregnancy 
and lactation is ATG7-independent (i.e. non-canonical autophagy). One key difference 
between the studies is that in our study one allele is a global null and the other is 
recombined in the mammary gland by WAP-Cre (WAP-Cre; Becn1fl/-) while Teplova et al. 
uses a WAP-Cre; Atg7fl/fl. This difference may be important since WAP-Cre; Becn1fl/fl 
females are able to sustain litters.  Since the embryonic lethality of the traditional Becn1 
KO mouse is a more severe phenotype than the other autophagy related protein KO 
models, our study and the results gleaned from the traditional Becn1 KO together 
indicate a higher echelon for Becn1 in the hierarchy of autophagy proteins.  The 
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possibility remains that the observed phenotypes, may be a result of both autophagy-
dependent and autophagy-independent functions of BECN1.  
Our in vitro experiments using BafA1 in lactogenic HC11 cells recapitulate the in 
vivo lipid droplet retention phenotype. Lactogenic, BafA1 treated HC11 cells retained 
significantly higher numbers of lipid droplets.   This result suggests that the lipid droplet 
retention is an effect of autophagy inhibition and not an autophagy- independent role of 
BECN1. Although the autophagy complex II (BECN1-UVRAG) is important for 
autophagosome fusion with the lysosome, other studies have shown that these 
autophagy proteins also function in endocytosis and exocytosis pathways.435 TEMs 
reveal that BafA1 treated cells contain both large, undigested autophagosomes and de-
acidified autolysosome remnants. Since direct autophagosome exocytosis has been 
shown in several model systems, there is a strong likelihood that autophagic proteins 
(including BECN1) are important for lipid droplet secretion in the lactating mammary 
gland.448, 449  
The implication of autophagy proteins and process associated with lipid 
secretion and lipid metabolism has been strengthened by recent work. It has been 
recognized for several years that autophagy traffics intracellular lipids to the lysosome 
for β-oxidation, termed macrolipophagy. In Atg7 cKO mice, lipids accumulate in large 
intracellular lipid droplets in the liver; furthermore, the inhibition of autophagy in other 
tissues has yielded similar results leading to the general conclusion that the most tissues 
utilize autophagy and/or autophagy proteins to regulate lipid metabolism.94 
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Additionally, acute lipid stimulation can inhibit autophagy, while a chronic increase in 
lipid stimulates autophagy, suggesting there are multiple regulatory mechanisms 
involved depending on the type and duration of  intracellular lipid content.450 Becn1 
expression is upregulated in response to an increase in lipid and cholesterol inclusions in 
models of Neimann-Pick C disease, a lipid storage disorder.268, 451, 452 Taken together it is 
apparent that the interplay of lipids and Becn1 is of paramount importance in 
development and misregulation is antecedent to numerous clinically-relevant 
pathologies.  
In future studies, our lab will use the tetracycline inducible system to perform 
BECN1 ablation and rescue experiments to understand the role of BECN1 during 
involution, a strategy developed and described by Creamer et al.453 This strategy will 
give us a broader and clearer picture of the roles for BECN1 throughout mammary gland 
development. 
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Figure 5.1 MMTV-CreD is a specific and effective driver for mammary specific 
recombination in nulliparous mice. 
(A) Control animals labeled with DAPI do not exhibit any red fluorescence of ducts or 
stroma while reporter females (B, C, D) exhibit red fluorescence that is highly restricted 
to mammary ducts and TEBs. Fluorescent whole mounts of inguinal mammary glands 
from reporter females (E, F) exhibit red fluorescence in primary and secondary ducts as 
well as TEBs visible at 5 weeks of age. The lymph node is also targeted by the transgene 
for recombination (E). A, B, D (200X magnification), C (100Xmagnification), arrowhead 
indicates mammary duct in longitudinal section, arrows indicate TEBs, LN- lymph node. 
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Figure 5.2 MMTV-CreD; Becn1fl/fl females exhibit hyper-branching phenotype.  
Whole mount analysis of inguinal mammary glands harvested from 5 week old females 
revealed signs of hyper-branching in the MMTV-CreD;Becn1fl/fl glands when compared 
to control (A), as indicated by arrowheads (B). Quantitative analysis of branching in 10 
week old females (C) confirmed these observations indicating a significant increase in 
secondary, tertiary, quaternary, and total number of branches, n=5 control and n=9 
mutants (*P < 0.05, Student t-test). 
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Figure 5.3 WAP-Cre; Becn1fl/- mammary glands have reduced BECN1 expression in the 
mammary gland from mid-gestation. 
IHC of BECN1 on P14.5 and P16.5 mammary glands (A). Glands harvested on the day of 
parturition exhibit a marked loss in total BECN1 protein abundance when compared to 
control animals by western blot (B).  
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Figure 5.4 WAP-Cre; Becn1fl/- mammary glands have impaired autophagy clearance of 
SQSTM1. 
SQSTM1 IHC of control (A) and Becn1 cKO (B) inguinal mammary glands on the day of 
parturition imaged at 400X magnification. Scale bars are 10µm. SQSTM1 protein is 
increased in Becn1 cKO mammary glands when compared to controls and normalized to 
GAPDH (C). TEM of control (D) and mutant glands (E, F) 48 hours after parturition, scale 
bars as indicated. Arrows indicate SQSTM1 positive aggregates, open arrowheads 
indicate autophagosomes 
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Figure 5.5 WAP-Cre; Becn1fl/- mammary glands show defects in gland organization and 
abnormal milk fat globule processing. 
Semi-thin sections of resin-embedded control (A) and WAP-Cre; Becn1fl/- glands (B) 48 
hours post parturition. Note the lack of milk fat globules in the lumens of (B). TEM of 
control (C, D) and mutant (E, F) glands, scale as indicated. (E) Lipid enveloping and 
secretion defects are noted with asterisks and arrowheads highlight lysosome 
abnormalities (F).  
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Figure 5.6 WAP-Cre; Becn1fl/- mammary glands receive typical extrinsically mediated 
signaling and CCND1. 
Phospho-STAT5 expression, as measured by IHC, is similar in both control and mutant 
glands (A).  CCND1 expression is indistinguishable between control and mutant glands 
(B). All glands are inguinal mammary glands harvested on the day of parturition.   
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Figure 5.7 Lactogenic HC11 cells recapitulate the lipid accumulation observed in 
primiparous Becn1 cKO mammary glands. 
HC11 cells were kept in growth media, differentiated (DIP), or differentiated and treated 
with BafA1 (DIP + BafA1) then all groups were stained with BODIPY 493/503, 
counterstained with DAPI and imaged (A). Mean lipid droplets per cell at 24 hours post 
treatment time point were calculated for each group (B) (*P < 0.05, Student t-test). TEM 
of HC11 cells from DIP (C), and DIP + BafA1 treated group (D) highlight the accumulation 
of autolysosomes in the DIP + BafA1 group as well as direct exocytosis of abnormal 
autophagosomes with undigested cargo (E). Scales as indicated.  
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Chapter Six: TSC1 is a Novel Interacting Partner of Beclin1 and Essential for Terminal 
Differentiation of the Mammary Gland 
Introduction 
Tuberous sclerosis 1 (Tsc1) and Tsc2 produce the gene products TSC1/2, also 
known as hamartin and tuberin respectively. The TSC1/2 heterodimer is a well 
characterized inhibitor of MTOR signaling. Typically TSC2, when bound to TSC1 for 
stability, uses its GTPase activating protein domain (GAP) to inhibit Rheb, a GTPase, 
which inhibits mechanistic target of rapamycin 1 (MTORC1) signaling. Tsc1 and Tsc2 are 
the causal genes of the disorder tuberous sclerosis complex (TSC), a diverse multi-
symptomatic autosomal dominant disease characterized by hamartoma formation that 
affects ~1 in 6,000 births to varying degrees.454 The Tsc1 knockout (KO) mouse model 
dies embryonically between E9 and E13.5 of liver hypoplasia and anemia.176 Notably the 
phenotype of the Tsc1 KO was milder than the Tsc2 KO where exencephaly was 
reported in addition to other developmental defects.243 Embryonic lethality prompted 
generation of the Tsc1 floxed model which has been used to ablate TSC1 in a myriad of 
cell types, tissues, and organs.455  For a table of published tissue-specific deletions see 
Table 6.1. 
Autophagy, an intracellular catabolic process enlisted to envelope and degrade 
damaged organelles and long-lived proteins, is essential for organismal vitality, growth, 
and development. Productive autophagy is characterized by four steps: initiation, 
elongation of a double membrane structure termed the autophagosome around cargo, 
fusion of autophagosome with a lysosome, and degradation of cargo by lysosomal 
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enzymes for recycling of macromolecules for energetic homeostasis. Canonically, 
MTORC inhibits autophagy at the level of the autophagy pre-initiation complex, which is 
a regulatory complex upstream of the initiation step, and impaired autophagy has been 
reported in several systems that compromise TSC1 function or expression.63, 456-459  
Beclin1 (BECN1) is an essential, pro-autophagic protein that serves as a scaffolding 
protein during the initiation stage of autophagy. Interestingly, human BECN1 was 
identified as a TSC1 binding partner in 293T cells by a high-throughput affinity capture 
experiment.460 This finding creates a link between two tumor suppressor genes, as well 
as suggests the potential existence of an uncharacterized regulatory loop with 
significant clinical relevance.  
Tsc1 and Tsc2 have been studied extensively in the context of inherited 
tumorigenic disease, and have been characterized as tumor suppressor genes. Fewer 
studies have examined Tsc1 in the mammary gland or in breast cancer. A single 
nucleotide polymorphism (SNP) analysis of Tsc1 and Tsc2 identified a single variant that 
associated with a significantly later age at diagnosis of estrogen receptor (EsR) positive 
ductal carcinoma.461 Additionally, TSC1 and TSC2 expression is reduced in invasive 
breast cancer and the TSC1 promoter is heavily methylated in several breast cancer cell 
lines and in most breast tumors while is only rarely methylated in normal tissue. This 
report also concluded that low expression of TSC1 is correlated with unfavorable clinical 
outcomes.462 Inducible Tsc1 deletion in primary mammary tumor cells results in hyper-
activation of MTORC, accelerated breast cancer progression, and changes in autophagy 
levels.463  Becn1 is a well-characterized tumor suppressor. Becn1 hemizygous mice are 
 158 
 
prone to spontaneous tumors, and, in humans, Becn1 is mutated or silenced in a 
majority of breast cancers investigated. 184, 185, 436 
In this study we report the interaction of mouse TSC1 and BECN1 in vitro and 
examine the in vivo consequences of ablating TSC1 expression in the mouse mammary 
gland. We hypothesize that TSC1 and BECN1 interact to complete a regulatory feedback 
loop and this interaction affects autophagy function and the MTORC signaling axis, thus 
cell growth and differentiation.  
Results 
TSC1 and BECN1 interact in vitro 
 Since the initial report that TSC1 and BECN1 are interacting partners used a 
human BECN1 expressed at supraphysiological levels it was important to determine if 
TSC1 and BECN1 interacted when both are expressed at endogenous levels. We used 
protein-protein interaction assay based rolling circle amplification. Briefly, cells were 
cultured as recommended then fixed and blocked. Primary antibodies raised in different 
species were applied. Secondary antibodies conjugated with oligo probes were applied 
and incubated. A ligation reaction and polymerase based amplification make physical 
interactions visible as a fluorescent puncta. Analysis is conducted using fluorescent 
microscopy (Figure 6.1A). We found that a significant 59.3% of NIH3T3 cells were 
positive for the TSC1 and BECN1 interaction (Figure 6.1B, C). On average, across all cells 
assayed, 1.14 TSC1-BECN1 associations per cell were counted (Figure 6.1D). Since we 
know that levels of TSC1 can affect autophagy dynamically in response to changes in 
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nutrient status we wanted to investigate the nature of the TSC1-BECN1 interaction 
under serum-starvation conditions. We subjected established cells to a prolonged serum 
starvation protocol (Figure 6.1E). Following an eight hour serum starvation the 
percentage of positive cells was reduced significantly from 29.6 % with complete media 
to 17.7% after serum-starvation (Figure 6.1F), suggesting that the TSC1-BECN1 
interaction is also nutrient responsive.  
TSC1 is important for mammary gland development  
 The mammary gland is a highly dynamic organ that undergoes the majority of its 
development in the adult animal. During pregnancy, estrogen and other circulating 
hormones stimulate the cell proliferation, growth, and branching of an arboreal ductal 
structure. Nearing the time of parturition secretory epithelia, positioned at the terminal 
points of branches, prepare for secretory activation and lactation. During lactation the 
epithelia must produce copious quantities of protein and lipid and secrete these into the 
ductal lumens for neonate support. After weaning the gland undergoes a bipartite 
involution stage where programmed cell death and efferocytosis remodel the gland into 
a resting-like state (Figure 6.2A).  
Relatively few studies have been conducted investigating the expression of Tsc1 
in the normal developing mammary gland. Studies in bovine have revealed that Tsc1 
expression is dynamic across pregnancy and lactation, notably Tsc1 expression increases 
significantly during mid-lactation (120 days post parturition in bovine), relative to late-
pregnancy levels.464 We assayed the expression of TSC1 in mouse mammary glands by 
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western blot across five stages of development; virgin, pregnancy (P) 14.5, P18.5, L1, 
Involution (I)2. We cannot directly compare our data with the bovine expression data 
but we corroborate the dynamic nature of TSC1 at the protein level across 
developmental time points. In mice, TSC1 expression is very low at the virgin stage so 
we compared protein expression relative to P14.5 (set to 1). TSC1 protein abundance 
increases 8.4-fold at P18.5, 6.6-fold at L1, and 4.7-fold at I2 (Figure 6.2B, C). Generally, 
expression is low in the resting gland, increases to a peak during late pregnancy, around 
the time of secretory activation, and begins to taper off as lactation and involution 
ensue.  
TSC1 is necessary for secretory activation of the mammary gland and lactation 
Since both TSC1 and BECN1 have been implicated in breast cancer and we know 
from previous studies that BECN1 is essential for mammary gland terminal 
differentiation we wanted to examine the consequences of deleting TSC1 in the 
mammary gland during pregnancy. We used a Cre transgenic in which the Whey Acidic 
Protein (WAP) promoter is used to drive Cre expression. The WAP-Cre transgenic line in 
combination with the Tsc1 floxed model that carries one germline recombined allele 
(Tsc1fl/-) resulted in an animal globally hemizygous for Tsc1 and recombination of the 
remaining floxed Tsc1 allele in the mammary gland from mid -pregnancy (P12.5) 
forward.441, 442   
 On the day of parturition the Tsc1 cKO females were unable to sustain litters. 
Pups did not have milk spots, indicating failure of nutrient transfer, but were 
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successfully fostered on control dams. IHC against TSC1 revealed a reduction in 
expression levels on the day of parturition in Tsc1 cKO glands when compared to control 
levels detected  (Figure 6.3 ).  
The Tsc1 cKO dams have a lactation defect. Whole mount analysis of inguinal 
glands harvested from Tsc1 cKO animals on the day of parturition revealed abnormal 
swollen and engorged alveoli (Figure 6.4A- D).  Histologically, retained milk fat globules 
in secretory epithelial cells and abnormal gland architecture could be observed in Tsc1 
cKO glands. Several lysed secretory cells can be identified. Overall reduction in secretory 
epithelia is observed. These histological abnormalities indicate a failure of secretory 
activation (Figure 6.5A-D).  
TSC1 cKO glands have altered MTORC signaling and reduced autophagy   
As discussed above, TSC1 is a known MTOR inhibitor and we investigated the 
implication of TSC1 ablation on the MTOR signaling pathway in the mammary gland. We 
found that total MTOR is increased 3.6-fold in Tsc1 cKO glands as compared to controls 
and normalized to GAPDH, as expected (Figure 6.6A). Downstream MTOR effector 
p4EBP1 expression was increased 1.7-fold in Tsc1 cKO glands as compared to controls 
and normalized to GAPDH (Figure 6.6B).   Since autophagy is inhibited by MTOR we 
decided to examine autophagy by looking at Sequestosome 1 (SQSTM1/p62) expression. 
SQSTM1 is selectively metabolized by the autophagic pathway and, when autophagy is 
inhibited or impaired SQSTM1, intracellular levels increase. Tsc1 cKO glands have a 2-
fold increase in SQSTM1 over control glands and normalized to GAPDH, indicating a 
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reduction in autophagy (Figure 6.6C). We did not detect any significant difference in cell 
proliferation rates as measured by phospho-histone H3 (pH3) staining (data not shown). 
TSC1 and BECN1 expression in breast cancer 
To examine the changes that occur during tumorigenesis we used a tumor tissue 
microarray to examine TSC1 expression in a variety of breast cancers. Each tissue core 
was scored 0-4, zero being no expression and 4 being the highest level of expression. In 
normal human breast tissue TSC1 is evenly distributed in the epithelia (Figure 6.7A). We 
found that 100% of scored breast cancer samples expressed TSC1 to some degree 
(n=34) and 41.2% had low TSC1 expression (Figure 6.7C, D). The remaining cores, 58.8%, 
had high expression (rated 3 or 4) (Figure 6.7B).  Typically epithelia stained more 
dramatically for TSC1 than stromal tissue which stained to varying degrees. TSC1 protein 
was localized to the cytoplasm in a diffuse pattern and spread throughout positively 
staining cells, even in the case of polarized secretory cells (Figure 6.7E, F). Amongst a 
group of breast ductal adenocarcinomas the level of TSC1 staining was similar to the 
level BECN1 staining in 81.3% of samples assayed (n=32), though in some cases the 
distribution was different. In this ductal adenocarcinoma pictured BECN1 staining is 
punctate and basally located in polarized cells while TSC1 is diffuse in the cytoplasm 
(Figure 6.7G, H). BECN1 staining is also more prevalent in the non-luminal cells. 
Discussion 
Using both in vitro and in vivo approaches we were able to investigate a novel 
protein-protein interaction and its implications in the development of an organ. We 
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report the novel interaction of murine TSC1 and BECN1 in vitro at endogenous 
expression levels. Furthermore, we show that the interaction is dependent upon 
nutrient condition. After serum-starvation the observed TSC1-BECN1 interactions were 
reduced, indicating that the interaction is nutrient-responsive. In vivo, mammary glands 
of Tsc1 cKO mice exhibit failed lactation, impaired secretory activation characterized by 
abnormal morphology at the organ level and the histological level. Engorged and 
expended alveoli are easily identified in Tsc1 cKO glands indicating retained lipids. At the 
histologic level, lipid droplets can be seen centrally located in the secretory epithelia 
cells and many cells have an uncharacteristic cuboidal appearance.  As expected, MTOR 
expression was increased in the Tsc1 cKO mammary glands and autophagy was 
compromised.  
This work begins to unravel the complex and likely ephemeral interaction 
between two tumor suppressor proteins; TSC1 and BECN1. Both traditional KO models 
are embryonic lethal very early in development and both have been studied intensively 
as tumor suppressors. We report here that ablation of Tsc1 in the developing mammary 
gland results in a lactation defect similar to Becn1 cKO mammary glands. It is interesting 
to note that others have reported that in Tsc1 cKO cells and Tsc1 cKO mammary tumor 
cells amino acid-starvation induced autophagy is decreased, as expected since MTORC is 
hyperactive, but in TSC1 cKO mammary tumor cells glucose-starvation induced 
autophagy is surprisingly increased.463 This differential response is important since 
autophagy has long been characterized as a “double edged sword” in cancer. 
Autophagic response is typically cytoprotective, allowing cells to survive stress and 
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protect cells from misfolded proteins or cytotoxic protein aggregates; however, after a 
tumor is established activation of autophagy can be permissive for tumor 
progression.465 Another tumor suppressor, RB1-inducible coiled-coil 1 (RB1CC1), has 
been reported to interact with TSC1 and is a known member of the autophagy pre-
initiation complex.466 The ULK1/2-ATG13- ATG101-RB1CC1 autophagy pre-initiation 
complex is directly downstream of MTOR, subject to its regulation, and upstream of the 
BECN1 anchored autophagy initiation complex.61 The interaction between RB1CC1 and 
TSC1 has been shown to regulate cell size, but not proliferation.466, 467  The regulation of 
these players, involved in nutrient responsive pathways as well as tumorigenesis, is 
more complex than has previously been appreciated. Thus, what we are proposing is a 
nutrient-sensitive, regulatory feedback loop that encompasses TSC1/2 complex 
inhibition of MTOR and regulation of autophagy and has consequence for normal 
development and possibly tumor initiation.  This work lays the foundation for a specific 
and directed interrogation of the role of TSC1 in mammary tumor establishment and 
progression.  
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Table 6.1 Tsc1ckO produced and corresponding phenotypes 
Central Nervous System 
Genotype Tissue Phenotype Reference  
Emx1-Cre; 
Tsc1fl/fl 
Embryonic neural 
progenitors 
Defective cortical lamination; 
enlarged abnormal astrocytes; 
decreased myelination 
468 
Nestin-CreEsRT2; 
Tsc1fl/fl 
(tamoxifen 
induced) 
Neuronal 
precursors and 
astrocytes 
Olfactory nodules; abnormal 
neuronal infiltration 
469 
Gbx2-CreEsR; 
Tsc1fl/fl 
 
Thalamus Enlarged thalamic neurons, 
disorganized circuitry; seizures; 
compulsive grooming behavior 
 
470 
Pomc-Cre; 
Tsc1fl/fl 
Pomc neurons of 
hypothalamus 
dysregulation of Pomc neurons 
and hyperphagic obesity 
471 
CaMKIIα-Cre; 
Tsc1fl/fl 
Neurons within 
the cortex and 
hippocampus 
Seizure activity; increased 
mortality; impaired autophagy; 
211 
SynI-Cre; Tsc1fl/fl Post mitotic 
neurons 
Seizures; 
abnormal/enlarged/ectopic 
neurons; myelination delay 
472 
Synapsin1-Cre; 
Tsc1fl/fl 
Neurons Increased excitability and a pro-
epileptogenic circuit 
473 
GFAP-Cre; 
Tsc1fl/fl 
Glia Seizures; increased astrocyte 
number; disorganized 
hippocampal neurons 
455 
GFAP-Cre; 
Tsc1fl/fl 
Glia Impaired astrocytic gap junction 
coupling and potassium buffering 
474 
GFAP-Cre; 
Tsc1fl/fl 
Glia Elevated glutamate levels in 
hippocampi; increased neuronal 
death in hippocampus and 
neocortex; impaired learning and 
memory 
475 
Cag-CreERT1; 
Tsc1fl/fl or Cag-
CreERT1; Tsc1fl/- 
(tamoxifen 
induced) 
Global Seizures; epileptogenesis 476 
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Table 6.1 Continued 
Peripheral Organs 
Genotype Tissue Phenotype Reference  
Fabp4-
Cre;Tsc1fl/fl 
Lung(pulmonary 
epithelial cells), 
heart, skin and 
kidney, and in 
liver and brain at a 
lower level 
Smaller; lung hemorrhages; 
reduced levels of surfactant 
proteins A and B 
477 
SPC-Cre-EsRT2; 
Tsc1fl/fl 
(tamoxifen 
induced) 
Lung alveolar 
epithelial cells 
No data, only recombination 
efficiency reported 
478 
SM22-Cre; 
Tsc1fl/fl 
Cardiovascular 
tissue 
 Cardiac hypertrophy; reduced left 
ventricular end-diastolic diameter 
479 
Alb-Cre; Tsc1fl/fl Liver Hepatocellular carcinomas 480 
Alb-Cre;Tsc1fl/fl Liver Protection from hepatic steatosis; 
defect in SREBP1c activation 
481 
Rip2-Cre; 
Tsc1fl/fl 
β-cells of 
pancreas, 
hypothalamus 
Improved glycemic control; 
obesity (off target effect) 
482 
Rip2-Cre; 
Tsc1fl/fl 
β-cells of 
pancreas, 
hypothalamus 
hyperphagia and obesity; enlarged 
neuron cell size in a number of 
hypothalamic populations 
471 
Emx1-Cre; 
Tsc1fl/fl 
Distal convoluted 
tubule 
Cystogenesis; elongated primary 
cilia 
483 
Nse-Cre; Tsc1fl/fl Subset of renal 
tubular cells 
polycystic kidney disease 457 
Tie2-Cre;Tsc1fl/fl Vasculature Embryonic lethality; 
cardiovascular defect; 
disorganization and failed 
sprouting of vasculature; defective 
mitochondrial and endoplasmic 
reticular morphology 
484 
K14-Cre; Tsc1fl/fl Epithelia Accelerated wound healing 485 
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Table 6.1 Continued 
Reproductive System 
Genotype Tissue Phenotype Reference  
PR-Cre; Tsc1fl/fl Uterus: 
epithelium, 
stroma and 
myometrium 
Infertility; oviductal hyperplasia; 
retention of embryos in the 
oviduct; implantation failure; 
epithelial hyperplasia; embryo 
development was disrupted 
486 
Amhr2-Cre; 
Tsc1fl/fl 
Uterus: stroma 
and myometrium 
As above with exception: embryo 
development was unaffected 
 
Amhr2-Cre; 
Tsc1fl/fl 
Granulosa cells of 
ovary; stroma of 
oviduct and uterus 
Poor oocyte quality, compromised 
implantation, infertility 
487 
Cyp19-Cre; 
Tsc1fl/fl 
Granulosa cells of 
ovary 
Hyperfertility; accumulation of 
corpus lutea 
488 
PB-Cre4; Tsc1fl/fl Prostate 
epithelium 
Neoplasia of prostatic epithelia 
progressing to more advanced 
lesions with increased age 
489 
Hematopoietic System 
Genotype Tissue Phenotype Reference  
Lck-Cre; Tsc1fl/fl 
CD4-Cre; Tsc1fl/fl 
T-Cells 
 
Loss of quiescence; reduced 
number of T-cells 
490 
CD19-Cre; 
Tsc1fl/fl 
B-cells partial block in B-cell maturation; 
reduction in the marginal zone 
population; defective immune 
response 
491 
MX-1-Cre; 
Tsc1fl/fl 
(polyinosine-
polycytidine 
induced) 
Hematopoietic 
stem cells 
Increased mitochondrial 
biogenesis; increased ROS; 
reduced hematopoiesis; reduced 
self-renewal 
492 
MX-1-Cre; 
Tsc1fl/fl 
(polyinosine-
polycytidine 
induced) 
Hematopoietic 
stem cells 
Premature aging of HSCs 493 
Rosa26- 
CreEsRT2; Tsc1fl/fl 
(tamoxifen 
induced) 
Global 
(hematopoietic 
organs) 
Polycystic kidney disease; failure 
to thrive; reduced HSCs; loss of 
quiescence; reduced self-renewal 
494 
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Figure 6.1 BECN1 and TSC1 interact in vitro.  
BECN1 and TSC1 are identified as interacting partners. (A) Schematic representation of 
protein-protein interaction assay depicts two primary and secondary antibodies binding 
to targets, ligation of conjugated oligos, and rolling circle amplification for visualization.  
(B) The control has very few interaction puncta while the BECN1-TSC1 panel has many 
puncta, cells are counterstained with DAPI. Overall 59.3% of cell are positive for the 
interaction (C), and on average, cells have 1.14 interactions each (D). When cell are 
subjected to a prolonged serum-starvation protocol (E), the number of interaction-
positive cells decreases significantly (F). *= statistically significant and refers to a p-
value<.05 
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Figure 6.2 TSC1 is expressed during normal pregnancy, lactation, and involution.  
Schematic representation of a pregnancy cycle is depicted (A). The mammary gland 
progresses through four phases: mature virgin (resting) which is quiescent, pregnancy, 
lactation, and involution. The depictions are stylized ductal structures and 
representative growth of the secretory epithelia as pregnancy and lactation progress. 
TSC1 is expressed at very low levels in the mature virgin gland and increases to a peak in 
late pregnancy. Expression remains high during lactation and during the early involution 
phases (B, C).  
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Figure 6.3 TSC1 protein is reduced in Tsc1 cKO glands at L1. 
Glands harvested from L1 controls have strong TSC1 staining in the secretory epithelia 
(A, E) as detected by IHC. In Tsc1 cKO glands (B, C, D, F) overall staining in the secretory 
epithelia is reduced. A-D 400X magnification; E, F 600X magnification; bar=25μm 
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Figure 6.4 Tsc1 cKO whole mount mammary glands are less dense and have abnormal 
secretory alveoli.  
Mammary glands collected on the day of parturition typically appear dense and 
differentiated as the control gland (A). Mutant glands (B-D) appear less dense and 
present with less secretory alveoli. In many cases secretory alveoli appear engorged and 
abnormal alveoli can be seen budding off of branches (open arrowheads). Bar= 1mm 
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Figure 6.5 Histologic analyses of Tsc1 cKO mammary glands.  
Control mammary glands collected on the day of parturition have undergone secretory 
activation and epithelia appear squamous, lipid droplets are secreted into large lumena 
(A). Mutant glands (B-D) contain secretory epithelia that appear cuboidal and many lipid 
droplets can be observed retained in the cytoplasm (asterisks). In many cases secretory 
epithelia has been lysed (asterisks).Bar=25nm 
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Figure 6.6 Tsc1 cKO mammary glands have increase MTOR pathway signaling and 
decreased autophagy.  
Total MTOR abundance in increased 3.6-fold in Tsc1CKO mammary glands (A) and 
downstream target p4EBP1 is increased 1.7-fold (B). SQSTM1 is increased 2-fold in Tsc1 
cKO mammary glands indicating that autophagy is reduced (C).  
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Figure 6.7 TSC1 expression in breast cancer is variable and typically trends with BECN1 
expression.  
In normal breast tissue TSC1 is expressed in a majority of cells’ cytoplasm (A). A panel of 
breast cancer cores was examined. In a breast ductal adenocarcinoma high expression 
can be seen in epithelia (B), and in similarly graded core expression is overall reduced 
(C-D).  TSC1 exhibits high expression (E-F) in a restricted patter and BECN1 also exhibits 
a high expression level but has a slightly different pattern of localization (G-H). A, B, C, E, 
G 200X Bar=25nm; inset images A, B, C, E, G 100X; D, F, H 400X, Bar=50nm 
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Chapter Seven: Conclusions and Future Directions 
Introduction 
 Through these studies we have explored the contribution of apoptosis and 
autophagy to mammary gland development and differentiation. Combined, they have 
focused our attention on the importance of balance and timing during dynamic 
remodeling and shifts in tissue function and physiologic demand. Perturbation of this 
system highlights the fragility of establishing and maintaining lactation. The WAP-Bax 
mice showed that overexpression of a single pro-apoptotic protein at an improper time 
leads to forced involution and lactation failure. Ablation of Becn1, viewed primarily as a 
cell survival protein, during pregnancy causes a similar gross outcome; lactation failure. 
Reconciliation of the delicate balance of pro-apoptotic and pro-survival signals is central 
to further our understanding of normal mammary development as well identifying and 
predicting pathologies, including cancer, which arise in this dynamic tissue. 
Furthermore, TSC1, an MTOR regulator and tumor suppressor never before examined in 
the mammary gland, also proved to be essential for lactation. Our continued exploration 
of the function of Tsc1 in vitro has revealed a novel protein-protein interaction between 
TSC1 and BECN1. This work has left us with many observations that push the boundaries 
of our knowledge regarding the regulation and function of autophagy pathway related 
proteins and the regulation of mammary gland development. 
 Since I have spent considerable time discussing the status of the field and our 
research findings, I intend to use this space for discussion, speculation, and to expound 
on experiments to further this line of thinking.  
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BECN1- More than an autophagy protein  
 Much has been published regarding the canonical function of Becn1, that is to 
say, the autophagy-promoting, initiation complex I-centric function. The studies 
described in this compilation push against this presumption and highlight alternative 
and non-canonical functions of BECN1, on which I wish to elaborate here.   
 By TEM, an accumulation of autophagosomes, both completed and incompletely 
closed, was identified in the Becn1 cKO model. This finding suggests that the engrained 
notion of BECN1 acting primarily in the autophagosome initiation complex is too 
simplistic. After Becn1 ablation we do not see an effect on autophagosome production, 
but we can identify a defect in functional autophagy, so three possibilities are feasible: 
1) the residual BECN1 is sufficient for autophagosome formation, 2) in the mammary 
gland non-canonical BECN1-independent autophagy is most common, or 3) BECN1 is 
unnecessary for autophagosome formation in this model system. 
We cannot completely discount the first possibility since there is no information 
regarding the stability of BECN1 in vivo; however we have shown that we significantly 
reduced BECN1 protein levels by both IHC and western blot. Since we are able to detect 
that functional autophagy is reduced by SQSTM1 accumulation, it is likely that 
autophagy in the mammary gland is impacted by BECN1 reduction and leads me to 
discount the second possibility. The third possibility holds water since we observe 
failure of autophagosomes to productively fuse with the lysosome. This supports an 
important and less-studied function of BECN1, its inclusion in “complex II” which 
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mediates fusion of the autophagosome with the lysosome. Interestingly, our lab as well 
as a collaborator’s lab, have identified similar accumulation of autophagosomes in at 
least two additional tissues (personal communication Rucker, Gawriluk, Wang) 
suggesting that this phenomenon is not restricted to the mammary gland. This working 
model is depicted schematically in Figure 7.1A.  
BECN1 and Lipid Droplets 
 My data also illuminate a novel role for BECN1 in regulating lipid trafficking and 
secretion. In vivo, lipid retention in the secretory epithelia is easily identified by 
histologic analysis in late pregnancy and early lactation phases.  We then moved to an in 
vitro system to evaluate lipid retention in lactogenic mammary epithelial cells and found 
that when cells were treated with the autophagy inhibitor BafA1, an inhibitor that 
targets autophagosome-lysosome fusion and prevents lysosomal re-acidification, lipid 
droplets were, again, retained. Tellingly, when I repeated this experiment with the 
inhibitor wortmannin, which inhibits autophagy specifically at the level of the initiation 
complex (complex I), I found no significant difference in lipid droplet accumulation in 
the treated vs. untreated cells (Figure 7.2). This difference is important as it also 
supports the hypothesis that BECN1, in a complex that mediates membrane fusion 
(complex II), is important for lipid trafficking and/or secretion. At this time I am 
proposing a working model in which BECN1 participates in at least two distinct 
complexes, and some complex components are shared between the roles of 
autophagosome-lysosome fusion, and lipid droplet regulation. 
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 The idea that autophagy proteins are important for lipid droplet synthesis, 
fusion, and trafficking is supported by studies in other model systems. Mammalian Atg2 
homologs, ATG2A and ATG2B, are important for lipid droplet size regulation and 
distribution. Additionally, silencing of Atg2A and Atg2B together results in a block in 
autophagic flux and accumulation of unclosed autophagic structures.495 In hepatocytes 
and cardiac myocytes LC3-II localizes to the surface of lipid droplets as well as 
autophagosomes under starvation conditions, and in Atg7-deficient livers lipid droplets 
were reduced and overall reduced in sized compared to controls.496  This work laid the 
foundation for the involvement of the ATG7 conjugation system in lipid droplet 
formation, and in further studies, LC3 was directly associated with lipid droplet 
formation.497 It seems that many of the classic autophagy related proteins have roles 
outside of autophagy and there is significant overlap with lipid droplet formation, 
regulation, and trafficking.  
 Similarities can also be pulled from studies focusing on lipid droplet formation 
and secretion in the mammary gland. The lipid droplet is thought to be formed at the ER 
and gain membrane material from many sources, similar to the autophagosome, before 
it is secreted (Figure 7.1D, II-IV). Droplets often fuse together in the cytoplasm with 
other lipid droplets and sometimes secretory vesicles before secretion (Figure 7.1D, III). 
The process of two distinct organelles fusing in the cytoplasm without any known 
control mechanisms or higher regulation is reminiscent of the fusion of 
autophagosomes and lysosomes, for which we have shown Becn1 is important. 
Interestingly, xanthine oxidase is a constitutive component of the milk lipid globule 
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membrane and in mice the knockout has a similar phenotype to the Becn1 cKO with 
regard to lipid retention and lactation failure.498 It would be interesting to look at 
potential BECN1 localization at sites of inception or fusion of lipid droplets. This 
technically challenging experiment would be best conducted using live imaging of cells 
to track a likely short and dynamic association.  
 Together these studies indicate that much of the machinery that has been 
classically describe as autophagy machinery is essential for lipid droplet formation and 
size regulation. Furthermore the nature of formation, elongation, and fusion are in 
many ways parallel between lipid droplet formation and secretion and autophagy.  It is 
therefore reasonable that BECN1 is a member of a complex, potentially complex II with 
UVRAG or other fusion proteins, which functions in lipid droplet formation, size 
regulation, trafficking, and fusion in addition to autophagic initiation and fusion.  
What About Unconventional Protein Secretion? 
 There have been many reports of autophagy related proteins being important 
for unconventional protein secretion, defined as a method for secretion that bypasses 
the ER-Golgi route and instead leaves the ER and may use a vesicular structure to be 
exocytosed. A simplistic schematic is depicted in Figure 7.1D, I. In yeast, Acyl coenzyme 
A (CoA)–binding protein (Acb1) is secreted in an unconventional process that is 
autophagosome and Atg11 dependent.499, 500 In mammalian cells, pro-inflammatory 
cytokine IL-1β depends on ATG5 and LC3 co-localizes in the cytoplasm, implicating an 
autophagic vesicle is required for its transport.501  
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 While my data yield no indication that protein secretion is impaired in Becn1 cKO 
mammary glands, as casein can readily be seen in any identifiable lumena, we did not 
specifically measure levels of secreted protein, thus cannot be certain. In our work we 
used total mammary gland for analysis, removing only the lymph node. A milk protein 
analysis from whole gland lysate did not reveal any difference between control and cKO 
mice across pregnancy time points (Figure 7.3). The caveat is that any proteins retained 
within the cells and not secreted would still contribute to the milk protein abundance 
represented on the gel. For studies focusing on the potential role of BECN1 in 
unconventional protein secretion, milk protein will need to be analyzed separate from 
the stromal and epithelial compartments of the mammary gland.  
 In sparse and old reports, a marrying of unconventional protein secretion and 
lipid secretion has been described.502 In short, secretory vesicles leaving the Golgi 
surround a lipid droplet in the cytoplasm and form a syncytial layer around the droplet 
(Figure 7.1D, IV). The outer membrane, which is now composed of secretory vesicles 
and cargo, fuses with the plasma membrane and is exocytosed to the lumen. I have 
identified some of these structures in control animals on the day of parturition by TEM 
(Figure 7.4 A, B), one of only a handful of reported examples of this phenomenon. 
When lipid droplets are enveloped with plasma membrane (Figure 7.1D, III) and 
secreted, chunks of plasma membrane sometimes remain associated with the globule in 
the lumen (7.4C, D). These enveloping defects occur in the first 24 hours of lactation in 
controls and are very rarely observed at later time points.    
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 When examining Becn1 ckO glands on the day of parturition, defining phenotypic 
differences based on errors in fusion and secretion can be ambiguous since control 
glands are also likely to make errors at this time. Many sections and individuals must be 
included in such a study. Preliminary, qualitative results gathered from Becn1 cKO 
glands harvested on the day of parturition are discussed here. In Becn1 cKO glands 
globules are readily identified in lumena. Incidences of secretory vesicles surrounding 
and depressing lipid droplets are seen (Figure 7.5A, B). In some cases it appears that 
membrane integrity has been compromised (Figure 7.5 C, D).  These results are brief but 
further investigation is needed. Quantification of lipid droplet size would be valuable 
but would require at least six animals of each genotype for comparison. This is a 
fascinating, understudied, and technically challenging area; as a result, much of the 
basic biology of lipid droplet secretion and mammary milk fat globules is still unknown.  
BECN1 During Involution 
 When we initially embarked on this journey we were interested in answering the 
open question of whether or not autophagy is important during mammary gland 
involution. Since the WAP-Cre; Becn1fl/- mice exhibit a lactation defect and precocious 
involution, a proper investigation of the role of Becn1 during involution was prohibited. 
Future studies using the MMTV-CreD; Becn1fl/fl model would be valuable to better 
examine this process. Involution would be forced at L10 by removal of the litter in 
mutant and control animals. Tissue would be assayed for proliferation index, apoptosis 
index, and examined for morphologic differences. Clusterin and pSTAT3 would be used 
as markers for involution stage by IHC and western blot.  
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BECN1, Tumor Suppressor? 
 Since Becn1 is purported to be a tumor suppressor gene, and our studies to date 
have not identified tumors in mammary-specific cKO animals, we have designed a study 
to more directly address the role of Becn1 in breast cancer. We are using the established 
MMTV-neu transgenic mouse model in combination with our mammary-specific Becn1 
cKO with WAP-Cre mediated deletion. This project necessitates backcrossing onto the 
tumor permissive FVB background (6 generations). Focal mammary tumors arise in 
MMTV-neu female mice beginning at 4 months with a median incidence of 205 days. In 
this model we can ablate Becn1 expression in primiparous mice and compare median 
tumor incidence to transgenic primiparous controls with full Becn1 compliment. This 
targeted experiment, conducted on a tumor-permissive background will support either 
1) the widely regarded notion that Becn1 is a tumor suppressor, or 2) the model that 
tumors are addicted to autophagy and ablation of Becn1 will delay tumor onset and/or 
retard growth.   If Becn1 is a tumor suppressor we will expect that tumors arise earlier in 
the Becn1-deficient animals. This scenario would be quantified by a shorter median 
incidence or that tumors arise with similar incidence but grow at a more rapid rate. 
Conversely, if autophagy promotes tumor incidence and growth by allowing them to 
survive sub-optimal nutrient and hypoxic conditions, we would expect that the Becn1 
cKO animals present with a longer median incidence and/or tumors that arise do not 
grow as rapidly as control animals. In essence, either outcome will be important to the 
research community and clarify the role of BECN1 in tumorigenesis.  
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High Energy, High Autophagy? 
Physiologically it is interesting that both Becn1 and Tsc1 are important for proper 
function of the mammary gland since cell survival pathways including MTOR and AKT, 
which inhibit autophagy and TSC1/2 complex respectively, have been shown to be 
active during this time. It has been proposed by others that in certain cell types which 
are either undergoing senescence, or highly metabolically active (e.g. podocytes), it is 
beneficial for autophagy (i.e. catabolic process) and protein synthesis (i.e. anabolic 
process) to be concomitantly operating and spatially linked. The authors propose that in 
cells under high demand to produce bulk synthesis of secretory products that the 
catabolic and anabolic machinery are spatially coupled for efficiency.503 The finding by 
our lab of yet another example of this and another level of interconnectedness between 
the MTOR pathway and the autophagic pathway in metabolically active and highly 
secretory cells beseeches more experiments be conducted teasing out this mechanism. 
A thorough understanding of the interplay between TSC1, BECN1, and MTOR is 
paramount.   
TSC1-BECN1 Interaction 
The interaction between BECN1 and TSC1 complicates the idea of MTOR 
pathway regulation, and reinforces the importance of multiple nutrient-sensitive 
regulatory levels. It has been well characterized that TSC1 is necessary for the stability 
of its binding partner TSC2, and in Tsc1 cKO animals TSC2 levels are undetectable at the 
protein level due to rapid degradation by the proteasome. The TSC1-BECN1 interaction 
could mediate the pool of BECN1 in the cytoplasm that is available for rapid response to 
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cellular insult (Figure 7.1B). Under this model  the stability of BECN1 in the Tsc1 cKO 
would be compromised, thus BECN1 would be less available to perform its cellular roles 
leading to a similar, though milder phenotype, to the Becn1 cKO (Figure 7.1C). This is 
precisely the results we have observed. Moving forward it is important to characterize 
the domains involved in this interaction, though it is probable that since both proteins 
contain a coiled-coil domain that this is the point of interaction. Protein-protein 
interaction assays (e.g. Duo-Link or co-immunoprecipitation) using constructs with 
targeted domain deletions and truncations will be useful for making this determination.   
Summary 
In closing, with the experiments that have been described as a foundation, the 
perceptions and boundaries of at least two fields have been challenged.  It is clear that 
BECN1 is far more that an autophagy protein and the extent of its importance during 
development is still being revealed. Our conditional Becn1 model will be a fruit-bearing 
asset to the autophagy community for many years. We have shown two new proteins 
that are essential for terminal differentiation in the mammary gland and proposed a 
mechanism based on a murine protein-protein interaction detected for the first time. In 
this chapter I have put forth ideas which are a result of an amalgamation of published 
literature and our findings. We have challenged the long-held characterization of BECN1 
as a tumor suppressor and will continue to directly address this question in the future.  
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Figure 7.1 BECN1 Working Model  
BECN1 is a member of two distinct complexes, complex I, which acts at the initiation 
stage and complex II, which functions at the autophagosome-lysosome fusion step. The 
two roles, depicted schematically in (A), have mutually exclusive binding partners and 
may include uncharacterized components. TSC1-BECN1 interaction stabilizes the 
available pool of BECN1 in cytoplasm and protects BECN1 from degradation (B), when 
the association is disrupted (C) either by knockout of Tsc1 or endogenous mutation, 
BECN1 is left unprotected and destabilized resulting in impairment of BECN1-dependent 
functions. In (D), autophagosome-dependent unconventional protein secretion (I) and 
several mechanisms of lipid secretion in the mammary gland (II, III, and IV) are depicted. 
Autophagosomes are pictured as orange vesicles; Lysosomes are pictured as blue 
vesicles; Green spheres represent lipid droplets; UPC, unconventional protein cargo; ER, 
endoplasmic reticulum; PM, plasma membrane; SV, secretory vesicle  
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Figure 7.2 Autophagy inhibition with wortmannin does not affect lipid droplet 
retention in vitro.  
HC11 cells were driven to lactogenic differentiation by supplementation with DIP (A, B). 
The treatment group (B) was concomitantly treated with wortmannin (100 nM). Both 
groups were stained with BODIPY 493/503 after 24 hours of treatment and cellular lipid 
droplets counted. The experiment was conducted in triplicate. No significant difference 
in lipid content was detected between groups by student’s t-test (C), p-value=.985. 
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Figure 7.3 Milk protein abundance is unchanged in Becn1 cKO mice  
Secretory activation in the mammary gland precedes milk production. Total protein was 
extracted from whole mammary glands of control and mutant primiparous females, 
from which the lymph nodes were removed. Coomassie brilliant blue stain was used to 
visualize the characteristic milk protein banding patterns. No difference in total protein 
abundance was detected between control and Becn1 cKO mice. WAP, whey acidic 
protein; CSNα, casein alpha; CSNβ, casein beta; CSNγ, casein gamma. 
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Figure 7.4 Secretory vesicles surround and plasma membrane envelopes lipid droplets 
in control mammary glands on the day of parturition.  
In control glands, units of secretory vesicles surrounding milk fat globules can be seen in 
the lumen on the day of parturition (A, B). Asterisks indicate the area around the milk 
fat globule (secreted lipid droplet) that is encapsulated by secretory vesicles. Note that 
not every globule is affected. In (C), and at higher magnification in (D), there is plasma 
membrane and one secretory vesicle surrounding the globule. Errors in enveloping, the 
most common method of droplet secretion, are common in controls in the first 24 hours 
of lactation but are rare after lactation is established.  Open arrowheads indicate areas 
where large amounts of plasma membrane remain on secreted lipid droplets. Scale bars 
and magnification are as shown below each panel.  
 194 
 
 
  
 195 
 
Figure 7.5 Becn1 cKO glands may have difficulty fusing membranes 
Becn1 cKO glands were harvested on the day of parturition and examined by TEM. 
Secretory vesicles, probably containing casein, can be seen surrounding lipid droplets (A, 
B). In some areas with secretory vesicle-lipid droplet contact the droplet appears 
distorted. Instances of secretory vesicle membrane fusion failure can also be identified 
(C, D). Open arrowheads point to areas of potential fusion failures. Scale bars and 
magnification are as shown below each panel. 
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Chapter Eight: Materials and Methods 
Generation of WAP-Bax Transgenic Mice 
The WAP-Bax construct was digested with NotI and gel purified with the Qiagen Gel 
Extraction Kit. The keratin 14 (K14)-agouti transgene 421 was digested with ClaI and also 
gel purified. Transgenes were co- injected at a final concentration of 2 μg/ml-1 into 
pronuclear-staged FVB embryos. Pups (3 weeks old) were genotyped for the Wap-Bax 
transgene with the following PCR primers and reaction conditions: forward (5’-TAG AGC 
TGT GCC AGC CTC TTC-3’); reverse (5’-GAC ACA GTC GAC TCA GAA CAT CTT CTT CCA G-
3’); cycling conditions of 94°C for 5 min (1 cycle), 94°C for 30 s, 58°C for 30 s, 72°C for 1 
min (32 cycles), and a final step of 72°C for 5 min. The product of 650 base pairs was 
resolved on a 1.5% agarose gel. Founders were backcrossed with C57/BL6 mice for five 
generations. WAP-Bax transgene copy number was determined using exon 3 and 4 
specific primers paired with an exon 3-specific TaqMan probe (5’-6FAM ATG CGT CCA 
AGA AGC TGA GCG TAMRA-3’ at 200 nM final) with cycling conditions of 50°C for 2 min 
(one cycle), 95°C for 10 min, 95°C 15 s, 60°C for 1 min (40 cycles) on an ABI Prism 7700 
thermocycler. Copy number was normalized to the endogenous Bcl2l1 gene (two 
copies). 
Gene targeting and generation of Becn1 cKO mouse 
For the targeting vector, a three loxP plasmid vector (ploxP3–NeoTK) with 
phosphoglycerol kinase (PGK)-neomycin and PGK–thymidine kinase cassettes for 
positive–negative selection was used. Genomic DNA isolated from 129SvEv mice was 
used to amplify three regions of homology for the targeting arms: a 2.7 kb Becn1 arm #1 
 197 
 
(Becn1 promoter sequence), a 3.0 kb Becn1 arm #2 (promoter, exon 1, intron 1, exon 2, 
and a portion of intron 2), and a 2.0 kb Becn1 arm #3 (intron 2 sequence). For the 
amplification, the AccuPrime Pfx was used according to manufacturer's directions to 
generate blunt PCR fragments that were gel purified (Gel extraction kit, Qiagen) and 
cloned into pBlunt vector (Invitrogen). For the electroporations, 25 μg NotI-linearized 
DNA was resuspended in 25 μl electroporation buffer (Chemicon, Billerica, MA, USA) and 
electroporated into 1×107 129SvEv ES cells using the GenePulser II (250 V and 500 μFd; 
Bio-Rad) with 0.4 cm cuvettes. G418 selection (200 μg/ml) was started on day 1 after 
electroporation and continued thereafter; ganciclovir selection (2 μM) was performed 
on days 4–7 after electroporation. On day 12, 3× 96-well plates were picked and 
expanded for cell stocks and DNA isolation. Clones were initially screened by pooled 
PCRs using LaTaq (Takara) with a 5′-flanking reverse primer (5′-CCC TAG CTG GCC TGG 
AAC TCA GAA ATC T-3′) and neomycin-specific reverse primer (5′-TAC CGG TGG ATG TGG 
AAT GTG TGC GA-3′) set. The presence of the third loxP site was confirmed using 
flanking PCR primers (forward: 5′-CAG GAG AAG TGC CAT GGT GCA TCC TCT T-3′; 
reverse: 5′-CAA AGC CAA GGT TTC CAT GCT AAT GCC-3′). Individual clones were 
subjected to PCR confirmation from positive pools. Positive clones were confirmed by 
Southern blot diagnostics with an external 5′ probe. Targeted mouse embryonic stem 
(ES) cells were expanded and used for blastocyst injections at the Transgenic Animal 
Core facility at Texas A&M University (College Station, Texas). 
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Generation of mammary gland specific Becn1 cKO mice  
Becn1fl/+ mice were generated by gene targeting in 129SvEv ES cells as described in 
previous section. A germline transmissible Becn1 null allele (Becn1-) was generated by 
breeding hemizygous Becn1fl/+ with MMTV-CreA mice. Presence of the null allele was 
confirmed by PCR analysis (sense: 5’-ATG GAA GGA AGG AAG GTT AG-3’; antisense: 5’-
CAA AGC CAA GGT TTC CAT GCT AAT GCC-3’). Mice carrying homozygous floxed alleles 
and neomycin cassettes were confirmed by PCR of tail-snipped DNA. True floxed alleles 
were generated by crossing Becn1flneo/+ and Ella-Cre mice.  Deletion of the neo cassette 
and production of “true floxed” allele was confirmed by PCR analysis (sense: 5’-ATG GAA 
GGA AGG AAG GTT AG-3’; antisense: 5’-GGT TGC ATG TTA AGT CTT TGT CGA-3’). WAP-
Cre; Becn1fl/- mice were generated by crossing WAP-Cre; Becn1fl/- males with Becn1fl/fl 
females. Presence of the WAP-Cre transgene was confirmed using PCR (sense: 5’- CAG 
ACA CTC AGA CAG CCA TCA GTC-3’; antisense: 5’- CCA TGA GTG AAC GAA CCT GGT CG-
3’) All animal work was conducted using protocols approved by the Institutional Animal 
Care and Use Committee at the University of Kentucky. 
Generation of mammary gland specific Tsc1 cKO mice  
Tsc1fl/+ mice (Tsc1tm1Djk/J) were crossed with Vasa-Cre transgenic line (FVB-Tg(Ddx4-
cre)1Dcas/J) to produce a germline transmissible Tsc1 null allele (Tsc1-). Presence of the 
null allele was confirmed by PCR analysis (sense: 5’- AGG AGG CCT CTT CTG CTA CC-3’; 
antisense1: 5’- CAG CTC CGA CCA TGA AGT G-3’; antisense2: 5’- AGC CGG CTA ACG TTA 
ACA AC-3’). Presence of the floxed allele was confirmed by PCR analysis (sense: 5’-GTC 
ACG ACC GTA GGA GAA GC-3’; antisense: 5’-GAA TCA ACC CCA CAG AGC AT-3’). WAP-
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Cre; Tsc1fl/- mice were generated by crossing WAP-Cre; Tsc1fl/- males with Tsc1fl/fl 
females. Presence of the WAP-Cre transgene was confirmed using PCR (sense: 5’- CAG 
ACA CTC AGA CAG CCA TCA GTC-3’; antisense: 5’- CCA TGA GTG AAC GAA CCT GGT CG-
3’). All animal work was conducted using protocols approved by the Institutional Animal 
Care and Use Committee at the University of Kentucky. 
Mammary gland collections 
Mutant and control animals were sacrificed at designated time points according to the 
experimental design. An incision at the midline, but not piercing the peritoneum of the 
abdominal cavity, is carried to the distal rib. A second incision is made to separate the 
fourth and fifth mammary glands, parallel to the femoral artery. The number four 
mammary gland is removed carefully and used for whole mount and histological 
analysis. RNA and protein samples are taken from the contralateral inguinal mammary 
gland, but exclude the inguinal lymph node. In some cases a thoracic gland is also 
removed in a similar manner, but never used for RNA or protein analysis due to its 
skeletal muscle component. 
Histology and Immunohistochemistry 
Inguinal mammary glands were fixed in 4% (w/v) paraformaldehyde or 10% neutral 
buffered formalin solution (WAP-Bax experiments) at 4° C overnight, then placed in 70% 
ethanol and stored at 4° C. Paraffin embedding was performed at the Histology 
Laboratory of the University of Kentucky Imaging Facility. Processed glands were 
sectioned (5-7 μm) and mounted on charged glass slides. Slides were then 
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deparaffinized and hydrated for immunohistochemistry (IHC) or deparaffinized and 
hydrated, stained with methyl green, nuclear fast red, hematoxylin, and/or eosin, and 
dehydrated and mounted.  For slides undergoing IHC, antigen unmasking was 
performed in citrate antigen unmasking buffer (Vector H-3300) followed by endogenous 
peroxidase quenching with 3% H2O2 diluted in methanol. Slides were blocked in 2.5% 
normal horse serum (Vector S-2012) for 20 minutes at room temperature. Primary 
antibodies against Bax (1:200; B.D. PharMingen 13686E), BECN1 (1:100, Santa Cruz 
Biotechnology sc-11427), Active Caspase-3 (1:50, B.D. PharMingen 559565), Caspase-3 
(1:50, Santa Cruz 556425), Cytochrome C (1:50, B.D. Phar- Mingen SC7159), SQSTM1 
(1:250, Sigma-Aldrich, P0067), TSC1 (1:100, Novus Biologicals, NB 100-80855),  
antibodies were diluted to indicated titers and incubated overnight at 4°C. ImmPRESS 
Reagent Kit-Anti-Rabbit IgG (Vector Labs, MP-7401) and ImmPACT DAB (Vector Labs, SK-
4105) were used according to manufacturer’s directions. Sections were counterstained 
with Hematoxylin QS (Vector Labs, H-3404) or eosin (Fisher Scientific, E-511) and 
visualized using an Olympus IX71 microscope (Olympus Corporation of the Americas). 
pSTAT5 and CCND1 IHC was performed at Epply Institute for Cancer and Allied Diseases, 
Omaha, Nebraska by our collaborators Dr. Kay-Uwe Wagner and Dr. Kazuhito Sakamoto.  
Tissue Array 
Tissue microarray slides were obtained from the Cooperative Human Tissue Network 
and the Tissue Array Research Program (TARP) of the National Cancer Institute, National 
Institutes of Health, Bethesda, MD, USA. The array analyzed in this study is the T-MTA-
6A.  
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Measurement of Apoptosis in WAP-Bax Mammary Gland Epithelial Cells 
For quantitation of apoptotic cells, the TUNEL-based Apoptag assay was performed 
according to the manufacturer on paraffin-embedded sections (Intergen). Briefly 
described, mammary gland tissue sections were deparaffinized, quenched in 3% 
hydrogen peroxidase and incubated with terminal transferase. After applying the anti-
digoxigenin conjugate, the color was developed in DAB peroxidase substrate for 6 min. 
Samples were counterstained with methyl green (Vector Labs). 
Mammary Gland Whole Mounts 
Inguinal mammary glands (#4) or thoracic (#3) mammary glands were removed and 
spread on a charged glass microscope slide. Glands were fixed with Carnoy’s fixative 
overnight (6 parts 100 % EtOH, 3 parts CHCl3, 1 part glacial acetic acid). Glands were 
washed in 70% ethanol for one hour then gradually hydrated. Glands were stained with 
Carmine Alum, prepared by placing 1 g carmine (Sigma C1022) and 2.5 g aluminum 
potassium sulfate (Sigma A7167) in 500 ml distilled water and boiling for 20 min. The 
final volume was adjusted to 500 ml with ddH2O and filtered before use, and kept at 4° 
C overnight or until a desirable stain was attained. Glands were then dehydrated with a 
series of graded ethanol and transferred to xylenes to clear. Glands were left in xylene 
until sufficiently cleared then mounted with Permount (Fisher Scientific SP15-500). The 
protocol is described at 
http://mammary.nih.gov/tools/histological/Histology/index.html. The processed glands 
were imaged using an Olympus SZ-PT dissecting microscope. Fluorescent Whole Mounts 
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were prepared as described in Landua et al. (Method 1, Protocol B).504 They were 
visualized using an Olympus IX71 microscope (Olympus Corporation of the Americas). 
Immunoblotting 
Tissues were lysed in RIPA and protease inhibitors (Santa Cruz Biotechnology sc-24948). 
An equal amount of protein from each cell lysate was resolved on a SDS-polyacrylamide 
gel and transferred to nitrocellulose membranes (Bio-Rad 162-0094). Nonspecific 
binding was blocked with 5% nonfat dry milk powder in TBST for 60 min. The blots were 
incubated overnight at 4°C with primary antibody followed by washing with TBST and 
incubation with anti-rabbit-HRP secondary antibody in 5% nonfat dry milk powder in 
TBST for 2 hours. After washing in TBST, the immunoblots were developed with 
enhanced chemiluminescence detection system (Amersham RPN-2108) as per the 
manufacturer’s instructions. GAPDH was used as loading control. Primary antibodies 
used: BECN1 (Santa Cruz Biotechnology, sc-11427), MTOR (Cell Signaling Technologies, 
2983P), p4EBP1 (Cell Signaling Technologies, 2855P) SQSTM1 (Sigma-Aldrich, P0067), 
and TSC1 (Novus Biologicals, NB 100-80855).  
HC11 cell culture 
HC11 cells (a generous gift from Dr. Kay-Uwe Wagner, University of Nebraska) were 
cultured on coverslips in growth media ( RPMI, 10% FBS, 5 µg/mL insulin, 10 ng/mL EGF, 
50 µg/mL gentamycin, 100 U/mL pen/strep) until confluent (at least 6 days). Induction 
media (RPMI, 10% FBS, 5 µg/mL insulin, 5 µg/mL prolactin, 0.1 µM dexamethasone, 50 
µg/mL gentamycin, 100 U/mL pen/strep) was added and the cells were maintained for 
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24 or 48 hours. At appropriate time points cells were prepared for light and fluorescent 
imaging as follows. Cells were washed three times with PBS, cells were fixed with 4% 
paraformaldehyde for 15 minutes, and then washed three times with ice cold PBS. To 
permeabilize cells, samples were incubated in PBS containing 0.25% Triton X-100 for 10 
minutes. Cells were washed three times with PBS, five minutes per wash. Coverslip were 
mounted onto microscope slides using VectaShield mounting medium for fluorescence 
with DAPI (Vector Laboratories Inc., H-1200). Slides were viewed using an Olympus IX71 
microscope (Olympus Corporation of the Americas) 
NIH3T3 Cell culture and Protein-Protein Interaction Assay 
NIH3T3 cells were cultured on coverslips or using chamber slides (Nunc, 154526) in 
growth media (DMEM supplemented with 10% bovine calf serum, and 100 U/ml 
penicillin and streptomycin) in a 5% CO2 incubator until confluent. Serum-free medium 
lacks the bovine calf serum. At designated time points, as dictated by experimental 
design, cells were prepared for protein-protein interaction assay according to 
manufacturer’s directions, using recommended protocol and wash buffers (Omega 
Bioscience, DUO-LINK II). TSC1 (Novus Biologicals, NB 100-80855) and BECN1 (Santa Cruz 
Biotechnology, sc-48381) antibodies were employed.  Coverslip were mounted onto 
microscope slides using VectaShield mounting medium for fluorescence with DAPI 
(Vector Laboratories Inc., H-1200). Slides were viewed using an Olympus IX71 
microscope (Olympus Corporation of the Americas). 
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Transmission Electron Microscopy (TEM) 
All TEM experiments were conducted under the supervision of the University of 
Kentucky Imaging Core. Briefly, mammary glands were harvested and minced into 1mm2 
pieces in cold fixative (3.5% glutaraldehyde in 0.1M cacodylate buffer, pH 7.4) for 1.5 
hours at 4°C.  Glands were washed in 0.1M cacodylate buffer with 5% sucrose (4 times, 
15 minutes each). Samples were post fixed with 1% osmium tetroxide for 1.5 hours at 
4°C then washed in cacodylate buffer. Tissues were dehydrated in graded ethanol, 10 
minutes each and transferred to propylene oxide (2 changes, 15 minutes each).  Tissues 
were infiltrated overnight with resin/propylene oxide overnight then put in 100% resin 
(2 changes, 1 hour each). Tissue was embedded in resin for 48 hours at 60°C, thin 
sectioned using Reichert Ultracut E, and imaged using a Philips Tecnai Biotwin 12 
transmission electron microscope. 
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Appendix: Abbreviations 
3-MA, 3-methyladenine; ATG, autophagy related; BafA1;bafilomycin A1; Bmp, bone 
morphogenic protein; BH3, Bcl2 homology domain; cKO, conditional knockout; DAPI, 4', 
6-Diamidino-2-Phenylindole, Dihydrochloride; DC, dendritic cell; DISC, death-inducing 
signaling complex; E, embryo(nic); E2, estrogen; ECM, extracellular matrix; EDD, 
endothelium-dependent dilatation; EM, electron microscopy; ER, endoplasmic 
reticulum; ERE, estrogen responsive element; ESCRTI/ESCRTIII, endosomal sorting 
complex required for transport complex I and III;  EsR, estrogen receptor; FFA, free fatty 
acids; FGF, fibroblast growth factor; GAS, γ- interferon activation sites; GD, glucose 
deprivation; GFP, green fluorescent protein; H/I, hypoxic/ischemic; HOPS, homotypic 
vacuole fusion protein sorting complex; HSC, hematopoietic stem cell; IL, interleukin; 
ITPR, Inositol trisphosphate receptor; JAK, Janus kinase; KO, knockout;  LD, lipid droplet; 
LIF, leukemia inhibitory factor; MEC, mammary epithelial cell; MEF, murine embryonic 
fibroblast; MMP, metalloproteinase; MOMP, mitochondria outer membrane 
permeabilization; Msx, homeobox, msh-like; MVB, multivesicular body; NBD-PS, 7-nitro-
2-1,3-benzoxadiazol-4-yl-phosphoserine; OMM, outer mitochondrial membrane, P, 
pregnancy; P4, progesterone; PCD, programmed cell death; PE, 
phosphatidylethanolamine; PGC, primordial germ cell; PM, plasma membrane; PR, 
progesterone receptor; PRL, prolactin; PRLR, prolactin receptor; PtdIns3P- 
phosphatidylinositol 3-phosphate; PThrP, parathyroid hormone related peptide; RANK, 
receptor activator of nuclear factor κβ; RANKL, RANK ligand ROS- reactive oxygen 
species; SCN, suprachiasmatic nucleus; SNARES, Soluble NSF attachment protein 
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receptors; SNP, single nucleotide polymorphism; STAT, signal transducers and activators 
of transcription; T2D, type 2 diabetes; Tbx, T-box protein; TEB, Terminal End Bud; TED, 
terminal end duct; TEM, transmission electron microscopy; Th, T helper; TUNEL, 
Terminal deoxynucleotidyl transferase dUTP nick end labeling; UPR, unfolded protein 
response; UPS, ubiquitin proteasome system; WAP, Whey acidic protein; XeB/XeC, 
xestospongin B/C  
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